

Final report

Pet health supplements using Australian Red Meat inputs – Phase 1

Project code: P.PSH.1614

Prepared by: Dr Mohamad Aramesh, Luke Sheats, Tom Woolley, Dr Anna Barlow
ACH Australia Pty Ltd, trading as Startupbootcamp

Date published: Draft: 24th September 2025

PUBLISHED BY
Meat & Livestock Australia Limited
PO Box 1961
NORTH SYDNEY NSW 2059

This is an MLA Donor Company funded project.

Meat & Livestock Australia acknowledges the matching funds provided by the Australian Government to support the research and development detailed in this publication.

This publication is published by Meat & Livestock Australia Limited ABN 39 081 678 364 (MLA). Care is taken to ensure the accuracy of the information contained in this publication. However MLA cannot accept responsibility for the accuracy or completeness of the information or opinions contained in the publication. You should make your own enquiries before making decisions concerning your interests. Reproduction in whole or in part of this publication is prohibited without prior written consent of MLA.

Abstract

This project was undertaken to address the challenge of entering the complex Australian pet supplement market by identifying key market opportunities. The primary goal was to pinpoint the most common and costly health issues affecting pets, thereby defining pet owner "pain points" to guide new product development. A novel approach was used, combining advanced artificial intelligence with expert human oversight. This method involved scanning over 10,000 scientific and market data sources to gather comprehensive information, which was then rigorously verified by specialists to ensure accuracy.

Key results confirmed a strong market opportunity driven by owners seeking preventative wellness solutions to offset high vet costs. The research identified that using palatable red meat ingredients can solve the critical challenge of supplement compliance, especially for the underserved cat market.

The primary benefit for the Australian red meat industry is a clear pathway to enter the growing, high-value pet supplement market. This creates a new opportunity for premium red meat ingredients, meeting strong consumer demand for natural, science-backed wellness products and positioning the industry for future innovation.

Table of contents

1. Executive Summary	7
2. Background	9
3. Objectives	10
4. Methodology	11
4.1 Overview	11
4.2 Phase 1: Strategic Scoping and Framework Development	11
4.3 Phase 2: Information Sourcing and Synthesis	11
4.4 Phase 3: Content Generation and Quality Assurance Protocol	12
4.4.1 AI-Assisted Content Drafting	12
4.4.2 Multi-Layered Validation Process	12
4.5 Limitations of the Methodology	12
5. Introduction & Context	13
5.1. Humanisation of Pets and Premium Supplement Trends in Australia	13
5.2. Current Supplement Formulations and the Red Meat Opportunity	14
6. Market Size & Opportunity	15
6.1 Global Pet Supplement Market Overview	15
6.2 Australian Pet Supplement Market Size & Value	16
6.3 Growth Trajectory & Forecasts (Australia vs. Global Benchmarks)	16
6.4 Key Market Drivers & Restraints	17
6.4.1 Market Drivers:	17
6.4.2 Market Restraints:	17
7. Australian Pet Ownership Landscape	18
7.1 Pet Demographics	18
7.2 Owner Profiles	20
8. Australian Pet Health-Care Landscape	21
8.1 Australians Vet Service Usage & Cost Burden	21
8.2 Australian Pet Major Health Issues	22
9. Competitive Analysis: Current Supplement Offerings	24
9.1 Product Segmentation by Pet Type (Dogs/Cats)	24
9.1.1 Canine Supplement Market: The Dominant Segment	24
9.1.1.1 Market Share and Dynamics	25
9.1.1.2 Key Product Categories & Applications (Canine)	25
9.1.1.3 Formulation and Ingredient Spotlight (Canine)	25
9.1.2 Feline Supplement Market: The Growth Frontier	25
9.1.2.1 Market Share and Growth Trajectory	26
9.1.2.2 Unique Feline Product Categories & Applications	26
9.1.2.3 Formulation and Ingredient Spotlight (Feline)	26

9.2 Product Segmentation by Form (Tablets, Chews, Liquids, etc.)	26
9.2.1 Chewable Supplements (Soft Chews, Tablets, Capsules): The Market Leader	26
9.2.2 Liquid and Powder Supplements: The High-Growth Frontier	27
9.2.3 Transdermal and Ophthalmic Forms: Niche, Medically-Adjacent Segments	28
9.3 Ingredient & Formulation Landscape	29
9.3.1 Vitamins, Minerals, Omega-3s and 6s, Probiotics, Botanical Extracts	29
9.3.2 Alternative Novelty Pet Supplement Products	31
9.3.2.1 Insect-Based Pet Supplements	31
9.3.2.2 Plant-Based Pet Supplements	32
9.3.2.3 Other Emerging Novel Sources	32
9.3.2.4 Additional Novel Functional Ingredients	33
9.3.3 Existing Use of Red Meat Ingredients	33
9.3.3.1 Common Red Meat Sources and Market Positioning	34
9.3.3.2 The Rise of Organ Meats as "Superfoods"	34
9.3.3.3 Ingredient Forms and Processing Technologies	34
10. Economic & Health Impact Assessment	36
10.1 Cost Analysis of Veterinary Treatments vs. Preventative Supplements	36
10.1.1 The Financial Burden of Reactive Veterinary Care	36
10.1.2 The Proactive Investment in Preventative Measures	36
10.1.3 Return on Investment (ROI) Analysis: Key Case Studies	37
10.1.3.1 Case Study 1: Canine Osteoarthritis (OA)	37
10.1.3.2 Case Study 2: Canine Periodontal Disease	37
10.1.3.3 Case Study 3: Canine Atopic Dermatitis	38
10.2 Side-Effect Profile of Current Therapies	38
10.2.1 Overview	38
10.2.2 Red-meat based	40
10.2.2.1 Achieving Nutritional Balance for Optimal Health	40
10.2.2.2 Ensuring Product Safety Through Quality Control	40
10.2.2.3 Understanding Allergenic Potential for Individualised Care	41
11. Regulatory & Compliance Review	42
11.1 Governing Bodies & Product Classifications	42
11.1.1 Governing Bodies	42
11.1.2 Product Classifications	44
11.2 Labelling, Safety, and Claims Restrictions	45
11.2.1 Labelling APVMA-Registered Therapeutic Products	46
11.2.2 Labelling Non-Therapeutic Supplements: Australian Standard AS 5812	46
11.2.3 The Overarching Influence of the ACCC: Substantiating All Marketing Claims	47
11.3 Pathways for Novel Ingredients (Red-Meat Derivatives)	48
11.3.1 Defining "Novelty" in the Australian Context	48
11.3.2 The APVMA Registration Pathway for Therapeutic Claims	48
11.3.3 The END Exemption Pathway for Nutritional Claims	48
11.3.4 Strategic Implications for Red-Meat Derivatives	49

11.4 Implications for 3D-Printed Nutraceuticals	50
11.4.1 Regulatory Ambiguity and Classification Challenges	50
11.4.2 Quality Control and Safety Implications	51
11.4.3 Potential Regulatory Pathways and Mitigation Strategies	52
12. Opportunity Analysis: Red-Meat Ingredients + 3D Printing	52
12.1 Market Gaps & White Spaces by Health Indication	52
12.1.1 Chronic and Lifestyle-Related Diseases: A Growing Burden	52
12.1.2 Addressing the "Humanisation" Paradox: Safety and Personalisation	53
12.1.3 Underserved Feline Market: Addressing Unique Needs	54
12.2 Technical Feasibility	54
12.2.1 Technological Foundation: Additive Manufacturing for Edible Constructs	54
12.2.2. Printable Meat Matrix: Ingredient Stability and Compatibility	55
12.2.3 Precision: Dosage and Stability of Active Ingredients	56
12.3 Consumer & Veterinarian Willingness-to-Pay	57
12.3.1 Pet Owner Willingness-to-Pay: A Multi-Layered Value Equation	57
12.3.2 Veterinarian Willingness-to-Adopt: Clinical, Pragmatic, and Economic Drivers	58
12.3.3 Bridging the Perception Gap: Strategic Implications for a 3D-Printed, Red-Meat Supplement	58
12.4. Competitive Positioning & Differentiation Strategy	59
12.4.1 Current Competitive Landscape	59
12.4.2 Differentiation Strategies in Action	60
12.4.3 Strategic Implications for Red Meat Ingredients + 3D Printing	60
12.5 Case Studies of Novelty Pet Supplements	61
12.5.1 Cannabidiol (CBD) in Companion Animals	61
12.5.1.1 Market Dynamics	61
12.5.1.2 Therapeutic Applications & Claims vs. Clinical Evidence:	61
12.5.1.3 Regulatory & Safety Challenges:	62
12.5.2 Functional Fungi	62
12.5.2.1 Myco-Nutrition for Pets	62
12.5.2.2 Emerging Applications and Sourcing Differentiators:	63
12.5.3 Novel and Alternative Proteins	63
12.5.3.1 Definition of novel proteins	63
12.5.3.2 Alternative Proteins, Insect Protein and Algal Oil:	63
12.5.4 Probiotics	64
13. Risk Assessment & Mitigation	65
13.1 Regulatory Approval Risks & Mitigation Pathways	65
13.1.1 Regulatory Ambiguity and Classification Risks	65
13.1.2 Technical and Safety Approval Risks	66
13.1.3 Mitigation through Strategic Positioning and Future Regulatory Foresight	67
13.2 Supply-Chain Quality & Traceability Risks	67
13.2.1 Overview of the Pet Supplement Supply Chain	67
13.2.1.1 The Global Sourcing of Ingredients	68

13.2.1.2 Manufacturing Models and Distribution Channels	68
13.2.2 Chain of Vulnerabilities: Quality and Contamination Risks	68
13.2.2.1 Raw Material Contamination and Adulteration	69
13.2.2.2 Manufacturing and Formulation Hazards	69
13.2.2.3 Packaging and Distribution Risks	69
13.2.3 The Traceability Imperative: Consequences and Solutions	69
13.3 Market Adoption Risks (Education, Pricing)	70
13.3.1 The Education Gap: A Primary Barrier to Adoption and Trust	70
13.3.1.1 Consumer Knowledge Gap: Myths, Misconceptions, and Misinformation	70
13.3.1.2 Credibility Conflict: Veterinary Counsel vs. The Uncontrolled Digital Landscape	71
13.3.1.3 Misleading Scientific Claims and the Efficacy Deficit: The Importance of Proof	71
13.3.1.2 Complex Regulatory Landscape: A Fragmented Oversight	71
13.3.2 The Price-Value Conundrum: A Barrier to Mass-Market Penetration	72
13.4 Technical Scale-Up and IP Risks	73
13.4.1 The Technical Pathway: From Concept to Commercial Scale	73
13.4.1.1 Formulation and R&D: The Triad of Efficacy, Palatability, and Stability	73
13.4.1.2 Supply Chain Integrity: The Foundation of Product Quality and Safety	73
13.4.1.3 The Manufacturing Scale-Up Pathway	74
13.4.2 The Intellectual Property Landscape: Protecting and Defending Innovations	74
13.4.3 Implications for 3D Printing Technology	75
14. Conclusion	75
14.1 Key Findings	76
14.2 Benefits to Industry	76
14.2.1 Practical application of the project's insights and implications to the red meat industry:	76
14.2.2 Benefits to the wider red meat industry as a result of this project and its outcomes:	77
15. Strategic Insights and Future Directions	77
15.1 Key Challenges and Successes	77
15.1.1 Key Challenges Identified:	77
15.1.2 Key Successes and Supporting Evidence:	78
15.2 Recommendations	78
15.2.1 Future R&D	78
15.2.2 Practical Application of Project Insights	79
15.2.3 Development and Adoption Activities:	79
16. References	80
17. Appendix - External Peer Review Report	116

1. Executive Summary

The present report identifies a significant and commercially viable opportunity for the Australian red meat industry to capture high-margin growth within the nation's large, resilient, and rapidly expanding pet supplement market. Driven by the powerful "humanisation" trend, where pets are considered integral family members, Australian owners are increasingly investing in preventative wellness solutions for their "fur babies". This study provides a strategic roadmap for developing and launching premium, red meat-based supplements that align directly with this pronounced market shift.

The Australian pet care market, valued at over AUD \$33 billion annually, is underpinned by a clear consumer pivot towards proactive health management. This has created a dynamic supplement sector poised for strong growth, fueled by a discerning "pet parent" demographic willing to pay a premium for natural, functional, and scientifically-backed products. Our analysis reveals that Australian red meat is uniquely positioned to meet this demand, leveraging its existing consumer perception as a high-quality, nutrient-dense ingredient. A key opportunity lies in value-adding to red meat outputs, particularly by repositioning organ meats from by-products into premium "superfood" ingredients, rich in essential vitamins and minerals.

The report establishes a compelling economic value proposition for these supplements, directly addressing the significant financial burden of reactive veterinary care on pet owners. With costs for common chronic conditions like osteoarthritis and skin allergies running into thousands of dollars annually, the findings demonstrate that proactive supplementation offers a significant return on investment through long-term health support and potential cost avoidance. This creates a powerful marketing narrative that reframes a premium supplement not as a discretionary expense, but as a prudent investment in a pet's longevity and wellbeing.

A clear, lower-risk pathway to market has been identified. By strategically managing marketing language to focus on wellness claims (e.g. "supports joint health") rather than therapeutic claims (e.g. "treats arthritis"), products can be classified as "Excluded Nutritional or Digestive" (END) supplements. This approach avoids the more onerous and costly registration process required for veterinary medicines, enabling a faster and more capital-efficient market entry.

Long-term success and market leadership, however, will be contingent on building trust with both consumers and the veterinary community. This requires a commitment to scientific validation through pet-specific clinical trials to substantiate health claims, coupled with rigorous supply chain management to ensure product safety and quality as part of an innovation plan.

The report further explores the frontier of innovation through advanced manufacturing. 3D printing technology presents a unique opportunity for market differentiation, enabling the creation of highly personalised supplements with precise dosages tailored to an individual pet's specific needs. While this pathway faces regulatory ambiguity, it offers a defensible competitive advantage through patentable processes and formulations, positioning a brand at the forefront of the "hyper-personalisation" trend in pet wellness.

In conclusion, this research provides the Australian red meat industry with an actionable blueprint to diversify into the high-growth pet wellness sector. As illustrated by Fig. 1, achieving success requires alignment across three strategic pillars:

1. leveraging the premium perception of red meat,
2. substantiating product efficacy with robust scientific evidence, and
3. navigating the regulatory landscape with carefully crafted, evidence-based marketing.

By executing this strategy, the industry can create new, high-value revenue streams and solidify its reputation as a leader in premium, health-focused animal nutrition.

Figure 1. Strategic blueprint for success of red meat-based supplement products in the Australian pet care market

STRATEGIC BLUEPRINT FOR SUCCESS



2. Background

The Australian pet care market is experiencing significant growth, driven by a cultural shift where pets are increasingly considered integral family members. This "humanisation" trend has fostered a resilient, premium-focused industry with consumers demonstrating a strong willingness to invest in products that support pet health and wellness. Market analyses confirm the expansion of the pet supplement sector, with forecasts projecting a compound annual growth rate (CAGR) of between 5.2% and 6.5% through to 2033 (Grand View Research 2025b; IMARC Group 2025). This growth is fueled by a clear consumer pivot towards preventative healthcare, creating demand for natural, functional, and scientifically backed wellness products (Business Daily Media 2025).

A 2019 review of the pet food category – "Identifying high value opportunity spaces for Australian red meat industry" by Meat & Livestock Australia (MLA) identified the pet food sector as a high-value opportunity for the Australian red meat industry, highlighting consumer demand for raw, fresh, and preservative-free products (Meat & Livestock Australia 2019). However, a knowledge gap remains in how to best leverage Australian red meat specifically within the sophisticated and rapidly expanding pet supplement category. While market research provides high-level data on the size and growth of the supplement market, there is a need for a targeted strategy that connects the premium perception of Australian red meat with the specific health needs of pets and the purchasing drivers of their owners.

This project seeks to address this gap by identifying the most effective positioning for Australian red meat-based ingredients within the pet supplement market. Answering this is critical for enabling the Australian red meat industry to capture greater value from its outputs, moving beyond commodity ingredients to develop premium, high-margin products. For consumers, this research aims to pave the way for new products that meet their demand for trusted, natural, and effective solutions to support the longevity and wellbeing of their pets (Business Daily Media 2025).

The primary audience for this report includes stakeholders within the Australian red meat industry and pet food and supplement manufacturers. These groups require a comprehensive analysis that extends beyond market size to include formulation opportunities, and an assessment of the competitive and regulatory landscapes. Other potential beneficiaries of this research are modern "pet parents," a demographic that is diligent in researching pet health and actively seeks out premium, evidence-based wellness solutions for their companion animals. This group can benefit from the insights provided by the research, as it highlights considerations that align with their pursuit of informed, high-quality care for their pets.

The results of this research are intended to serve as a strategic roadmap for product innovation and market entry. While previous reports have identified the broad opportunity, this project is unique in it is a focused approach to creating an actionable strategy for red meat in the supplement space. It synthesises market data, consumer trends, veterinary health priorities, and the Australian regulatory framework to define specific, commercially viable opportunities. By providing a detailed assessment of potential red meat ingredients, target health applications, and recommended next steps, this report will provide the foundation for developing a new category of premium, Australian-made pet health solutions.

3. Objectives

The core objectives for this milestone were to build a foundational understanding of the Australian pet supplement landscape. This milestone has successfully met these objectives as follows:

- **To conduct a market review of pet ownership and the pet health care landscape in Australia, defining the major veterinary services treating common health problems for cats and dogs.** The analysis confirmed a large, resilient market driven by the "humanisation" trend. It identified the specific health conditions that represent the most significant burden on pet owners and highlighted key market drivers, including the high cost of veterinary care and low insurance penetration, which create a clear need for preventative health solutions.
- **To analyse current available supplement formulations and their efficacy.** This objective was met by reviewing and analysing the dominant market forms, such as chews, liquids, and powders. The analysis identified the commercial drivers and formulation trade-offs for each, noting that while chews are the market leader, powders and liquids represent the highest-growth frontier.
- **To identify the opportunity for Australian red meat ingredients within this defined space.** This objective was successfully achieved by identifying key white space opportunities. These include rebranding organ meats as superfoods, developing adjunctive therapies for chronic diseases, leveraging red meat's palatability to target the underserved feline market, and using novel processing to ensure safety and nutritional value.
- **To assess the impact on pet ownership care, including the cost of treatments and any known side effects of red meat.** This objective has been met by quantifying the significant financial burden of reactive veterinary care, establishing a clear return on investment for proactive supplementation. The analysis also documented the well-established risks associated with red meat, such as allergenicity and microbial contamination, framing them as manageable formulation challenges.
- **To review the existing regulatory framework for pet health care supplements in Australia.** This objective was achieved by analysing Australia's fragmented regulatory system. The review identified the two primary pathways to market: the high-burden APVMA registration for therapeutic products and the lower-burden Excluded Nutritional or Digestive pathway (END) for wellness products, confirming that market entry is strategically dictated by marketing claims rather than ingredients.
- **To assess the current and potential uses of red meat in pet health and recommend next steps.** This objective was met by assessing the current use of red meat as a premium protein source and identifying its potential as a foundational ingredient in targeted supplements. The analysis highlighted opportunities to develop adjunctive therapies for chronic diseases like osteoarthritis and cancer, and to create highly palatable solutions for the underserved feline market. Recommended next steps include pursuing the lower-burden END regulatory pathway for initial market entry, followed by investment in clinical trials to substantiate therapeutic claims for future product evolution. A focus on science-backed formulations to build veterinary trust is also recommended as a key strategic step.
- **To define the value proposition for Australian pet supplements with the inclusion of red meat.** This objective was achieved through a synthesis of all research findings, culminating in the identification of two primary value propositions: leveraging the superior palatability of red meat to ensure compliance, and developing safe solutions for high-cost chronic diseases.

4. Methodology

4.1 Overview

This section outlines the systematic methodology employed to conduct the feasibility study on novel red meat-based pet supplement products with the potential of utilising 3D printing technology through the later stages of the project. The research was executed using a hybrid methodology that combines the efficiency of GenAI systems with the critical evaluation and contextual knowledge of SMEs in the fields of food science and market analysis. Having expert humans in the loop, a range of proprietary and state-of-the-art GenAI tools have been employed to deliver a comprehensive, accurate, and actionable report that directly addresses the project's strategic objectives.

4.2 Phase 1: Strategic Scoping and Framework Development

The initial phase of the study focused on establishing a robust research framework. For that purpose the project objectives were meticulously defined in collaboration with internal SMEs to ensure a clear and precise scope. Following this, generative AI (GenAI) tools were utilised to propose multiple structural outlines for the final report. This process ensured that all facets of the project's goals were addressed, including market opportunity, technological viability, regulatory landscape, and consumer trends. The final report structure was selected by the project leads to guarantee comprehensive coverage, while excluding extraneous information, thereby focusing the research within the scope and objectives of the project.

4.3 Phase 2: Information Sourcing and Synthesis

A multi-faceted approach was used to gather data from a wide array of credible sources. The research process was designed to capture a holistic view of the pet supplement industry. The study drew upon a diverse range of information channels to ensure a well-rounded analysis. These included:

- Academic and Veterinary Journals
- Global and Australian Market Research Reports
- Patents and Intellectual Property Databases
- Regulatory and Compliance Databases
- Pet Food and Health Industry Publications
- Reports on Meat Sector Sustainability and Technology

To efficiently process the vast amount of available information, the study utilised AI-powered search and analysis tools. These tools systematically scanned a corpus of over 10,000 online sources to identify the most relevant and authoritative documents. This AI-assisted process enabled the research team to efficiently pinpoint over 500 credible sources that form the evidence base for this report, ensuring the findings are grounded in current and reliable data.

4.4 Phase 3: Content Generation and Quality Assurance Protocol

4.4.1 AI-Assisted Content Drafting

The generation of this report followed a structured process designed to ensure accuracy, objectivity, and relevance. This process involved AI-assisted drafting followed by a multi-layered human-led validation protocol. Initial drafts of the report's sections were generated using proprietary and most recent and advanced GenAI tools. The quality and relevance of the AI-generated text were guided by a disciplined prompt engineering process. This involves crafting precise, context-rich instructions to direct the large language models (LLM) to produce content that is unbiased, factually oriented, and directly aligned with the specific requirements of each section.

4.4.2 Multi-Layered Validation Process

Recognising the limitations of current GenAI technologies, a rigorous, multi-step validation protocol was implemented to verify all generated content.

- **Source Grounding and Citation:** All AI-generated statements were required to be "grounded" in the information collected during the sourcing phase. This means every claim and data point is directly traceable to a specific, verifiable source, which is cited in-line. This practice is fundamental to mitigating the risk of "hallucinations," where a large language model may generate factually incorrect information.
- **Automated & Manual Fact-Checking:** Each statement was cross-referenced against its cited source. This was performed using specialised AI tools for initial verification, followed by manual checks from the research team to confirm that the information was accurately represented and contextually appropriate.
- **Objectivity and Bias Review:** The content was reviewed to identify and mitigate potential biases. This involved designing prompts that requested a balanced and neutral perspective, utilising specialised AI tools and processes for fact-checking, and a subsequent human review to ensure the final text presented a comprehensive and impartial picture of the subject matter.
- **Final Subject Matter Expert (SME) Verification:** The ultimate quality assurance step was a thorough review of the entire report by SMEs. These experts assessed the content for technical accuracy, industry relevance, and strategic soundness, ensuring the final conclusions and recommendations are robust and reliable, and free from unnecessary hyperbole.
- Review by a qualified veterinarian with an interest in product development of premium pet snacking products (Dr Paul Ramos, <https://www.linkedin.com/in/pwramos/>), a copy of the review is attached to this report.

4.5 Limitations of the Methodology

It is critical to note that this study is an analysis of secondary data, which is a common practice for research and review of existing domains. The report does not include primary empirical research, such as laboratory testing of the formulations or direct surveys with pet owners. Therefore, the conclusions regarding technical feasibility and consumer acceptance are predictive and have not been physically validated.

5. Introduction & Context

5.1. Humanisation of Pets and Premium Supplement Trends in Australia


The Australian pet care market is undergoing a significant transformation, primarily driven by the "humanisation" trend, where companion animals are increasingly regarded as integral family members rather than mere pets (Insyncfm 2025). This shift in consumer attitudes and behaviours has impacted spending priorities, leading to a rapidly expanding premium pet care industry (getthewordout.com.au 2025).

This humanisation effect is particularly pronounced among younger demographics. Millennial and Gen Z "pet parents" are often delaying traditional life milestones, redirecting emotional and financial investment towards their "fur babies" (Insyncfm 2025). A 2024 survey highlights this, revealing that 75% of Australians aged 28-37 own a dog, with this group being the most likely to cite mental health benefits as a primary reason for pet ownership, indicating a deeper, more symbiotic relationship (Budget Direct 2024). Australia's high pet ownership rate, with approximately 69% of households owning a pet and the pet population exceeding the human population, supports this trend (AgFood Fund 2024; Budget Direct 2024). The COVID-19 pandemic further accelerated this dynamic, leading to a surge in pet adoptions as people sought companionship during lockdowns (myNZTE 2023).

The reclassification of pets has economic consequences. Australians now spend over AUD \$33 billion annually on pet care, a figure that has demonstrated resilience even amidst economic pressures, indicating that pet wellness spending is a priority for many (Animal Medicines Australia 2022; Insyncfm 2025).

While pet food constitutes the majority of spending at 51%, pet healthcare products, including supplements, represent a substantial 9% share, estimated at AUD \$2.9 billion annually (Animal Medicines Australia 2022; Cosgrove 2025; getthewordout.com.au 2025). Veterinary services account for a further 14%, with products and accessories contributing another 9% (Animal Medicines Australia 2022). Fig. 2 presents the distribution of market share among the various segments of the Australian pet industry. It is noteworthy that around 89% of this total expenditure is on dogs and cats (Animal Medicines Australia 2022).

Figure 2. Market share of Australian pet industry segments.



The average Australian dog owner is projected to spend approximately \$25,000 over their pet's lifetime, with annual costs averaging around \$3,218, supporting investment in premium products (Cosgrove 2025). Generational spending patterns reinforce this, with Gen Z pet owners spending more on veterinary care and life-saving treatments, suggesting their commitment will continue to drive growth in premium and wellness categories (Zielinski 2025).

A key behavioural shift influencing the supplement market is the pivot to a preventative approach to pet health (Animal Medicines Australia 2022; getthewordout.com.au 2025). Pet owners are seeking natural, organic, and functional products to enhance longevity and wellbeing, mirroring human wellness trends (getthewordout.com.au 2025). This proactive mindset fuels demand for supplements targeting specific health applications such as joint, skin, and digestive health, with ingredients like probiotics, omega-3 fatty acids, and botanicals gaining popularity (getthewordout.com.au 2025). Modern pet parents are also diligent researchers, spending time online investigating their pets' nutritional requirements, which in turn drives demand for specialised, premium, and scientifically-backed products (AgFood Fund 2024).

5.2. Current Supplement Formulations and the Red Meat Opportunity

The pet supplement market is a segmented landscape, shaped by consumer demand for convenience, palatability, and targeted health outcomes. The dominant delivery format is the chewable supplement, encompassing soft chews and tablets, which commands market revenue due to their ease of administration and the "treatification" of health products that aligns with the humanisation trend (Grand View Research 2024; Petfood Industry 2023; UK Pet Food 2025). Powders and liquids represent a high-growth segment, appealing to pet owners who prefer to integrate supplements directly into meals as nutritional enhancers, reinforcing the shift towards customised feeding routines (Grand View Research 2024; Petfood Industry 2023).

These products are typically formulated to address specific, well-defined health concerns. Joint support is a large and established application category, driven by the prevalence of mobility issues in ageing pets (Fortune Business Insights 2025; Grand View Research 2024). This is followed by expanding segments for skin and coat health, digestive wellness supported by probiotics, and calming aids for behavioural issues (Allied Market Research 2024; Grand View Research 2024; Howarth 2025). This market is further segmented by species, with the canine sector representing a mature, dominant share, while the feline sector is a fast-growing frontier, presenting formulation challenges centred on the selective palate of cats (Grand View Research 2024; Hewitt 2025; Pet Honesty 2024; Under the Weather Pet 2025).

Underpinning these formulations is an array of functional ingredients, including vitamin and mineral premixes, omega-3 fatty acids, probiotics, and a growing category of botanical extracts (Elanco 2025; Guo et al. 2024; Lee et al. 2022; The Vets 2025). Amidst this landscape of specialised additives, a market opportunity is emerging from the strategic use and premium positioning of foundational whole-food ingredients, most notably red meat. Red meat already has a presence in the pet food industry, valued by consumers as a high-quality source of protein, B-vitamins, iron, and zinc essential for muscle development, energy metabolism, and immune function (Bet Pets 2025; Cooper 2024; Portland Pet Food Company 2025).

The humanisation trend is fueling demand for supplements that mirror human "superfood" concepts, creating a pathway for red meat-based formulations. Leading brands are capitalising on this by

explicitly featuring nutrient-dense organ meats like beef liver on their labels. This strategy allows them to highlight these ingredients as natural sources of Vitamin A and highly bioavailable heme iron, appealing to consumers seeking transparent, "clean label" products (Best Friends Veterinary Hospital 2025; Cooper 2024; Oma's Pride 2024; Raw & Fresh 2022a). Furthermore, the market already demonstrates consumer appetite for a hierarchy of quality among red meats. Sources like grass-fed lamb, venison, and bison are positioned in premium and super-premium segments as novel or "ancestral" proteins, catering to pets with food sensitivities and owners seeking lean, digestible options (Addiction Pet Foods 2025; Barrington 2025; Bet Pets 2025). This existing market acceptance validates the opportunity to develop supplements centred on the nutritional value and premium appeal of red meat.

Looking ahead, the convergence of these nutritional trends with advanced manufacturing technologies presents a frontier for innovation. Specifically, 3D printing technology offers a potential pathway for the production of red meat-based supplements. This approach could enable customisation, allowing for the creation of supplements with precise dosages, unique textures, and complex geometries tailored to an individual pet's breed, age, or health requirements. The viability of this technology for creating palatable and functional red meat matrices represents a compelling area for future product development and market differentiation.

6. Market Size & Opportunity

This section analyses the global and Australian pet supplement markets, detailing current market size, value, and growth forecasts. It also examines key market drivers and restraints, providing context for strategic decision-making.

6.1 Global Pet Supplement Market Overview

The global pet supplement market is experiencing sustained growth. While estimations of its precise value vary across market research firms, this reflects differences in methodology and market definition. Projections for the market's value in 2024 range from USD 2.27 billion to USD 16.18 billion (The Business Research Company 2025; Market Research Future 2025).

This discrepancy is primarily due to the lack of a standardised definition for "pet supplement." Reports with lower estimates adopt a narrow scope, focusing on traditional vitamins and minerals, while reports with higher valuations use broader terms like "dietary supplements" or "nutraceuticals," encompassing a wider array of products including functional treats, fortified foods, and probiotics. Other factors contributing to the varied estimates include differences in valuation points (retail vs. manufacturer pricing) and geographic scope, with some reports focusing on global figures while others analyse specific regions. Despite numerical differences, a consistent theme across analyses is a robust and expanding market driven by the increasing humanisation of pets and a growing focus on preventive health.

Regionally, North America leads the market, accounting for over 48.4% of global revenue in 2024 (Mordor Intelligence 2025b). This can be attributed to high pet ownership rates, significant consumer spending power, and a mature retail and veterinary infrastructure. Europe follows as the second-largest market, valued at USD 3.3 billion in 2023, with strong demand for natural and sustainable products in countries like the UK and Germany (Fortune Business Insights 2025; Verified Market Research 2025). The Asia-Pacific region is identified as the fastest-growing market, with a projected

CAGR of 7.4%, driven by rising disposable incomes and evolving pet care norms in China, Japan, and India (Mordor Intelligence 2025b).

Market segmentation reveals clear patterns in consumer demand. The dog segment is the largest, representing up to 77% of total sales, driven by higher ownership rates and the prevalence of health conditions like joint issues in larger breeds (IMARC 2024; Business Research Insights 2025). The cat segment, while smaller, is the fastest-growing as owners seek solutions for feline-specific health concerns such as urinary tract and kidney issues (Mordor Intelligence 2025b).

In terms of supplement type, multivitamins are a major category, holding a 28.7% market share as a common entry point for consumers (Mordor Intelligence 2025b). Condition-specific formulas are also gaining prominence, with hip and joint supplements commanding the largest share at 31.2%, propelled by the needs of an aging pet population (Mordor Intelligence 2025b).

6.2 Australian Pet Supplement Market Size & Value

The Australian pet supplement market, while smaller in absolute terms, is a dynamic and growing segment within the Asia-Pacific region. The market was valued at USD 26.0 million in 2024 (IMARC 2024) and a higher estimate places the market at USD 33.09 million in 2025 (Cognitive Market Research 2025).

The pet nutraceuticals and supplements category is a fast-growing segment within the broader Australian pet food market. It is projected to expand at approximately 12% between 2024 and 2029, outpacing other categories and highlighting a strong consumer shift towards health-focused products (Mordor Intelligence 2025a).

6.3 Growth Trajectory & Forecasts (Australia vs. Global Benchmarks)

The growth outlook for the pet supplement market is robust both globally and in Australia. Global forecasts project a strong CAGR ranging from 5.2% to 8.7% over the next decade (Zion Market Research 2025; MarketsandMarkets 2025). The Global market is forecasted to reach USD 3.31 billion by 2029 at a 7.9% CAGR (The Business Research Company 2025), with some growth projections of up to USD 32.23 billion by 2034 at a 7.1% CAGR (Market Research Future 2025). The Australian market's growth trajectory is closely aligned with these global trends. The forecasts suggest that the market will reach USD 41.0 million by 2033, reflecting a steady CAGR of 5.2% (IMARC 2024). However, there are more aggressive forecasts available with a projected CAGR of 7.8% (Cognitive Market Research 2025).

When benchmarked against the United States, the world's largest single market for pet supplements, the disparity in scale is evident. The U.S. market is projected to reach USD 1.36 billion by 2032, overshadowing Australia's current USD 26.0 million valuation (Fortune Business Insights 2025; IMARC 2024). However, both markets exhibit sophisticated consumer behaviour, including a strong demand for premium, condition-specific products and a reliance on e-commerce channels. The U.S. market, with its established FDA and AAFCO regulatory environment, often influences global trends in product innovation and safety standards (Global Market Insights 2025; Allied Market Research 2024).

6.4 Key Market Drivers & Restraints

6.4.1 Market Drivers:

- **Rising Pet Ownership and Humanisation:** This is a primary force propelling the market forward. As consumers view pets as family members, their willingness to spend on health and wellness products rises (Global Market Insights 2025; MarketsandMarkets 2025). In the U.S., where 76% of owners consider pets family, an estimated USD 147 billion was spent on pet expenses in 2023 (IMARC 2024; Business Research Insights 2025). This trend is mirrored in Australia, where a strong pet ownership culture fuels demand.
- **Increased Focus on Preventive and Holistic Healthcare:** There is a clear market shift from reactive treatment to proactive, preventive care. Pet owners are actively seeking supplements to support long-term wellness and address potential health issues like arthritis, digestive problems, and allergies (Verified Market Research 2025; Market Research Future 2025). This is a key driver in both global and Australian contexts (IMARC 2024).
- **Expansion of E-commerce and DTC Channels:** The accessibility and convenience of online retail have fundamentally changed the market. The global e-commerce share of pet supplement sales grew from 20% in 2018 to 37% in 2023 (Business Research Insights 2025). In Australia, where the overall e-commerce market was valued at USD 536.0 billion in 2024, online channels provide a strong platform for growth, offering consumers a wider selection and educational content (IMARC 2024; MarketsandMarkets 2025).
- **Innovation in Personalisation and Natural Ingredients:** Technological innovation is creating new avenues for growth. In Australia, there are already AI-powered tools for personalised pet care advice, exemplifying this trend (IMARC 2024). Concurrently, consumer demand for natural, evidence-based ingredients is strong, creating opportunities for startups that focus on natural formulations (IMARC 2024).

6.4.2 Market Restraints:

- **Regulatory Hurdles and Lack of Standardisation:** The global regulatory landscape for pet supplements is fragmented and can be less stringent than for human products, potentially leading to inconsistent quality and consumer skepticism (Business Research Insights 2025; Zion Market Research 2025). In mature markets like the U.S., gaining approval from bodies like the FDA and AAFCO can be a costly process for novel ingredients (Allied Market Research 2024).
- **High Cost of Premium Products:** Scientifically formulated supplements with natural or organic ingredients carry a premium price tag. This can be a barrier for price-sensitive consumers, particularly during periods of economic uncertainty (MarketsandMarkets 2025).
- **Limited Consumer Awareness in Developing Regions:** While awareness is high in developed markets, some pet owners in emerging economies still believe that standard pet food provides all necessary nutrition. Overcoming this perception and educating consumers on the specific benefits of supplementation remains a challenge to market expansion (Business Research Insights 2025; Zion Market Research 2025).

Fig. 3 Summarises the market drivers and market restraints.

Figure 3. The drivers and restraints of the Australian red meat-based pet supplements market


7. Australian Pet Ownership Landscape

This section analyses the Australian pet ownership landscape, examining the demographic characteristics of pets and their owners. It explores the prevalence of different companion animals, their geographic distribution, and the significant influence of housing on ownership rates. Owners are profiled by age, family structure, and spending behaviour to create a picture of the target consumer base for pet health supplements.

7.1 Pet Demographics

Australia has a high rate of pet ownership, a figure that has grown in recent years. As of 2022, 69% of Australian households own a pet, an increase from 61% in 2019, establishing a prevailing trend for pet ownership post-pandemic (Animal Medicines Australia 2022; RSPCA Knowledgebase 2023). This translates to an estimated 28.7 million pets residing in 6.9 million homes, with the total pet population now exceeding the human population at a ratio of approximately 101 pets for every 100 people (Animal Medicines Australia 2022).

As Fig. 4 illustrates, while the overall pet population in Australia is substantial, dogs and cats, as primary companion animals, exhibit distinct demographic and acquisition profiles.

Figure 4. Dogs and cats' demographics and acquisition sources.

- **Dogs:** As the most popular companion animal by household, dogs are present in 48% of Australian homes, with a total population of approximately 6.4 million (Animal Medicines Australia 2022). The average dog-owning household has 1.3 dogs, indicating that single-dog ownership is the prevailing norm (Ballard 2025). The primary acquisition channel for dogs is commercial breeders, with 51% of owners in Victoria sourcing their pets this way, highlighting the influence of the formal breeding industry (Agriculture Victoria 2025).
- **Cats:** Cats are found in 33% of Australian households, with a total population of 5.3 million (Animal Medicines Australia 2022). In contrast to dogs, cat-owning households are more likely to be multi-pet, with an average of 1.6 cats per home (Pet Memorial Australia 2025). Acquisition pathways for cats differ markedly from those for dogs. Only 10% of cats are sourced from breeders, while a significant proportion come from rehoming organisations (28%), animal shelters (22%), or informal channels such as friends, family, or as strays (Agriculture Victoria 2025; Budget Direct 2024). This contributes to the burden on the animal welfare sector; for instance, it is reported that some shelters have received 26,704 cats compared to 17,468 dogs in the 2023-2024 financial year (RSPCA 2024).

Pet ownership in Australia is not uniform and is influenced by geography, housing type, and tenure, creating an urban-regional divide.

- **Geographic and Housing Determinants:** The "average pet-loving household" is more likely to be situated in a rural or regional area, whereas households least likely to own a pet are typically "couples and singles without children who rent in urban areas" (Animal Medicines Australia 2019). This pattern is driven by the physical and legal constraints of urban living. The

trend towards high-density housing, such as apartments with limited or no private yard space, can discourage pet ownership, particularly for dogs (Animal Medicines Australia 2016). This is compounded by strata title and body corporate bylaws that frequently prohibit or restrict pets (Animal Medicines Australia 2022).

- **Housing Tenure and Socio-Economic Factors:** Housing tenure presents a barrier. Renters are less likely to own pets due to "no pets" clauses in tenancy agreements, a factor that contributes to an estimated 15% to 25% of all pet surrenders to shelters (Animal Medicines Australia 2019; Australian Housing and Urban Research Institute 2021). While housing issues are a primary reason for relinquishment across all socio-economic groups, the rate is highest among guardians from areas of lower-than-average socio-economic status (SES), indicating that systemic vulnerabilities like housing and financial precarity are challenges (McDowall et al. 2024). Recent legislative reforms in jurisdictions like Victoria and the Northern Territory aim to mitigate these barriers by making it more difficult for landlords to unreasonably refuse pets (Australian Housing and Urban Research Institute 2021).

The confluence of these factors creates a "spatial sorting" of pet ownership, where the ability to own a pet is increasingly tied to the affordability of freestanding homes in suburban or regional locations, which may limit access to pet companionship for some urban renters (Australian Housing and Urban Research Institute 2021).

7.2 Owner Profiles

An understanding of Australian pet owners, segmented by generation, family structure, and spending habits, is essential for market strategy. While some data is US-based, the observed trends in pet humanisation and consumer behaviour are broadly applicable to the Australian market.

- **Generation Z (approx. 18-26):** As an emerging consumer group, Gen Z owners show more diverse pet preferences, with higher ownership rates of reptiles, birds, and small animals (Megna 2025). They are engaged with pet technology and show a preference for raw food diets over supplements compared to Millennials (PetExec 2025).
- **Millennials (approx. 27-42):** This cohort is at the forefront of the "pet parent" movement, viewing their animals as integral family members and "starter children" (HealthforAnimals 2022). This emotional bond drives their willingness to spend on premium products, including wellness supplements and comprehensive health insurance (PetExec 2025).
- **Gen X (approx. 43-58) and Baby Boomers (approx. 59-77):** These established segments often own pets for companionship and stress reduction, with 75% of owners aged 50-80 reporting that their pets provide purpose and alleviate stress (Cornell University College of Veterinary Medicine 2025a). Their approach to veterinary care is often more traditional, favouring in-person examinations (American Veterinary Medical Association 2023).

Household composition is a significant predictor of pet ownership. An owner's age can be a predictor of their dog's diet, with younger owners favoring kibble and older owners opting for canned or home-cooked meals (McCafferty 2025). Households with children have higher odds of owning a pet, particularly a dog, which can be compatible with a child-centric lifestyle (Marx et al. 1988; Schwarz et al. 2007). Child-free couples are as likely to own dogs as families with young children and are more likely to own cats (Lawton 2025). Pets fulfill companionship roles in these non-traditional family structures, with a strong sentiment (95-98%) among all owners that pets are family members (American Veterinary Medical Association 2022).

The economic landscape of pet ownership is defined by the concurrent rise of premium spending and an affordability crisis.

- **Humanisation and Premiumisation:** The cultural shift towards viewing pets as family is a primary driver of economic growth in the sector (PetExec 2025). This "humanisation" trend fuels "premiumisation," where owners demand high-quality, natural, and organic products that mirror human consumer trends, driving a growing market for supplements projected to exceed \$1 billion by 2025 (Verdon 2022; PetExec 2025). Spending is not uniform; it is often predicted more by an owner's psychological involvement than by income. For example, the "Pampered Pets" segment, often single and child-free, exhibits the highest spending, while "Casual Caretakers" spend the least, regardless of income (American Veterinary Medical Association 2022).
- **Affordability Crisis:** Despite this premium spending, some owners face an affordability crisis, underestimating the lifetime cost of pet care (CARE for Pets™ 2025). The cost of veterinary services has increased by over 40% since 2019, leading nearly one-third of dog owners to choose between pet expenses and essential bills (Lopez 2025; Special Reports Team 2025).

8. Australian Pet Health-Care Landscape

This section examines the current state of veterinary care in Australia, detailing service usage patterns, the financial burden on owners, and the health challenges facing the nation's companion animals. Understanding this landscape is critical to identifying market gaps for preventative health solutions.

8.1 Australians Vet Service Usage & Cost Burden

The "humanisation" of pets in Australia has reshaped the veterinary service landscape, elevating companion animals to family members and driving an increase in demand for advanced and frequent veterinary care (Forbes et al. 2018). This cultural shift is a primary driver behind the current pressures on the nation's veterinary system, leading to an interplay of service usage patterns and increasing cost burdens for pet owners.

Australia's pet population size directly impacts veterinary service usage. As of 2022, 69% of Australian households own at least one pet, totalling an estimated 28.7 million pets (Animal Medicines Australia 2022; RSPCA Knowledgebase 2023). This represents an expansion from 61% in 2019, attributed to the "pandemic pet boom" (Animal Medicines Australia 2022). This surge created a demand for routine services like vaccinations, microchipping, and desexing. As this cohort of "pandemic pets" ages, the demand for more complex and costly age-related care is expected to continue over the next decade (Animal Medicines Australia 2022).

While pet ownership is correlated with higher-income households and those with children, the motivation for seeking veterinary care is overwhelmingly emotional (Budget Direct 2024; Farmer Pete's 2025). Companionship is cited as the primary reason for pet acquisition by over 70% of owners, and 85% report a positive impact of pets on their lives (Animal Medicines Australia 2022; Budget Direct 2024). This emotional imperative means owners are often less sensitive to the cost of veterinary visits and more inclined to follow veterinary advice, driving demand for advanced diagnostics and specialist care (Forbes et al. 2018; U.S. Chamber of Commerce 2022).

However, this demand can be constrained by practical barriers. The national veterinary workforce shortage can lead to longer wait times and reduced access to care, particularly in emergencies

(Australian Veterinary Association 2024; Niemiec et al. 2024). A 2022 Animal Medicines Australia report found that 68% of Australian owners had considered not visiting a vet when needed, a decision influenced by logistical hurdles as much as cost (Animal Medicines Australia 2022). These access issues are more pronounced in rural and regional areas, where the workforce shortage is more severe, leading to a scarcity of local clinics and after-hours emergency services (New South Wales Parliament. Legislative Council. Portfolio Committee No. 4 - Regional NSW. 2024).

The financial commitment of pet ownership in Australia is considerable. In 2022, Australians spent over \$33 billion on pet-related products and services, with veterinary services representing the second-largest category at 14%, after pet food (51%) (Animal Medicines Australia 2022). However, veterinary expenses are a volatile and unpredictable component, ranging from routine care to emergency procedures (Field 2024).

The unpredictability of high-cost events creates a financial risk that many owners are unprepared for (Field 2024). Indicative costs can range from \$50 for a standard consultation to over \$25,000 for tick paralysis cases (Dial A Vet 2025; RSPCA Pet Insurance 2020). Surgeries like cruciate ligament repair can cost up to \$5,500, while skin conditions can incur bills of \$20,000 (PetSure 2024b; CHOICE 2024). The cost of desexing varies significantly by animal, gender, and size, from as low as \$120 for a male cat to over \$725 for a large female dog (Hanly Vet Clinic 2024; Brisbane Pet Surgery 2025).

The current cost-of-living crisis has increased this financial pressure. A 2024 survey revealed that half of all Australian pet owners have reduced spending on veterinary care due to financial pressures (PetSure 2024b). This "false economy" of cutting back on preventative care risks leading to more severe and costly conditions in the future, transforming an immediate affordability problem into a potential animal welfare and public health concern (PetSure 2024b).

Despite pet insurance being a theoretical solution, its penetration in Australia is low. In 2022, only 17% of dog owners and 12% of cat owners held policies, down from 30% and 21% in 2019, respectively (Animal Medicines Australia 2022). High premiums and a perception of poor value, often due to exclusions for routine care and pre-existing conditions, are cited as reasons for low uptake (Animal Medicines Australia 2022; CHOICE 2024). This market dynamic suggests that the product designed to mitigate financial risk is largely inaccessible or undesirable to many pet owners (Animal Medicines Australia 2022).

8.2 Australian Pet Major Health Issues

The health landscape of Australian companion animals is shaped by common ailments, a growing prevalence of chronic and lifestyle-related diseases, environmental threats, and the burden of inherited conditions. These clinical challenges are intertwined with the economic and societal factors previously discussed.


Data from a pet insurance administrator highlights common conditions that frequently lead to veterinary consultations (PetSure 2024b). For dogs, the most prevalent issues are skin conditions (infections, allergies), gastrointestinal (GIT) issues, and ear infections. For cats, claims most frequently involve GIT conditions, urinary tract disorders, and skin conditions (PetSure 2024b). The costs for these common ailments can be substantial; for example, the average claim for a GIT condition is \$694 for a dog and \$703 for a cat, with maximum recorded claims exceeding \$18,000 and \$14,000, respectively (PetSure 2024b).

Dental disease is another pervasive health issue. While a focus of preventative care, professional scale and polish procedures under anaesthesia can range from \$500 to over \$2,000, with extractions adding

further cost (Australian Animal Oral Care 2025). The Australian Veterinary Association (AVA) has raised concerns about "anaesthesia-free dentistry," clarifying that it is a cosmetic procedure that fails to address pathology below the gumline, which can only be properly treated under anaesthesia (Greystanes Vet 2024; Vet Voice 2025). The demand for such cheaper alternatives is a direct consequence of the financial pressures faced by owners (Greystanes Vet 2024).

Mirroring trends in human health, Australian pets are increasingly affected by chronic and lifestyle-related diseases, reflecting their integration into modern households. Figure 5 illustrates some of the common health issues of Australian cats and dogs.

Figure 5. Common chronic and lifestyle-related diseases of Australian cats and dogs.



- **Obesity:** Recognised as a prevalent form of malnutrition in Australian pets, surveys indicate that up to 41% of dogs and 32% of cats are overweight or obese (PPIAA 2020). Obesity is a condition linked to a higher risk of osteoarthritis, cardiovascular disease, and a shorter lifespan (Greenpet 2024).
- **Arthritis:** A cause of chronic pain, particularly in older animals. Some existing data indicates arthritis is the top health condition for dogs over eight years old, affecting nearly 40% of pets in this age group, with annual management costs ranging from \$600 to \$1,600 (PetSure 2025b). Breeds like Labrador Retrievers and Golden Retrievers show a high incidence of claims for this condition (RSPCA Pet Insurance 2020).
- **Cancer:** A costly disease, with one in four dogs having a claim for cancer during their lifetime (PetSure 2024a). In 2023, total cancer claims for dogs and cats in Australia exceeded \$31 million (PetSure 2025b). Treatment costs are substantial, with average claims for common malignancies like Mast Cell Tumours and Lymphoma ranging from \$2,859 to \$3,636, but maximum costs can exceed \$41,000 (Field 2024; PetSure 2025b).

The rise of these chronic diseases transforms pet ownership into a long-term financial and emotional commitment, supporting demand for premium foods, supplements, and advanced medical treatments (Field 2024). Apart from the chronic diseases, Australia's environment presents specific health risks to pets too.

- **Tick Paralysis:** Caused by the *Ixodes holocyclus* tick, this is a life-threatening emergency prevalent along the eastern seaboard (Animal Emergency Service 2022). Treatment is intensive and expensive, averaging around \$2,000 but with maximum claims reaching over \$53,000 for dogs (GapOnly 2024; Lever 2025). The traditional "tick season" is lengthening, with cases now reported year-round, necessitating continuous parasite prevention (University of Queensland 2023; Animal Medicines Australia 2023).
- **Snake Bites:** A frequent and costly emergency. A single vial of antivenom can cost from \$500 to over \$2,000, with multiple vials often required, leading to total bills in the thousands (Davidson 2025; Coghill 2023).
- **Infectious Diseases:** Despite the availability of effective vaccines, preventable diseases remain a threat. Canine parvovirus affects an estimated 20,000 dogs annually, primarily unvaccinated puppies (McConnochie 2024). Leptospirosis, a bacterial disease, can cause severe organ damage (Australia Wide First Aid 2024). The AVA's vaccination guidelines emphasise core vaccines as crucial for prevention (Australian Veterinary Association 2009).

The increasing popularity of brachycephalic (flat-faced) dog breeds like the French Bulldog and Pug represents an animal welfare concern driven by human aesthetic preferences (Australian Veterinary Association 2023; Pet Insurance Australia 2025). The shortened skull of these breeds leads to Brachycephalic Obstructive Airway Syndrome (BOAS), which compromises breathing, exercise, and thermoregulation (RSPCA Knowledgebase 2025; SPCA New Zealand 2025). Snorting and snoring are clinical signs of respiratory distress, not normal breed characteristics (RightPaw 2023). These breeds also suffer a higher incidence of spinal malformations, eye conditions, and skin disease (RSPCA Knowledgebase 2025). The financial cost is considerable. Corrective BOAS surgery is complex, ranging from \$1,500 to over \$5,500, with some insurance data showing an average claim of \$1,321 and a maximum claim reaching \$12,294 (CHOICE 2024; Melbourne Pet Surgery 2025b; Sydney Bulldog Clinic 2025; SASH Vets 2025).

9. Competitive Analysis: Current Supplement Offerings

9.1 Product Segmentation by Pet Type (Dogs/Cats)

This dominance is due to higher dog ownership rates in key Western markets and a longer history of product development targeting canine health issues (Grand View Research 2024). This segmentation reflects differing ownership rates, historical product development, and the unique health concerns prevalent in each species.

9.1.1 Canine Supplement Market: The Dominant Segment

The canine supplement market forms the foundation of the global industry, consistently commanding the largest share of revenue. This dominance is primarily due to higher dog ownership rates in key Western markets and a longer history of product development targeting common canine health issues (Grand View Research 2024).

9.1.1.1 Market Share and Dynamics

The dog supplement segment consistently captures the largest portion of market revenue, with reports estimating a share of more than 41% of total sales (Grand View Research 2024). The practice

of supplementing canine diets also has a longer history, leading to more mature and well-defined product categories and higher consumer awareness.

9.1.1.2 Key Product Categories & Applications (Canine)

The canine market is highly segmented by specific health concerns, with clear leaders in consumer demand:

- **Hip & Joint Support:** This is the largest and most established application segment, accounting for over 21-25% of the market (Grand View Research 2024; Fortune Business Insights 2025). Its prominence is driven by the high prevalence of osteoarthritis and mobility issues, particularly in large, senior, or genetically predisposed breeds. Key ingredients include glucosamine and chondroitin sulfate (Fortune Business Insights 2025).
- **Skin & Coat Health:** This category addresses common complaints such as excessive scratching, hair loss, dandruff, and allergy-related skin irritation (Grand View Research 2024). Formulations are often rich in omega-3 and omega-6 fatty acids, biotin, and zinc (Natural Dog Company 2025).
- **Digestive Health & Probiotics:** This category is experiencing a surge in popularity, mirroring the human focus on gut health (Howarth 2025). Products feature probiotics, prebiotics, and digestive enzymes to support a balanced intestinal environment (Grand View Research 2024).
- **Behavioural & Calming Aids:** This niche targets anxiety from stressors like separation, thunderstorms, and travel (Allied Market Research 2024). Formulations include traditional herbal ingredients like chamomile and passionflower, and increasingly, cannabidiol (CBD) (Precedence Research 2025b).
- **Multivitamins & Minerals:** Representing a foundational category of preventive care, multivitamins remain the largest segment by product type, distinct from application-specific formulas (Precedence Research 2025b).

9.1.1.3 Formulation and Ingredient Spotlight (Canine)

- **Delivery Forms:** Palatability and ease of administration are paramount. Chewable supplements are the dominant delivery form, accounting for approximately 70% of global revenue, while powders are the second most popular and are growing quickly due to ease of mixing into food (Grand View Research 2024).
- **Ingredient Trends:** The "clean label" movement drives demand for natural and recognisable ingredients, including botanicals like turmeric, green-lipped mussel extract, and spirulina (Supplement Factory UK 2025). Major players are developing science-backed formulations to meet this demand (Grand View Research 2024).
- **Personalisation:** The market is moving towards life-stage-specific formulas (e.g., puppy, adult, senior) and breed-specific products targeting known health predispositions (Hewitt 2025).

9.1.2 Feline Supplement Market: The Growth Frontier

While the canine market is the industry's established core, the feline market is a significant growth frontier. Historically underserved, the cat supplement segment is now experiencing rapid expansion, driven by shifts in owner demographics and a growing recognition of cats' unique health needs.

9.1.2.1 Market Share and Growth Trajectory

The cat supplement market holds a smaller revenue share than the dog segment, estimated at around 21% of sales in one analysis (Hewitt 2025). However, it is projected to have a high CAGR, with some forecasts as high as 10.4% (Grand View Research 2024). This accelerated growth is propelled by an

increase in multi-cat households and the emergence of younger, highly engaged male cat owners among Millennials and Gen Z, who are more likely to invest in premium products and specialised supplements (Muller 2025).

9.1.2.2 Unique Feline Product Categories & Applications

The feline market is defined by several highly specific health issues requiring targeted solutions:

- **Urinary Tract and Kidney Support:** This is a critical and distinct category, as cats are prone to Feline Lower Urinary Tract Disease (FLUTD) and chronic kidney disease (Under the Weather Pet 2025). Demand is strong for supplements with ingredients like cranberry extract, D-mannose, and N-acetyl glucosamine (Under the Weather Pet 2025).
- **Hairball Control:** A uniquely feline challenge stemming from meticulous grooming habits. Products typically use fibre (e.g., psyllium husk) to aid hair passage or focus on improving skin and coat health to reduce shedding (NaturVet 2025; Wellnenergy Pets 2025).
- **Calming & Anxiety Relief:** Relevant for modern housecats, addressing stress from indoor confinement or environmental changes. Innovation includes science-backed ingredients like specific probiotic strains (Purina Pro Plan Veterinary Supplements 2025).
- **Dental Health:** Given the difficulty of brushing cats' teeth, owners often turn to functional treats and supplements to help reduce tartar buildup (Grange Co-op 2025).

9.1.2.3 Formulation and Ingredient Spotlight (Feline)

Success in the feline supplement market hinges on addressing the discerning nature of cats.

- **Palatability is Paramount:** The greatest challenge is ensuring consumption. This drives innovation in delivery forms, with a strong preference for highly palatable options like powders mixed into wet food, savory liquids, and soft chews with appealing flavours (Under the Weather Pet 2025; Pet Honesty 2024). Traditional pills are often a last resort.
- **Ingredient Focus:** Formulations must be tailored to feline physiology, including essential nutrients like taurine, which is crucial for heart and eye health (Under the Weather Pet 2025). It is equally important to avoid ingredients toxic to cats but safe for dogs. Leading brands emphasise expert-led, science-backed approaches for feline-specific needs (Purina Pro Plan Veterinary Supplements 2025).

9.2 Product Segmentation by Form (Tablets, Chews, Liquids, etc.)

The physical form of a pet supplement is a strategic determinant, influencing consumer preference, manufacturing complexity, and regulatory navigation. Understanding the nuances of each form is essential for effective market positioning.

9.2.1 Chewable Supplements (Soft Chews, Tablets, Capsules): The Market Leader

The chewable segment, encompassing soft chews, chewable tablets, and traditional capsules, is a leading segment in the pet supplement market. Its dominance stems from a deep understanding of consumer psychology and formulation science that prioritises convenience and palatability. Chewable forms command a significant portion of the global pet supplement market, with estimates of their share ranging from 46% to 70% of total revenue (Grand View Research 2024). This market leadership is a direct result of consumer demand for convenience and ease of administration (Petfood Industry 2023).

- **Soft Chews:** These are highly palatable, often positioned as a "preferred delivery method" by manufacturers and pet owners (Garmon Corp. 2025). Their success lies in the "treatification" of health products, transforming daily supplementation into a positive, rewarding interaction that strengthens the human-animal bond (UK Pet Food 2025). This strategy aligns perfectly with the pet humanisation trend. Examples include joint support, multivitamins, and calming aids (DiLonardo 2024). A formulation consideration is that binders, fillers, and flavourings necessary for texture and taste can dilute the concentration of active ingredients, potentially requiring a larger serving size (Nyamweya and Kimani 2020).
- **Tablets & Capsules:** The key advantage of tablets and capsules is their ability to deliver a higher concentration of active ingredients in a more compact and often more cost-effective format (Garmon Corp. 2025). This makes them well-suited for more therapeutic applications or for ingredients with strong, unpleasant tastes difficult to mask in soft chews (Nyamweya and Kimani 2020). A consideration is administration difficulty, as some pets resist "pilling," which can lead to stress for both owner and animal and reduced compliance (Chewy 2025b). This form is also frequently used by compounding pharmacies for precise medication doses (Chewy 2025b).

The "treatification" of chewable supplements, while enhancing palatability, creates a strategic and health-related challenge. Regulatory bodies like the Association of American Feed Control Officials (AAFCO) differentiate between a "treat" (not required to be nutritionally complete) and "food" (which must be) (AAFCO 2025a). The U.S. Food and Drug Administration (FDA) regulates pet supplements as food (FDA 2024). When palatable chewable supplements are marketed and used like treats, there is a risk of pet owners administering more than the recommended dose, potentially leading to overconsumption of certain nutrients or unbalancing an already complete diet (UK Pet Food 2025). This blurred line creates consumer confusion and liability risk for manufacturers, necessitating careful consideration in product labeling, dosage instructions, and marketing communications.

9.2.2 Liquid and Powder Supplements: The High-Growth Frontier

While chewables are a dominant form, the liquid and powder segments represent a high-growth frontier, appealing to a different consumer mindset and presenting unique formulation considerations and opportunities. Market analyses consistently identify powders and liquids as the fastest-growing forms. Powders are projected to exhibit the highest CAGR, valued for their ease of use and effectiveness with picky eaters who may reject solid chews (Grand View Research 2024). They can be seamlessly mixed into a pet's regular meal, making administration effortless. Prominent examples include probiotic powders and comprehensive nutritional powders (DiLonardo 2024).

The liquid segment is a particular area of innovation, with brands aggressively marketing products as "meal toppers" or "in the bowl" enhancers (Petfood Industry 2023). Companies are launching liquid supplements with appealing bases like salmon oil and bone broth, boosted with active ingredients (Business Wire 2024). This format is especially popular for delivering omega-3 fatty acids and high-calorie supplements for weight gain or recovery (Chewy 2025a).

A key selling point for liquid and powder supplements is the claim of faster or enhanced absorption compared to solid forms (Grand View Research 2024). This aligns with consumer intuition and bioavailability principles, suggesting nutrients in a less-processed state may be more readily absorbed (Houston 2025). This benefit comes with increased formulation complexity and considerations for product stability. Unlike solid forms, liquids and powders are highly susceptible to degradation. Key active ingredients, particularly fat-soluble vitamins (A, D, E) and certain B vitamins, can be affected by

oxidation when exposed to moisture, oxygen, heat, light, and reactive trace minerals (Mavromichalis 2016). To counteract this, formulators must employ advanced techniques, such as using more stable esterified forms of vitamins, protective coatings, microencapsulation technologies, and adding stabilisers and antioxidants (Mavromichalis 2016). Consequently, the shelf life of liquid products is often shorter and more dependent on proper storage conditions (e.g., refrigeration, protection from light) than solid counterparts (South Surrey Veterinary Hospital 2012).

Table 1 provides a summary of the findings around the main supplement forms.

Delivery Form	Key Advantages	Key Considerations & Challenges
Soft Chews	High palatability; positioned as a treat. Leverages pet humanisation trend. Strong consumer preference and convenience.	Binders and fillers can dilute active ingredient concentration. Risk of over-dosing by owners viewing it as a treat.
Tablets & Capsules	Delivers higher concentration of active ingredients. More cost-effective format. Suitable for ingredients with unpleasant tastes.	Administration can be difficult, leading to owner stress and reduced compliance.
Powders & Liquids	Fastest-growing segment. Easy to administer by mixing into food, ideal for picky eaters. Can claim faster/enhanced absorption.	Susceptible to degradation from moisture, oxygen, and heat. Shorter shelf life and requires specific storage. Higher formulation complexity to ensure stability.

9.2.3 Transdermal and Ophthalmic Forms: Niche, Medically-Adjacent Segments

Transdermal and ophthalmic delivery systems do not operate within the conventional over-the-counter (OTC) pet supplement market. They are typically delivery mechanisms for veterinary drugs, governed by different rules and facing unique scientific considerations.

- **Transdermal Delivery:** This involves applying a drug, formulated into a gel, cream, or patch, to the skin for systemic absorption (Boothe 2024). It is advantageous as it bypasses the gastrointestinal tract, useful for pets that are vomiting or for drugs heavily metabolised by the liver (Boothe 2024). Common transdermal veterinary drugs include methimazole for feline hyperthyroidism, fluoxetine for behavioural disorders, and fentanyl for pain management (CareFirst Specialty Pharmacy 2025). Despite its potential, the efficacy of transdermal drug delivery in veterinary patients is a topic of scientific debate due to the skin's barrier and variable absorption influenced by factors like fur, skin thickness, and species-specific physiology (Mills and Cross 2006). Research shows that simple extrapolation of data between species is unreliable (Mills and Cross 2006), and studies on the same drug can yield conflicting results regarding absorption and efficacy (Marks 2003). For these reasons, veterinarians often caution against using compounded transdermal drugs unless oral routes are impossible and clear clinical endpoints can track effectiveness (Little 2008). The scientific hurdles and variable performance make this route generally unsuitable for the less rigorous standards of OTC supplements.
- **Ophthalmic Delivery:** This category is dominated by pharmaceutical products. True ophthalmic delivery systems, such as topical eye drops or ointments, are used to administer

drugs directly to the eye for conditions like glaucoma or bacterial infections (Hamilton 2024). Biological barriers to ocular delivery are significant, including the tear film and cornea's multiple layers, making effective topical delivery challenging (Weiner and Gilger 2010). The term "ophthalmic supplement" in the consumer market almost always refers to oral supplements formulated to support eye health. These products come in conventional forms like soft chews or capsules and contain ingredients scientifically linked to ocular health, such as lutein, zeaxanthin, omega-3 fatty acids, and Vitamin A (Animal Necessity 2025). Therefore, the viable strategic path for a non-pharmaceutical company is not to develop a topical eye drop, but to formulate an oral product that taps into the growing consumer interest in preventative eye care.

9.3 Ingredient & Formulation Landscape

The formulation of pet supplements, particularly those with a red meat base, involves the strategic inclusion of various functional ingredients to enhance their nutritional profile and deliver targeted health benefits. While red meat provides a foundation of protein and certain micronutrients, strategic fortification can enhance its profile to create a comprehensive and functional product.

9.3.1 Vitamins, Minerals, Omega-3s and 6s, Probiotics, Botanical Extracts

Red meat is a natural source of several essential vitamins and minerals, including B-vitamins (especially B12), heme iron, zinc, and selenium (The Vets 2025). To ensure a complete and balanced product and meet consumer demand for comprehensive nutritional solutions, commercial supplements are often fortified with additional vitamins and minerals via premixes (The Vets 2025; Sustainable Pet Foods 2025).

While essential for life, the necessity of additional vitamin and mineral supplementation for pets consuming complete and balanced commercial diets is debated within the veterinary community. Healthy pets on AAFCO or FEDIAF compliant diets generally receive 100% of their daily nutrient requirements, making additional supplementation often unnecessary (Purina Institute 2025; Heinze 2018). Over-supplementation, particularly with fat-soluble vitamins (A, D, E, K) and certain minerals, can lead to accumulation and potentially toxic levels in the body, causing issues such as bone malformations, kidney damage, or urinary stones (Heinze 2018; Coates 2023).

Despite these risks, the market for these supplements is driven by consumer perception of "nutritional insurance" and the desire to provide "optimal fitness and health" (The Vet Is In 2016). For red meat-based supplements, the inclusion of organ meats like liver can naturally boost the content of Vitamin A and iron, providing a "whole food" narrative for marketing and enhancing the nutritional profile (The Vets 2025; Sustainable Pet Foods 2025). Formulators may also consider organic or chelated mineral forms, which are believed to offer superior bioavailability (Barroso, Fonseca and Cabrita 2024).

Essential fatty acids (EFAs), particularly omega-3s and omega-6s, are crucial for health but cannot be synthesised by pets, making dietary intake essential (Elanco 2025). This presents a formulation consideration: while red meat provides a palatable base, it is naturally rich in omega-6 fatty acids, which are precursors to pro-inflammatory molecules (Elanco 2025; Dog Food Advisor 2024). If not properly balanced, a red meat-heavy supplement could contribute to inflammation.

To achieve a therapeutic, anti-inflammatory effect, red meat-based supplements can be effectively fortified with concentrated sources of omega-3s, specifically eicosapentaenoic acid (EPA) and

docosahexaenoic acid (DHA), primarily sourced from marine oils like fish oil (Bauer 2011). Plant-based omega-3s, such as alpha-linolenic acid (ALA) from flaxseed oil, are less efficiently converted to EPA and DHA in pets, making marine sources superior for therapeutic purposes (Bauer 2011). The clinical evidence supporting the efficacy of EPA and DHA for joint health, skin conditions, and cognitive function in pets is robust, making this fortification a valuable strategy for creating a high-value product (Purina Institute 2025; Elanco 2025).

Probiotics, live beneficial microorganisms, are a leading category in pet supplements, driven by the growing understanding of the gut microbiome's impact on digestion, immunity, and overall wellness (Lee et al. 2022; Honest Paws 2025). Common genera used include *Lactobacillus*, *Bifidobacterium*, and *Enterococcus*, along with the beneficial yeast *Saccharomyces boulardii* (PetMD Vet Advisory Panel 2025).

The efficacy of probiotics is strain-specific and species-dependent, meaning research-backed, species-appropriate strains are crucial for effective products (Lee et al. 2022; Vetster Editorial Team 2024). For instance, *Enterococcus faecium* SF68 is proven to manage acute diarrhea in dogs and cats, while *Bifidobacterium longum* BL999 has shown promise in reducing anxiety-related behaviours in dogs (Lee et al. 2022; Cornell University College of Veterinary Medicine 2025b). A key consideration in formulating probiotic supplements, especially within a red meat matrix, is ensuring the viability of the microorganisms through manufacturing, shelf life, and the pet's digestive tract (Jeromin 2018). Dosage is measured in Colony Forming Units (CFUs), and many commercial products fail to meet their label claims for live bacteria (Jeromin 2018; Dog Is Human 2025). Strategies to overcome this include selecting robust, shelf-stable strains (e.g., spore-forming bacteria like *Bacillus coagulans*), utilising protective technologies like microencapsulation, and conducting rigorous stability testing (Sandra 2024; Only Natural Pet 2025). The inclusion of prebiotics (e.g., inulin, FOS) can further support probiotic efficacy by providing a food source for beneficial gut bacteria (Honest Paws 2025).

Botanical extracts, or phytogenics, are a growing segment driven by consumer demand for "natural" solutions, often marketed for their antioxidant and anti-inflammatory properties (Guo et al. 2024; Innova Market Insights 2024). However, this category can be characterised by a gap between anecdotal claims and validated evidence, with considerations related to bioavailability and safety (Vetster Editorial Team 2024; Guo et al. 2024).

- **Turmeric (Curcumin):** While in vitro research shows curcumin's potent anti-inflammatory properties, its practical application is severely limited by extremely poor bioavailability; less than 1% of orally administered curcumin from simple turmeric powder is absorbed (DogCancer.com 2024). Effective formulations must use enhanced-bioavailability forms, such as combinations with piperine or patented technologies, to be clinically relevant (Silver 2007).
- **Milk Thistle (Silymarin):** Widely recognised for liver support, silymarin is believed to act as an antioxidant and anti-inflammatory agent (Gollakner and Yuill 2022). Despite its widespread use and acceptance by veterinarians, large-scale, randomised, placebo-controlled clinical trials in dogs and cats are lacking, with much evidence being anecdotal or extrapolated from human studies (Gollakner and Yuill 2022; Brooks 2020).
- **Ashwagandha:** This adaptogenic herb is gaining traction for its anti-stress properties. Recent double-blind, placebo-controlled trials in stressed cats showed a significant decrease in serum cortisol and inflammation markers, while a study in geriatric dogs indicated beneficial modulation of gut microbiome metabolites (Devarasetti et al. 2024; Bharani et al. 2025). This emerging, pet-specific clinical data provides a strong scientific basis for its use.

The "Natural Fallacy", i.e., the assumption that natural ingredients are inherently safe, is a consideration, as many botanicals lack proven efficacy and some can be toxic to pets (Vetster Editorial Team 2024; Guo et al. 2024). For red meat-based supplements incorporating botanicals, the focus is on standardised, bioavailable extracts with clinical evidence in the target species to build credibility.

9.3.2 Alternative Novelty Pet Supplement Products

The landscape of pet supplements is continually evolving, driven by consumer demand for specialised and health-focused products. This has led to the emergence of "novelty pet supplements," which encompass ingredients and products that are new or uncommon to a pet's diet, specifically chosen because the animal has not been previously exposed to them (Thrive Pet Healthcare 2025). These ingredients typically exclude widely used proteins such as lamb, chicken, and beef (Thrive Pet Healthcare 2025). Their primary purpose often revolves around strategic nutritional approaches for managing food allergies and sensitivities in dogs and cats, as allergic reactions can develop through repeated exposure to specific proteins (Lloyd 2025; Thrive Pet Healthcare 2025). Beyond allergy management, these supplements can also play a role in addressing gastrointestinal conditions like inflammatory bowel disease (IBD) (Thrive Pet Healthcare 2025). The scope of "novel ingredients" extends beyond just protein sources to include those offering unique nutritional or functional benefits, such as specific botanicals, prebiotics, and probiotics not traditionally common in pet diets (Adolphe 2017).

9.3.2.1 Insect-Based Pet Supplements

The protein density of insect sources is a competitive advantage. Their amino acid profiles provide all ten essential amino acids required by dogs and taurine for cats (UK Pet Food 2021).

- **Nutritional Profile and Benefits:** Beyond protein, insect-based ingredients are rich in beneficial fats, particularly unsaturated fatty acids like oleic and linoleic acids. Black Soldier Fly larvae, for example, contain higher levels of lauric and myristic acids, with lauric acid demonstrating antibacterial and anti-inflammatory properties (Useful Fly Trading LLC 2025; Wall 2025). A key advantage is their high digestibility due to a balanced amino acid profile, low chitin content, and absence of anti-nutrients (Nature's Protection 2025). This makes them an option for hypoallergenic or elimination diets due to their novelty (Thrive Pet Healthcare 2025). Furthermore, chitin, a natural fibre found in insects, contributes to gut health by acting as a prebiotic, fostering beneficial gut bacteria, aiding digestion, and strengthening intestinal immunity (Useful Fly Trading LLC 2025). Despite their potential, nutritional adequacy is a consideration. While many products meet basic AAFCO guidelines for crude protein and fat, studies have revealed discrepancies between labeled and actual nutrient content in some commercial insect-based pet foods, with potential deficiencies or imbalances in essential minerals such as calcium, phosphorus, zinc, iron, and copper (Wall 2025). Imbalances in the crucial calcium-to-phosphorus ratio and unfavorable omega-6 to omega-3 fatty acid ratios have also been noted (Wall 2025). These imbalances could potentially contribute to long-term health issues like skeletal disorders or inflammatory conditions, particularly in growing animals (Wall 2025). More extensive, long-term research is needed to fully evaluate their nutritional adequacy, safety, and long-term health effects across all pet life stages (Wall 2025). Allergenicity is another consideration; while marketed as hypoallergenic, studies suggest a potential for cross-reactivity between mealworm proteins and mites (a common dog allergen), given their phylogenetic relationship as arthropods (Pajer 2024; Premrov Bajuk et al. 2021). The presence of specific insect proteins, like tropomyosin and alpha-amylase, known human allergens, also raises questions about their universal hypoallergenic status for pets

(Premrov Bajuk et al. 2021). Contamination risks from infectious organisms and heavy metals also necessitate control measures during production (Bosch et al. 2014).

9.3.2.2 Plant-Based Pet Supplements

Plant-based pet supplements are free from animal-derived ingredients.

- **Nutritional Profile and Benefits:** These supplements can offer high-quality proteins from sources like peas, lentils, quinoa, and yeast, which are capable of providing all essential amino acids required by dogs (Ali 2025). Soy is also a recognised and nutritious plant protein source (Market.us 2025). A key benefit is their potential for allergy relief, making them suitable for pets with food sensitivities (Lloyd 2025). Plant-based formulations are often rich in fibre from ingredients like sweet potatoes, brown rice, and oats, which promotes healthy digestion, ensures regular bowel movements, and supports overall gut health (Ali 2025). Their typical composition, often lower in unhealthy fats and high in nutrient-dense ingredients, can also aid in healthy weight management (Ali 2025).
- **Specific Functional Ingredients:** Many plant-based supplements incorporate specific functional ingredients that offer targeted health benefits (Austin and Kat 2025):
 - **Anthocyanins (blueberries):** Beneficial for eye and nervous system health, brain protection, memory, cognitive function, and stabilising sleep cycles, particularly in senior dogs.
 - **Sulforaphane (broccoli sprouts):** Contributes to a strong immune system, aids in defense against pathogens and microbes, and supports age-related immunity.
 - **Boswellia (frankincense) extracts:** Effective at reducing occasional joint pain and supporting bone structure, joint mobility, and even digestion.
 - **Cinnamon extracts:** Possess powerful antioxidants that can help improve joint health, support active muscles, and normalise systemic inflammation.

Challenges: Plant-based pet diets present considerations concerning their nutritional adequacy and bioavailability, especially for cats, who are obligate carnivores with exacting nutritional needs. Cats require essential nutrients like taurine, preformed vitamin A, and cysteine, which are minimal or absent in plant ingredients (Harsini et al. 2024). Considerations exist regarding the bioavailability of synthetic supplements used to fortify vegan diets (BVA 2024). Surveys of vegetarian dogs have found deficiencies in protein, essential amino acids, calcium, zinc, and vitamins D and B12 (FEDIAF 2024). The body of long-term research on the nutritional adequacy and safety of vegan pet diets is still developing (BVA 2024; Domínguez-Oliva et al. 2023).

9.3.2.3 Other Emerging Novel Sources

Beyond insects and plants, other innovative sources are emerging for pet supplements.

- **Cultivated Meat (Lab-Grown Meat):** This technology involves growing animal cells in a controlled environment (Marlin 2025). Cultivated meat offers potential for consistent nutritional profiles (Marlin 2025). It could also be engineered to eliminate specific proteins that trigger allergic reactions, providing a truly novel solution for sensitive pets (Marlin 2025). Peer-reviewed research supports the safety, high digestibility, and potential gut health benefits of certain cultured proteins in adult dogs (Petfood Industry 2025).
- **Single-Cell Proteins (SCPs):** Also known as microbial proteins, SCPs are derived from microbial biomass, including yeast, fungi, and algae (Zhuang et al. 2024). They are characterised by their protein content, typically ranging from 30% to 75% by dry cell weight, often surpassing that of soy, fish, meat, and whole milk (Zhuang et al. 2024). The spectrum of SCPs offers diverse nutritional profiles and functional benefits:

- **Algae (Microalgae):** Often considered "superfoods" for pets due to their nutritional content, providing quality protein (typically 50-70% dry weight), vitamins (B vitamins, vitamin A precursors, vitamin E), and minerals (iron, magnesium) (Phycom 2025). Benefits include immune system modulation, support for skin and coat health through omega fatty acids and antioxidants, digestive support, gut health via fibres and prebiotics, and detoxification capabilities (Phycom 2025). Omega-3 algae oil can provide essential DHA and EPA (Pet Releaf 2024).
- **Fungi (Mushrooms, Mycoproteins):** Medicinal mushrooms such as Turkey Tail, Red Reishi, and Lion's Mane are sources of beta-glucans, known to promote immune health by activating white blood cells and reducing inflammation (Standard Process 2025). Mycoproteins, another fungal protein, demonstrate high digestibility and have been shown to improve gut microbiome diversity in dogs (Jose 2025).

9.3.2.4 Additional Novel Functional Ingredients

Beyond novel protein sources, the market incorporates innovative functional ingredients that target specific physiological functions. While some ingredients might have traditional counterparts, their specific forms or targeted applications within the "alternative" segment signify their novelty.

- **N,N-Dimethylglycine (DMG):** This amino acid derivative supports cardiovascular health, liver function, detoxification, neurological health, brain activity, and immune response, while also helping to reduce lactic acid buildup (VetriScience Pro Line 2025).
- **Colostrum:** Bovine colostrum is utilised for its ability to support brain activity, promote relaxation and cognitive function, and bolster the immune system (Standard Process 2025).
- **Green Lipped Mussel Powder (GLMP):** A natural source of Omega-3 fatty acids (EPAs, DHAs, ETAs) that play a supportive role in normal joint function (Australian Pet Organics 2025).

The focus on these novel and alternative ingredients reflects a strong consumer demand for "clean label" and "natural" products, often seeking to avoid common ingredients like artificial additives, soy, and corn (Wellness Pet Food Australia 2025). These novel sources can effectively fill this market niche by offering alternatives to these often-avoided components.

9.3.3 Existing Use of Red Meat Ingredients

Red meat ingredients, including various cuts and by-products, are foundational components within the Australian pet supplement and food market, driven by consumer demand for "humanisation" and "clean label" products. The industry leverages specific red meat types and forms to cater to diverse consumer preferences and nutritional needs, often employing strategic marketing narratives to highlight quality.

9.3.3.1 Common Red Meat Sources and Market Positioning

Different red meat sources are positioned to appeal to specific consumer segments, from mainstream to super-premium.

- **Beef:** As a widely used primary protein source, beef is valued for muscle development and energy provision. It is frequently listed as the first ingredient in formulations, a key purchasing driver for consumers seeking "real meat" in products (ACANA 2025; Bet Pets 2025). Beef muscle meat provides high-quality protein, B vitamins (like B12), zinc, and iron, which support

metabolism, red blood cell production, and immune function (Cooper 2024; Portland Pet Food Company 2025).

- **Lamb:** Often marketed as a "novel protein," lamb is a popular choice for pets with food sensitivities or allergies to common proteins like beef or chicken (Barrington 2025). It is promoted as a highly digestible protein rich in essential amino acids and fatty acids, beneficial for skin and coat health (Bet Pets 2025). Grass-fed lamb, in particular, is highlighted for its higher omega-3 fatty acid content, which offers anti-inflammatory benefits for joint health and overall wellness (Barrington 2025).
- **Venison & Bison:** These meats are positioned in the premium and super-premium segments, marketed as lean, digestible, and "ancestral" protein sources (chrisandtonya519 2025). Venison is a lean option suitable for pets with food sensitivities or those on weight management plans, providing B vitamins (B6, B12), iron, zinc, and phosphorus (Addiction Pet Foods 2025). Bison is also a high-protein, lean alternative, noted for its iron, zinc, and selenium content, with beta-carotene in its fat supporting skin and eye health (Buck Wild Bison 2024; NutriSource Pet Foods 2025).

9.3.3.2 The Rise of Organ Meats as "Superfoods"

A significant trend in premium supplements is the explicit naming of organ meats on ingredient labels, moving away from the generic "meat by-products" term (Lambrakis and Kersey 2021). This strategic shift allows manufacturers to highlight the nutritional value of these ingredients, rebranding them as "superfoods" due to their dense nutrient profiles.

Beef liver is widely regarded as a premier "superfood." It is a concentrated natural source of Vitamin A (vital for vision and immune function), B vitamins (especially B12 for nervous system health), highly bioavailable heme iron (for preventing anemia), copper, and zinc (Best Friends Veterinary Hospital 2025; Cooper 2024; Oma's Pride 2024; Raw & Fresh 2022a). This concentration of Vitamin A, however, presents a consideration for toxicity that limits its practical inclusion in pet food formulations to 5-10% of dry matter (Kim et al. 2023). Recent innovations in processing have shown that the Vitamin A content can be substantially reduced, potentially enabling higher inclusion rates. Post-extraction liver could be safely incorporated at levels of 18-37% for fresh liver products and over 46% for dehydrated liver products, transforming it into a more versatile and valuable bulk ingredient (Kim et al. 2023).

Other organs are also increasingly featured in premium formulas. Beef tripe is included for its digestive enzymes and probiotics, beef heart is prized for its high concentration of Coenzyme Q10, and lamb heart and kidneys are valued for taurine and selenium, respectively (Zealandia 2025).


9.3.3.3 Ingredient Forms and Processing Technologies

The physical form and processing method of red meat ingredients significantly impact the final product's nutritional makeup, cost, and consumer perception.

- **Whole/Fresh/Raw vs. Meal:** While "Real Beef First Ingredient" is a marketing tool, this claim can be misleading. Fresh meat contains 70-80% water, which is removed during processing (Kinetic Dog Food 2024). As illustrated by Fig. 6, a product listing "Beef Meal" (a concentrated, rendered protein powder) as a second or third ingredient may ultimately provide more actual animal protein by dry weight than a product that lists "Beef" as the first ingredient (Kinetic Dog Food 2024). This distinction is critical for assessing the true protein content of a supplement.
- **Innovative Processing Methods:** To bridge the gap between convenience and the perceived benefits of raw diets, manufacturers are employing advanced processing technologies.

- **Freeze-Dried Coatings:** This technique involves applying a coating of freeze-dried red meat (e.g., beef, lamb) to conventional supplements or kibble. Freeze-drying preserves the original structure, flavour, and nutritional content by avoiding high heat, allowing brands to market a "taste of raw" (Chen et al. 2021; Yao et al. 2023). However, it is an expensive, energy-intensive process, and a safety consideration is that it preserves bacteria rather than killing them, posing a microbial risk if the raw meat is contaminated (Jessica 2021; Yao et al. 2023). Some freeze drying companies have built in "kill steps" into their freeze drying processes such as Forager Foods (Barlow 2025).
- **Cold-Pressing:** Marketed as a "gently cooked" alternative, cold-pressing involves processing ingredients at low temperatures (42-46°C). This method aims to retain more natural nutrients, flavours, and aromas than high-heat extrusion, resulting in highly digestible and palatable products. The trade-off is often a shorter shelf life due to higher moisture content and the absence of preservatives (Jessica 2021).

Figure 6. The potential of innovative processing methods (Beef Meal) to provide higher protein content rather than a meat-first ingredient option (Real Beef).



The formulation of red meat supplements is an interplay of nutritional science, processing technology, and marketing strategy. Manufacturers often leverage the semantic gap between technical definitions (e.g., AAFCO ingredient definitions) and consumer interpretations to differentiate products and highlight perceived quality (AAFCO 2025b).

10. Economic & Health Impact Assessment

10.1 Cost Analysis of Veterinary Treatments vs. Preventative Supplements

The financial commitment of pet ownership in Australia is substantial and growing, with average annual household expenditures reaching \$4,247 for dogs and \$2,718 for cats (Choosi 2025). A significant portion of this spending is directed towards veterinary services and healthcare products, with average annual veterinary bills for owners who visit a vet within a year being \$631 for dogs and \$388 for cats (Choosi 2025). This section provides a cost analysis, comparing the financial impact of reactive veterinary treatments with the investment in preventative supplements, aiming to establish a data-driven framework for the economic value proposition of preventative care.

10.1.1 The Financial Burden of Reactive Veterinary Care

Reactive care involves managing health conditions after they manifest, incurring costs that can place a burden on pet owners.

- **Foundational and Emergency Expenses:** A standard veterinary consultation typically ranges from \$50 to \$110, with extended consultations costing up to \$180 (Dial A Vet 2025). These costs escalate dramatically in emergencies, with after-hours consultations starting at \$200 to \$400 before any diagnostics or treatments are administered (Choosi 2025).
- **Acute and Critical Intervention Costs:** Common illnesses can lead to notable bills. Treating gastrointestinal upsets averages \$416 to \$636, while skin allergies average \$520 for dogs and \$451 for cats (McGrath 2023). Major medical events represent significant financial risks. Surgery for a cranial cruciate ligament (CCL) rupture can range from \$2,000 to \$8,000, while removing an ingested foreign object averages \$1,800 to \$2,800 but can escalate to as high as \$41,000 in complex cases (Choosi 2025; Paszkowski 2025a; Sandringham Vet Hospital 2025; Melbourne Pet Surgery 2025a). Cancer treatment can range from \$700 for simple lump removal to over \$30,000 for complex cases, and environmental emergencies like tick paralysis or snake bites average between \$1,859 and \$2,500 per incident (Choosi 2025; Thach 2025).
- **Long-Term Cost of Chronic Disease Management:** Managing chronic conditions incurs cumulative financial burdens. Canine osteoarthritis (OA) can cost over \$1,000 annually for medications and injections alone, excluding regular check-ups (PetSecure 2017). Feline chronic kidney disease (CKD) can cost over \$400 per month, totaling nearly \$5,000 annually for specialised diets, medication, and fluid therapy (Localvet 2024).

10.1.2 The Proactive Investment in Preventative Measures

A proactive strategy involves smaller, regular investments in preventative measures designed to maintain health and mitigate the risk of costly diseases.

Essential Prophylactics: Core preventative care includes parasite control and vaccinations. All-in-one monthly chewables for a large dog cost approximately \$26 each, leading to an annual cost of around \$315 (Vets Love Pets 2025; Pacific Pet Supplies 2025). Annual booster vaccinations and health checks typically cost \$90–\$145 (RSPCA New South Wales 2025).

Preventative Supplements: The cost of supplements varies by health indication and formulation.

- **Joint Health:** For a medium-sized dog, annual costs can range from approximately \$228 for a powder product to around \$324 for a premium capsule product (VetProductsDirect 2025; VetShopAustralia 2025; Petz Park 2025).
- **Digestive Health:** Daily use of a probiotic powder can lead to an annual cost of approximately \$460 (Pet Chemist 2025).
- **Skin & Coat (Omega-3s):** For a medium-sized dog, an omega-3 oil supplement costs approximately \$154 annually (Budget Pet Products 2025; VetShopAustralia 2025).

Preventative Dental Care: While a professional dental cleaning under anaesthesia costs \$300–\$800 and can exceed \$2,000 with extractions, at-home preventative measures are significantly cheaper (Dial A Vet 2025; Melbourne Pet Surgery 2025a). Daily VOHC-accepted dental chews can cost as little as \$74 annually (VetShopAustralia 2025).

10.1.3 Return on Investment (ROI) Analysis: Key Case Studies

By directly comparing reactive and proactive costs for common chronic conditions, a potential Return on Investment (ROI) for preventative strategies becomes apparent.

10.1.3.1 Case Study 1: Canine Osteoarthritis (OA)

Reactive Pathway (5-Year Projection): Managing mild hip OA after diagnosis, including injections, and NSAIDs, totals approximately \$5,000 over five years. This does not include bi-annual check-ups or other potential issues (PetSecure 2017).

Proactive Pathway (5-Year Projection): Investing in a high-quality Omega-3 supplement at an annual cost of \$324, starting two years prior to typical diagnosis, totals \$1,620 over five years (VetShopAustralia 2025).

Analysis & ROI: A proactive investment of \$1,620 versus a reactive cost of 7,240 yields a potential saving of over 5,600. This financial case is supported by scientific evidence showing Omega-3s can reduce inflammation and pain, potentially delaying onset or reducing the need for NSAIDs (Barbeau-Grégoire et al. 2022; Kampa et al. 2023).

10.1.3.2 Case Study 2: Canine Periodontal Disease

Reactive Pathway (6-Year Projection): A small breed dog with no at-home care might require a professional dental cleaning for Grade 2 disease (~\$700) and a later, more extensive procedure with extractions (\$1500-\$1950) and for a total reactive cost of \$2,200-\$2,650 (Melbourne Pet Surgery 2025a; Walkerville Vet 2024).

Proactive Pathway (6-Year Projection): Consistent daily use of VOHC-accepted dental chews at an annual cost of ~\$200 totals about \$1200 over six years (Veterinary Oral Health Council 2022; Petbarn 2025).

Analysis & ROI: A proactive investment prevents a reactive cost that is about two times higher. VOHC-accepted products are clinically proven to reduce plaque and tartar, directly slowing disease progression and delaying or preventing costly procedures (Stuart 2024; Hennet, Servet and Venet 2006).

10.1.3.3 Case Study 3: Canine Atopic Dermatitis


Reactive Pathway (Annual Cost): Managing flare-ups with multiple vet consults, allergy testing, and expensive pharmaceuticals can cost \$1,000-2,500+ annually (Chircop 2024).

Proactive Pathway (Annual Cost): Daily Omega-3 supplementation (~154/year) and probiotic supplementation (~60/year) total approximately \$214 annually (Pet Chemist 2025; Budget Pet Products 2025).

Analysis & ROI: A proactive investment of about \$614 compares favorably to reactive costs of \$1,000-2,500+ per year. Clinical trials also show Omega-3s can improve atopic dermatitis and reduce reliance on expensive drugs (Müller et al. 2016; Mueller et al. 2004).

Fig. 7 illustrates these case studies highlighting that proactive, supplement-based pathways offer long-term financial savings and improved quality of life for pets, making a compelling economic argument for evidence-based prevention.

Figure 7. Cost comparison of proactive pet care and Reactive pet treatment for some common canine health issues.



10.2 Side-Effect Profile of Current Therapies

10.2.1 Overview

The side-effect profiles of current pet therapies are diverse, reflecting the mechanisms of action of different treatment modalities. Understanding these profiles is crucial for managing pet health and owner expectations. While much of the detailed research originates from human medicine, the principles of toxicity and side-effect management are broadly applicable to veterinary medicine, particularly in areas like oncology where similar drug classes are used. Current pet therapies, especially those in advanced veterinary care, can have side effects across several categories.

Conventional Chemotherapy: Similar to human oncology, chemotherapy in pets targets rapidly dividing cells, leading to expected side effects. These commonly include myelosuppression (low blood cell counts, increasing infection and bleeding risk), gastrointestinal issues (nausea, vomiting, diarrhea, appetite changes), and alopecia (hair loss) (American Cancer Society 2025a). Organ-specific toxicities, such as cardiotoxicity or nephrotoxicity, can also occur depending on the specific agent (American

Cancer Society 2025a). The concept of "dose-limiting toxicity," where the maximum dose is determined by the harm to healthy tissues, is a central principle in veterinary oncology as well (Sino Biological 2025).

Targeted Therapies: These agents aim to interfere with specific molecules involved in disease progression, intending to spare normal cells (American Cancer Society 2025c). While "targeted," they present a distinct spectrum of toxicities (Baldo 2022).

- **Small Molecule Inhibitors (e.g., Tyrosine Kinase Inhibitors - TKIs):** In veterinary medicine, these can cause dermatologic issues (rashes, dry skin), gastrointestinal toxicity (diarrhea), and potentially cardiovascular effects or hepatotoxicity (Cleveland Clinic 2023; Płużański and Piórek 2016).
- **Monoclonal Antibodies (mAbs):** These large protein-based drugs can lead to infusion-related reactions (e.g., fever, chills, rash), hypersensitivity reactions, and immunogenicity (the body's immune response to the drug, potentially leading to loss of efficacy) (Baldo 2022). Target-specific toxicities also occur, such as hypertension with agents affecting blood vessel growth (American Cancer Society 2025b).

Immunotherapies and Cellular Therapies: While less common in routine veterinary practice, immunotherapies are emerging. These therapies harness the pet's immune system, leading to unique side effects related to immune activation. In human medicine, these include immune-related Adverse Events (irAEs) affecting various organ systems (Baldo 2022). For advanced cellular therapies like CAR-T (Chimeric Antigen Receptor T-cell therapy), which is still largely experimental in veterinary medicine, the primary toxicities in humans are Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), which are severe systemic inflammatory responses (Memorial Sloan Kettering Cancer Center 2025).

Gene Therapies: These therapies, which aim for permanent genetic modification, are largely in the research phase for pets. In human medicine, their long-term effects are a concern, including potential insertional mutagenesis (where the new gene inserts into an undesirable location, potentially causing secondary malignancies) and unintended immune responses to the viral vector or gene product (FDA 2020; Premier Research 2020). Long-term follow-up is crucial due to the potential for delayed adverse events (FDA 2020).

The management of these side effects often involves proactive supportive care, including prophylactic medications and patient education (Yale Medicine 2025). For novel toxicities, highly specialised, protocol-driven interventions are developed, such as those for CRS and ICANS in human CAR-T therapy (Memorial Sloan Kettering Cancer Center 2025). The integration of pharmacogenomics (PGx) is also a promising area, allowing for personalised drug selection and dosing based on an individual's genetic makeup to prevent adverse reactions (BlueGenes 2024).

10.2.2 Red-meat based

Red meat ingredients are a cornerstone of the pet food market, valued by consumers for their alignment with "natural" and ancestral diets (Lyu et al. 2025). To ensure these ingredients deliver their potential, it is important to be mindful of several considerations in formulation and sourcing. By proactively addressing factors in the nutritional, microbial, and allergenic domains, a well-designed supplement can offer benefits while managing potential health and economic impacts for pet owners.

10.2.2.1 Achieving Nutritional Balance for Optimal Health

The key to unlocking the benefits of a meat-based diet lies in ensuring it is balanced and nutritionally complete (Lyu et al. 2025). A thoughtfully formulated product addresses the natural composition of meat to create a diet that supports long-term health and avoids the financial costs of managing nutritional issues.

- **Mineral and Vitamin Balance:** A primary consideration in formulation is balancing the calcium-to-phosphorus ratio. Meat is naturally rich in phosphorus and low in calcium, so a diet of boneless meat alone would require calcium supplementation to be complete (Tazerji et al. 2024). Awareness of this is key, as high dietary phosphate has been linked to increased vulnerability to chronic kidney disease (CKD), and a mineral imbalance can lead to conditions like secondary hyperparathyroidism and bone decomposition (Tazerji et al. 2024). Similarly, including organ meats like liver helps provide essential vitamins A and D, supporting robust skeletal health (Tazerji et al. 2024). Studies of various raw meat-based diets (RMBDs) have highlighted the importance of careful formulation to meet mineral and vitamin requirements (Díaz-Regañón et al. 2025). For example, a 2001 US study noted that some RMBDs had a calcium-to-phosphorus ratio of just 0.20 and vitamin D concentrations nearly double the AAFCO maximum, which in one case was associated with vitamin D-dependent rickets in a growing dog (Callahan 2023).
- **Metabolic and Organ Support:** For dogs, the inclusion of digestible carbohydrates and fibre complements a meat-based diet, providing readily available glucose and preventing the body from needing to rely on protein for energy, which supports gastrointestinal health (Tazerji et al. 2024). For cats, ensuring adequate taurine is essential for heart and eye health (Tazerji et al. 2024). Furthermore, selecting leaner cuts of red meat helps manage saturated fat content, which supports healthy weight and reduces the risk of pancreatitis and cardiovascular issues (Homer and Simon 2025).
- **Economic Considerations:** Proactive nutritional management helps pet owners avoid significant veterinary expenses. For instance, emergency hospitalisation for pancreatitis can range from AUD \$1,000 to \$5,000 (Bond Vet 2023). Likewise, the ongoing management of chronic conditions like CKD involves costs for consultations (averaging AUD \$119 in Australia), medications, and specialised diets, creating a cumulative financial commitment (Paddington Vet 2024).

10.2.2.2 Ensuring Product Safety Through Quality Control

Ensuring microbial safety is a priority in product formulation, particularly given the attention on raw meat diets. This focus on quality control directly addresses concerns raised by veterinary and public health bodies, such as the American Veterinary Medical Association (AVMA), regarding the feeding of raw animal-sourced protein (American Veterinary Medical Association 2025).

- **Pathogen Prevalence:** Responsible manufacturing practices are informed by data on microbial presence in raw meat products. Ensuring microbial safety is a priority in product formulation, particularly given the attention on raw meat diets.
- **Public Health Responsibility:** Safety standards also protect the home environment. When pets consume food with controlled microbial counts, it minimises the risk of them becoming subclinical shedders of pathogens, which is a consideration for households with children, the elderly, or immunocompromised individuals (American Veterinary Medical Association 2025; Díaz-Regañón et al. 2025).

- **Antimicrobial Resistance (AMR):** The challenge of AMR is another area where responsible production plays a role. Because some studies have found that raw pet food can contain bacteria with resistance genes (Davies et al. 2019; Díaz-Regañón et al. 2025), sourcing from trusted suppliers and employing safe handling protocols are critical steps in promoting public health. The Australian red meat industry's AMR plan is world renowned presenting an ideal launching pad to leverage.
- **Economic Considerations:** A commitment to safety helps prevent the costs associated with microbial issues, including veterinary bills for treating bacterial enteritis in a pet, potential medical costs from zoonotic illness in humans, and the societal cost of addressing AMR (Solís et al. 2022).

10.2.2.3 Understanding Allergenic Potential for Individualised Care

As with many nutritious food ingredients, it is helpful for pet owners to be aware of the potential for individual sensitivities, including allergies. This allows for informed choices to best suit each pet's unique needs.

- **Prevalence and Clinical Signs:** A 2016 systematic review noted that beef was a reported food allergen in dogs and cats (Mueller et al. 2016). For sensitive pets, an immune hypersensitivity to beef proteins can trigger inflammation, commonly appearing as non-seasonal itching, skin and ear issues, or gastrointestinal upset (Cormanes 2025).
- **Economic Impact:** Managing a food allergy involves a commitment to finding the right diet for the pet. The diagnostic process may involve an elimination diet trial using specialised therapeutic foods (Gaffud 2024; Spanner 2021). Addressing the clinical signs of allergies is a notable part of veterinary expenditure in Australia. Skin conditions are a common reason for pet insurance claims, with 2022 data showing the average cost for treating skin allergies in dogs was AUD \$520, and some claims reaching as high as AUD \$17,460 (Bow Wow Meow 2024; Everyday Insurance 2025). Other data reports average claim amounts for dermatitis at AUD \$832 (RSPCA Pet Insurance 2025).

In conclusion, while the use of red meat ingredients requires consideration of nutritional balance, microbial safety, and potential allergens, these factors are well-understood and can be effectively managed through thoughtful formulation, quality control, and transparent communication. This ability to meticulously manage these factors presents a clear market opportunity for a product to differentiate itself by offering the appeal of red meat with a high standard of safety and nutritional completeness. By addressing these considerations, a red meat-based supplement can be a valuable and popular component of a pet's diet, aligning with consumer preferences while supporting pet health.

11. Regulatory & Compliance Review


11.1 Governing Bodies & Product Classifications

The regulatory landscape for pet supplements in Australia is characterised by a fragmented system, lacking a single, overarching authority. Instead, oversight is determined by a product's specific ingredients and, critically, its marketing claims (Sentient 2018). This section details the primary governing bodies and the crucial product classification system that dictates the regulatory pathway for any new pet supplement entering the market.

11.1.1 Governing Bodies

Several federal and state bodies, along with industry associations, share responsibility for the regulation of pet supplements, creating an interconnected system of mandatory and voluntary compliance. Fig. 8 provides an overview of the regulatory landscape.

Figure 8. Australia's Pet Supplement Regulatory Landscape



The Australian Pesticides and Veterinary Medicines Authority (APVMA) is the primary federal regulator for veterinary chemical products in Australia (Australian Pesticides and Veterinary Medicines Authority 2024). Established under the Agricultural and Veterinary Chemicals (Administration) Act 1992, the APVMA's core function is to evaluate and register agricultural and veterinary (agvet) chemical products to ensure their safety and efficacy for people, animals, and the environment (Australian Pesticides and Veterinary Medicines Authority 2016; Productivity Commission 2016).

The APVMA's jurisdiction is specifically triggered when a product meets the legal definition of a "veterinary chemical product" (Australian Pesticides and Veterinary Medicines Authority 2015). This classification applies if a product is used, or intended to be used, on an animal to:

- Prevent, diagnose, cure, or alleviate a disease or condition;
- Modify the physiology of the animal; or
- Make a therapeutic or cosmetic claim (Australian Pesticides and Veterinary Medicines Authority 2024).

If a pet supplement makes any such claim, it falls under the APVMA's authority and requires a registration process involving an evaluation of the product's safety, efficacy, manufacturing quality, and labelling (Australian National Audit Office 2006; Australian Pesticides and Veterinary Medicines Authority 2015).

A portion of the pet supplement market operates outside the APVMA's direct registration requirements through the "Excluded Nutritional or Digestive (END)" product mechanism (Australian Pesticides and Veterinary Medicines Authority 2025). This exclusion is important for general nutritional supplements that do not make therapeutic claims. To qualify as an END product, an item

must be voluntarily consumed and satisfy four mandatory tests (Australian Pesticides and Veterinary Medicines Authority 2024):

1. **Ingredients:** All ingredients must be demonstrably safe and listed on accepted "generally recognised as safe" (GRAS) lists (Australian Pesticides and Veterinary Medicines Authority 2024; Australian Pesticides and Veterinary Medicines Authority 2025).
2. **Manufacturing:** The product must be manufactured in accordance with a recognised quality assurance (QA) system, such as the Australian Standard AS 5812 (Australian Pesticides and Veterinary Medicines Authority 2025).
3. **Labelling:** The label must clearly state its purpose and limitations, often including a statement like, "Nutritional supplement product for inclusion in animal's feed. Product has no therapeutic effect" (Australian Pesticides and Veterinary Medicines Authority 2024).
4. **Claims:** This is a critical test. A product is disqualified from END status if it makes a claim to cure a disease. Any representation implying suitability for curing a condition will trigger APVMA registration (Australian Pesticides and Veterinary Medicines Authority 2024; Australian Pesticides and Veterinary Medicines Authority 2025). An exception exists for "therapeutic pet foods" (veterinary diets) that make claims to nutritionally manage a disease, provided they are supplied by or on the instructions of a registered veterinarian and supported by high-quality scientific evidence (Australian Pesticides and Veterinary Medicines Authority 2025).

The END framework creates a commercial incentive for manufacturers to carefully craft claims using non-therapeutic phrasing like "supports," "maintains," or "promotes" to avoid the APVMA registration process (Australian Pesticides and Veterinary Medicines Authority 2024).

For the majority of pet supplements and foods that qualify as END products, regulatory oversight shifts to a self-regulatory model led by the Pet Food Industry Association of Australia (PFIAA) (Sentient 2018). The PFIAA is the peak industry body, representing over 95% of the prepared pet food market volume in Australia (Pet Food Industry Association of Australia 2020; Parliament of Australia 2018).

The Australian Standard for the Manufacturing and Marketing of Pet Food (AS 5812) is a cornerstone of this system (Sentient 2018). Developed by the PFIAA in conjunction with government and animal welfare bodies, AS 5812 provides detailed guidance on ingredient sourcing, manufacturing safety (HACCP), and labelling (Department of Climate Change, Energy, the Environment and Water 2022; Parliament of Australia 2018). It mandates specific label information, including ingredient lists, typical analysis, and feeding directions, and references the nutrient profiles of the Association of American Feed Control Officials (AAFCO) for products claiming to be "complete and balanced" (Pet Food Industry Association of Australia 2016; Raw & Fresh 2022b).

A key aspect of AS 5812 is its voluntary nature (Sentient 2018). While PFIAA members must adhere to the standard, there is no legal obligation for non-members, which can allow non-compliant products to be legally sold. This gap was a finding of the 2018 Senate Inquiry into pet food safety, which concluded that the self-regulatory model required review (Parliament of Australia 2018; Sentient 2018, 253). To enhance credibility, PFIAA members' facilities undergo independent audits, allowing manufacturers to use a "Tick of Approval" logo (Parliament of Australia 2018; PFIAA 2025). The PFIAA, AVA, and RSPCA Australia have collectively called for AS 5812 to be made mandatory (RSPCA Australia 2021).

The Australian Competition and Consumer Commission (ACCC) is the primary consumer protection agency, operating under the Australian Consumer Law (ACL) (Product Safety Australia 2025). Its role

in the pet supplement market is to enforce against misleading or deceptive conduct, such as unsubstantiated claims about product benefits, ingredients, or origins (Australian Competition and Consumer Commission 2025; RPC 2025). However, the ACCC's power to regulate pet food safety is limited, as it interprets the product safety provisions of the ACL as applying to risks of injury to humans, not animals. The ACCC has concluded it lacks the power to create a mandatory safety standard for pet food based on risk of injury to animals (Department of Agriculture, Water and the Environment 2021; Parliament of Australia 2018).

Food Standards Australia New Zealand (FSANZ) is the statutory authority responsible for the Australia New Zealand Food Standards Code, which regulates food for human consumption only (Department of Health 2023; Food Standards Australia New Zealand 2025). It is a misconception that FSANZ has a role in pet food regulation; its mandate is limited to human food, and it possesses no authority or expertise in animal nutrition or pet food safety (Food Standards Australia New Zealand 2019). The 2018 Senate Inquiry's recommendation to expand FSANZ's remit to include pet food was not adopted by the government (Department of Agriculture, Water and the Environment 2021; Parliament of Australia 2025).

Under Australia's constitutional framework, the power to legislate on matters such as animal welfare and local manufacturing standards rests with the states and territories (Department of Climate Change, Energy, the Environment and Water 2022). The federal government has identified this as the proper channel for any future mandatory pet food regulation (Department of Climate Change, Energy, the Environment and Water 2022). To date, state and territory action has been limited (Parliament of Australia 2018). However, recent developments, such as South Australia's proposed bill in June 2024 to mandate AS 5812, signal potential legislative action at the state level (Rubio and Tisnadibrata 2025).

11.1.2 Product Classifications

A product's regulatory pathway is fundamentally determined by its classification, which hinges on the claims made on its packaging and in its marketing (Australian Pesticides and Veterinary Medicines Authority 2024). The framework establishes four primary categories, summarised in Table 2.

Table 2: Regulatory Classifications of Pet Food and Supplements in Australia

Product Category	Defining Characteristics & Claims	Primary Regulatory Body/Standard	Key Requirements	Illustrative Example
General Pet Food	Claims to be "complete and balanced" for a specific life stage. Makes only nutritional claims.	PFIAA / AS 5812 (Voluntary)	Adherence to AS 5812, including labelling and safety standards. Nutritional adequacy is often benchmarked against AAFCO profiles.	A bag of dry kibble labelled "Complete and Balanced for Adult Dogs."
Nutritional Supplement (END Product)	Provides specific nutrients. No therapeutic claims. Label may state "for general wellbeing" or	PFIAA / AS 5812 (Voluntary)	Must pass all 4 END tests (Ingredients, Manufacturing, Labelling, Claims). Label must state it has	A fish oil capsule for dogs labelled "Supports a healthy coat and skin."

	"supports health."	"no therapeutic effect."	
Therapeutic Pet Food (Veterinary Diet)	Makes claims to APVMA (Exclusion "nutritionally manage" possible) / PFIAA a specific disease or condition.	Can be excluded from APVMA registration only if sold by/via a veterinarian AND all claims are backed by scientific evidence.	A canned food labelled "Veterinary Diet for Urinary Health," available only at a vet clinic.
Registered Veterinary Chemical Product	Makes direct APVMA therapeutic claims (Mandatory (e.g., "treats," "cures," "prevents" a disease or injury).	Must be registered with the APVMA. Requires submission of a data package proving safety and efficacy.	A tablet containing glucosamine and chondroitin labelled "For the treatment of arthritis in dogs."

11.2 Labelling, Safety, and Claims Restrictions

A product's label serves as its primary communication tool, guiding consumers, undergoing scrutiny from regulators, and acting as marketing collateral. In Australia, the labelling requirements for pet supplements are bifurcated, mirroring the regulatory divide between therapeutic and non-therapeutic products. Veterinary Chemical Products (VCPs) registered with the Australian Pesticides and Veterinary Medicines Authority (APVMA) are subject to a strict, mandatory code, while non-therapeutic END products are guided by a voluntary industry standard. Superimposed over both is the Australian Consumer Law (ACL), which governs the truthfulness of all marketing claims (Givoni 2025; O F Packaging 2025).

11.2.1 Labelling APVMA-Registered Therapeutic Products

When a pet supplement is classified as a VCP and registered with the APVMA, its label must strictly comply with the Veterinary Labelling Code (VLC) (APVMA 2025a). The VLC is a set of non-negotiable rules that dictate not only the content of the label but also its presentation and layout. The goal is to ensure that veterinarians and pet owners receive clear, accurate, and consistent information for the safe and effective use of a therapeutic product (APVMA 2025a).

Key mandatory information that must appear on the label of a therapeutic pet food or supplement includes (APVMA 2025c):

- **Product Name and Type:** A clear product name and an indication of its type (e.g., "food," "supplement").
- **Nutrient and Claim Information:** A description of the product's use and the specific claim being made, along with the nutrient composition that relates to that claim.
- **Net Contents:** The net weight of the product in metric units.
- **Directions for Use:** Clear and concise instructions, including dosage rates, duration of use, and any other information affecting safety or efficacy.
- **Veterinary Direction:** The explicit and mandatory statement: 'Use under directions of a veterinarian'.
- **APVMA Approval Number:** The unique number assigned by the APVMA upon label approval.

- **Date and Storage:** A 'use before,' 'best before,' or expiry date, and specific storage instructions (e.g., "to be stored below 30°C, in a cool dry place").
- **Contact Information:** Details for the manufacturer or distributor.

The VLC also recommends, but does not mandate, the inclusion of a full ingredient list and a feeding guide (APVMA 2025c). To differentiate these products from other veterinary medicines, the label may carry the statement 'for animal consumption only,' but the heading 'for animal treatment only' is not permitted (APVMA 2025c).

11.2.2 Labelling Non-Therapeutic Supplements: Australian Standard AS 5812

For supplements sold as non-therapeutic END products, the primary source of labelling guidance is the Australian Standard AS 5812: Manufacturing and Marketing of Pet Food (O F Packaging 2025). While compliance with this standard is legally voluntary, it is an accepted industry benchmark and is followed by manufacturers representing a significant portion of the market (PFIAA 2018). Adherence is a commercial necessity for gaining access to retail channels and is a prerequisite for the END product exemption itself (APVMA 2025b).

Key labelling requirements under AS 5812 include (PFIAA 2016):

- **Identification as Pet Food:** The label must conspicuously feature the words "PET FOOD ONLY" (or similar) and an illustration of the target animal species (e.g., a dog or cat).
- **Nutrition Information Panel:** A statement of the guaranteed or typical (average) percentage of crude protein and crude fat is required.
- **Nutritional Adequacy Statement:** The label must state whether the product is "complete and balanced" for a particular life stage (e.g., "for adult dogs") or if it is intended for "intermittent or supplemental feeding only" (e.g., a treat or supplement). These statements are typically substantiated against the nutritional profiles established by the Association of American Feed Control Officials (AAFCO).
- **Ingredients List:** Ingredients must be listed in descending order by pre-processing weight. The list must identify the species of any meat used (e.g., chicken, beef) and declare all additives. Notably, the standard specifically requires that preservatives like sulphur dioxide or sulphites be identified on the label by their name or FSANZ code number, a response to safety concerns about thiamine deficiency (PFIAA 2016).
- **Directions for Use:** A feeding guide providing recommended daily amounts based on the pet's size or age.
- **Date and Traceability:** A 'best before' or 'use by' date and a batch or lot number to enable traceability in the event of a quality or safety issue.

Table 3 provides an overview of each labelling approach.

Feature	APVMA-Registered Therapeutic	Non-Therapeutic END Products
Governing Standard	Mandatory Veterinary Labelling Code (VLC)	Voluntary Australian Standard AS 5812
Primary Goal	Ensure clear, accurate information for safe quality, safety, and effective therapeutic use.	Provide industry benchmarks for information.
Mandatory Statements	Use under directions of a veterinarian	“PET FOOD ONLY” (or similar)
Product Identification	APVMA Approval Number	Illustration of the target animal species
Nutritional Info	Nutrient composition related to the specific claim.	Guaranteed or typical percentage of crude protein and crude fat.
Nutritional Adequacy	Not specified as a primary requirement.	Statement if “complete and balanced” or for “intermittent or supplemental feeding only.”
Ingredients List	Recommended, but not mandatory.	Mandatory, listed in descending order by pre-processing weight.
Directions for Use	Mandatory, including dosage rates and duration.	Mandatory, a feeding guide based on pet's size or age.
Date & Traceability	Mandatory “use before,” “best before,” or expiry date.	Mandatory “best before” or “use by” date and a batch/lot number.

11.2.3 The Overarching Influence of the ACCC: Substantiating All Marketing Claims

Regardless of whether a product is a registered VCP or an END product, all claims made on its label are subject to the Australian Consumer Law's (ACL) prohibition on misleading and deceptive conduct (ACCC 2025). This means that every marketing claim, from the product's name to descriptive terms like "natural" or "premium", must be truthful, accurate, and substantiated with evidence (ACCC 2025).

The Australian Competition and Consumer Commission's (ACCC) focus is on the overall impression created in the mind of a consumer (Martin 2006). A business cannot rely on fine print or a technically correct ingredient list to correct a misleading headline claim. For example:

- A claim of "100% natural" implies the absence of artificial additives, colours, preservatives, GMOs, hormones, or antibiotics (Givoni 2025b).
- A claim of "organic" should be supported by certification or adherence to a recognised standard like AS 6000-2009 (Givoni 2025b).
- A claim like "veterinarian recommended" must be backed by credible evidence, such as a formal survey of veterinarians, and not just imply a general endorsement that does not exist (O F Packaging 2025).

The ACCC's enforcement actions demonstrate that it will challenge not just explicit falsehoods but also any representation that has the potential to mislead consumers about a product's composition, origin, or benefits (Givoni 2025a).

11.3 Pathways for Novel Ingredients (Red-Meat Derivatives)

The introduction of novel ingredients, particularly red-meat derivatives, into the Australian pet supplement market requires navigating specific regulatory pathways. Unlike centralised systems in other jurisdictions, Australia's framework is fragmented, with the primary trigger for federal oversight

being the claims made about the final product, rather than solely the novelty of the ingredient itself (APVMA 2024; Laila and Me 2024).

11.3.1 Defining "Novelty" in the Australian Context

In Australia, the concept of "novelty" for pet food ingredients is less about a historical cut-off date or a lack of prior approval. Instead, the key determinant for the regulatory pathway is whether the final product containing the novel ingredient makes a therapeutic or health claim APVMA 2024; Laila and Me 2024).

While Food Standards Australia New Zealand (FSANZ) has a standard for "Novel Foods" (Standard 1.5.1) that requires pre-market clearance for human consumption, its direct authority over pet food is limited (Food Standards Australia New Zealand 2025; PFIAA 2025). Therefore, for pet supplements, the regulatory focus shifts to the Australian Pesticides and Veterinary Medicines Authority (APVMA) and the claims-based framework it oversees.

11.3.2 The APVMA Registration Pathway for Therapeutic Claims

The APVMA registration pathway for a novel red-meat derivative is triggered if the final pet supplement product makes a therapeutic or health claim. In such cases, the product is classified as a "Veterinary Chemical Product" (VCP) and requires mandatory registration with the APVMA (APVMA 2024; Arki Labs 2025).

For a novel red-meat derivative to be included in an APVMA-registered VCP, the manufacturer must submit a comprehensive dossier of scientific evidence. This evidence must substantiate the claims made about the product's efficacy (e.g., "improves joint mobility") and demonstrate the safety of the novel ingredient for the target animal species (APVMA 2024).

11.3.3 The END Exemption Pathway for Nutritional Claims

A strategic avenue for novel red-meat derivatives is the END product pathway. This pathway allows products to be exempt from APVMA registration, provided they meet four specific and mandatory tests related to their ingredients, manufacturing, labelling, and claims (APVMA 2025b). This is particularly relevant for novel ingredients intended for general nutritional support or wellness, rather than explicit therapeutic purposes.

For a novel red-meat derivative to qualify for the END pathway, it must:

- 1. Ingredients:** Not contain prohibited substances. All ingredients must be listed on specified Generally Recognised As Safe (GRAS) lists or be recognised as edible substances of plant or animal origin (APVMA 2025b). This means that while the derivative might be "novel" in its processing, its base material (e.g., beef, lamb) and safety profile can align with existing recognised safe ingredients.
- 2. Manufacturing:** Be manufactured under a recognised Quality Assurance (QA) system, such as the Australian Standard AS 5812:2023, "Manufacturing and marketing of pet food," or APVMA Good Manufacturing Practice (GMP) (APVMA 2025b). While AS 5812 is technically voluntary, adherence is a commercial advantage and a prerequisite for the END exemption (PFIAA 2018).
- 3. Labelling:** Comply with specific labelling requirements, including clear identification as "PET FOOD ONLY" and accurate ingredient declarations (PFIAA 2001).
- 4. Claims:** Crucially, the product must not claim to cure a disease, condition, or injury. It may make general health claims (e.g., "supports health") if supporting evidence is available upon


request, or "nutritional management" claims if supplied by a veterinarian and backed by high-quality scientific evidence (APVMA 2025b). This is a primary regulatory consideration and a key strategic decision point for novel ingredients.

11.3.4 Strategic Implications for Red-Meat Derivatives

The Australian regulatory model's emphasis on claims offers strategic flexibility for introducing novel red-meat derivatives.

- **Phased Market Entry:** A company could initially introduce a novel red-meat derivative (e.g., a specific hydrolysed protein or a unique organ meat extract) to the Australian market as a general nutritional ingredient, making wellness claims like "supports overall vitality." This would allow the product to enter the market via the END pathway, avoiding the extensive APVMA registration process. This approach enables market testing, revenue generation, and the collection of real-world data.
- **Subsequent Claim Substantiation:** Once a market position is established and further research is conducted, the company could then invest in clinical trials to substantiate more specific health claims (e.g., "improves joint function in older dogs"). With this scientific evidence, the company could then pursue APVMA registration to market the product as a VCP with therapeutic claims, potentially commanding a higher price point and gaining veterinary endorsement.
- **Transparency and Traceability:** Regardless of the pathway, ensuring transparency and traceability of the red-meat derivative from source to final product is critical. This addresses consumer concerns about "by-products" and aligns with the "upcycling" narrative, which can transform a perceived negative into a positive marketing attribute (Miller 2025a).

In summary, the Australian regulatory landscape for novel red-meat derivatives is characterised by a dual pathway system. As illustrated by Fig. 9, the choice between APVMA registration (for therapeutic claims) and the END exemption (for nutritional/wellness claims) dictates the regulatory burden. This framework allows for strategic, phased market entry, where the initial focus might be on general wellness claims to gain market access, followed by more specific, evidence-backed therapeutic claims once scientific validation and regulatory approval are secured.

Figure 9. Market Entry Pathway for a Novel Pet Supplement

11.4 Implications for 3D-Printed Nutraceuticals

The emergence of 3D printing technology in the nutraceutical sector presents regulatory challenges and opportunities within the Australian context. While the technology offers Personalisation and on-demand manufacturing, its integration into the existing regulatory framework for pet supplements is complex and largely undefined.

11.4.1 Regulatory Ambiguity and Classification Challenges

The primary challenge for 3D-printed pet nutraceuticals in Australia stems from the ambiguity in classifying these novel products. The Australian regulatory landscape for pet supplements is fragmented, with the Australian Pesticides and Veterinary Medicines Authority (APVMA) primarily regulating products based on their therapeutic claims, and the Australian Consumer Law (ACL) governing all marketing and labelling (Australian Pesticides and Veterinary Medicines Authority 2024; Laila and Me 2024).

A 3D-printed pet nutraceutical could potentially fall into several categories, each with different regulatory implications:

- **Veterinary Chemical Product (VCP):** If a 3D-printed supplement makes explicit therapeutic claims (e.g., "treats canine arthritis"), it would likely be classified as a VCP and require full APVMA registration. This would necessitate submitting scientific data to substantiate the claims and demonstrate the safety and efficacy of both the active ingredients and the 3D printing process itself (Australian Pesticides and Veterinary Medicines Authority 2024). The novelty of the manufacturing method would add complexity to the data requirements.
- **Excluded Nutritional or Digestive (END) Product:** If the 3D-printed supplement is marketed with general wellness claims (e.g., "supports joint health") and avoids therapeutic language, it could potentially qualify as an END product. This would exempt it from APVMA registration, provided it meets the four tests for ingredients, manufacturing, labelling, and claims (APVMA 2025b). However, the "manufacturing" test would be scrutinised for 3D-printed products, requiring robust quality assurance systems to ensure safety and consistency.
- **Food Product:** If the 3D-printed item is considered a general pet food (e.g., a personalised treat), it would primarily fall under the voluntary Australian Standard AS 5812, administered by the Pet Food Industry Association of Australia (PFIAA) (PFIAA 2025).

The core regulatory ambiguity lies in the "who is the manufacturer?" question, a global challenge for 3D printing (Arki Labs 2025). If a veterinary clinic or a pet owner prints a customised supplement, who bears the responsibility for quality, safety, and compliance? The current frameworks are designed for centralised mass production, not decentralised, point-of-care manufacturing (APVMA 2025b).

11.4.2 Quality Control and Safety Implications

The safety and quality control challenges of 3D printing have implications for Australian regulation:

Microbial Contamination: The complex geometries and components of 3D food printers pose a risk of microbial growth (Zhu et al. 2023). Regulators would need assurance that these risks are effectively mitigated, potentially through cleaning protocols or single-use components.

- **Material Safety:** The safety of "food inks" and printer components is paramount. Australian regulators would require evidence that all materials in contact with the product are food-grade and do not leach toxic chemicals (PFIAA 2018). The use of novel red-meat derivatives as "inks" would add a layer of scrutiny regarding their stability and safety during the printing process.
- **Active Ingredient Stability:** Many nutraceuticals are heat-sensitive (PFIAA 2001). The thermal processes involved in some 3D printing methods could degrade active ingredients, reducing efficacy. Regulators would need data demonstrating that the final printed product delivers the claimed potency.
- **Dosage Accuracy and Consistency:** While 3D printing promises precise dosing, ensuring this consistency across individual prints, especially in a decentralised model, would be a key regulatory concern. Traditional quality control methods are not easily applied to unique, on-demand products (Miller 2025a).

11.4.3 Potential Regulatory Pathways and Mitigation Strategies

Australia's Therapeutic Goods Administration (TGA) has been proactive in addressing 3D-printed medical devices, introducing the concept of a "medical device production system" (MDPS) (Mezher 2017). This model regulates the entire system, including printer, software, and raw materials, as a single, integrated unit, shifting the primary regulatory burden from the end-user (e.g., a clinic) to the system developer (Therapeutic Goods Administration 2020).

While this MDPS framework currently applies to human medical devices, it offers a potential model for regulating 3D-printed pet nutraceuticals in Australia. If a similar approach were adopted by the APVMA, it could provide a clearer pathway by:

- **Validating the System:** Approving a specific 3D printing system (printer, software, and proprietary red-meat derivative "ink" cartridges) as capable of producing safe and effective pet nutraceuticals within defined parameters.
- **Clarifying Liability:** Placing the primary regulatory and liability burden on the developer of the 3D printing system, rather than on individual veterinarians or pet owners who use it.
- **Ensuring Quality:** Mandating that the system developer implements robust quality management systems (e.g., GMP) for the production of the "ink" materials and the design of the printer and software.

Without such a clear, integrated regulatory framework, the widespread adoption of 3D-printed pet nutraceuticals in Australia will remain limited to niche applications where the benefits of personalisation outweigh the regulatory and safety uncertainties.

12. Opportunity Analysis: Red-Meat Ingredients + 3D Printing

12.1 Market Gaps & White Spaces by Health Indication

The Australian pet health sector, while robust and growing, presents market gaps and white spaces that can be strategically targeted by solutions leveraging red-meat ingredients and 3D printing technology. These opportunities are identified through an analysis of prevalent pet health issues, current treatment limitations, and emerging consumer demands for personalised and preventative care.

12.1.1 Chronic and Lifestyle-Related Diseases: A Growing Burden

Mirroring human health trends, Australian pets are affected by chronic and lifestyle-related diseases, leading to long-term management challenges and associated costs (PetSure 2025b). These conditions represent a market gap for preventative and adjunctive therapies that can improve quality of life and potentially reduce the reliance on reactive veterinary interventions.

- **Obesity and Metabolic Health:** Obesity is a prevalent form of malnutrition in Australian pets, affecting up to 41% of dogs and 32% of cats (PFIAA 2020). It is a precursor to conditions such as osteoarthritis and cardiovascular disease (Greenpet 2024). While dietary management is the primary intervention, compliance is a major challenge for pet owners (PFIAA 2020).
 - **Market Gap:** There is a gap for palatable, precisely dosed supplements that can support weight management and improve metabolic function. A 3D-printed, red-meat-based supplement could offer a palatable, portion-controlled, and nutrient-dense option to support healthy weight, potentially incorporating ingredients like L-carnitine or specific fibre types.
- **Osteoarthritis (OA) and Joint Health:** Arthritis is a major cause of chronic pain, particularly in older animals, affecting nearly 40% of dogs over eight years old (PetSure 2025b). While supplements like glucosamine and chondroitin are widely used, their efficacy is debated, and compliance with daily administration can be an issue (McKenzie 2010; Morrison 2023).

- **Market Gap:** A white space exists for bioavailable joint support supplements that offer efficacy and palatability. Red-meat ingredients, particularly those rich in collagen or specific peptides, combined with precisely delivered anti-inflammatory compounds (e.g., highly bioavailable omega-3s), could offer a compelling alternative. 3D printing allows for customised shapes and textures that enhance palatability, thereby improving compliance.
- **Cancer Support:** One in four dogs will have a claim for cancer during their lifetime, with total claims exceeding \$31 million in 2023 (PetSure 2024a). Treatment costs are substantial, often exceeding \$10,000 for complex cases (Field 2024).
 - **Market Gap:** While direct therapeutic claims for cancer are highly regulated, there is a white space for adjunctive supplements that support overall well-being, immune function, and appetite during cancer treatment or in palliative care. Red-meat ingredients can provide digestible protein to combat cachexia, while 3D printing could enable the precise incorporation of immune-modulating ingredients (e.g., specific mushroom extracts like Turkey Tail with documented immune benefits (Basedow and Hass 2024)) in a palatable format for pets with reduced appetite.

12.1.2 Addressing the "Humanisation" Paradox: Safety and Personalisation

The humanisation trend drives demand for premium products but also introduces considerations, particularly concerning raw feeding and the desire for human-like solutions (Clearly Loved Pets 2025). This creates white spaces for products that bridge the gap between perceived "naturalness" and scientific safety.

- **Microbial Safety in Raw/Minimally Processed Diets:** The popularity of raw or minimally processed red-meat diets is driven by humanisation, but these diets present challenges regarding microbial contamination (e.g., *Salmonella*, *Listeria*) and nutritional imbalances (Lyu et al. 2025; FDA 2018). These challenges are important for both pet and human health (American Veterinary Medical Association 2025). Typically raw products are freeze dried to derive more convenient (but expensive) shelf stable rather than frozen raw product.
 - **White Space:** A white space exists for red-meat-based supplements that deliver the perceived benefits of raw meat (palatability, nutrient density) without microbial risks. 3D printing, combined with patented methods for stabilising meat slurries through fermentation (Smittle and Phelps 2014), offers a unique opportunity to create a safe, shelf-stable, and palatable red-meat product. This addresses a safety consideration while catering to consumer preferences for "real meat."
- **Personalised Nutrition and Dosage Precision:** The humanisation trend fuels demand for personalised pet care, moving beyond one-size-fits-all solutions (Hardt 2025). Current supplements often come in fixed dosages, making precise tailoring for individual pet weight, age, or specific health needs challenging.
 - **White Space:** 3D printing offers a unique white space for truly personalised pet supplements. This technology allows for the precise deposition of active ingredients, enabling customised dosages based on a pet's exact weight or specific veterinary recommendations (Hardee et al. 2018). This level of precision is unattainable with traditional manufacturing methods and aligns perfectly with the growing demand for individualised pet health solutions.

12.1.3 Underserved Feline Market: Addressing Unique Needs

While dogs dominate the supplement market, the feline segment is the fastest-growing, yet often underserved frontier (Grand View Research 2023). Cats have unique physiological needs and are known for their selective palates, creating specific market gaps.

- **Urinary Tract and Kidney Support:** Cats are highly prone to Feline Lower Urinary Tract Disease (FLUTD) and chronic kidney disease (CKD) (Under the Weather Pet 2024). These are chronic conditions requiring long-term management, and palatability of supplements is a major challenge for cat owners.
 - **Market Gap:** There is a significant gap for highly palatable, cat-specific supplements for urinary and kidney health. A 3D-printed, red-meat-based supplement could be formulated with specific ingredients (e.g., cranberry extract, omega-3s) in a texture and flavour highly appealing to cats, overcoming the administration challenges of pills or powders.
- **Dental Health:** Dental disease is pervasive in both dogs and cats, often requiring expensive professional cleanings under anesthesia (Australian Animal Oral Care 2025). At-home preventative measures are often insufficient or difficult to administer.
 - **Market Gap:** A white space exists for innovative, highly palatable dental supplements that effectively reduce plaque and tartar in both dogs and cats. A 3D-printed red-meat chew could be designed with specific textures and active ingredients (e.g., enzymes, anti-plaque compounds) to promote dental hygiene, making daily dental care a treat rather than a chore.

By strategically targeting these identified market gaps and white spaces, a proof-of-concept utilising red-meat ingredients and 3D printing technology can position itself as an innovative, science-backed solution addressing critical unmet needs in the Australian pet health sector.

12.2 Technical Feasibility

The technical feasibility of producing 3D-printed pet health supplements incorporating red-meat ingredients is supported by the maturity of underlying 3D printing technologies and patented solutions for ingredient stabilisation and multi-material deposition. The core challenge lies not in the mechanics of 3D printing, which are established, but in the formulation of a printable, stable, and palatable red-meat "ink" capable of delivering precise nutritional dosages.

12.2.1 Technological Foundation: Additive Manufacturing for Edible Constructs

Three-dimensional food printing is an evolution of food processing technologies, particularly extrusion. Early patents, such as a 1983 patent detailing an apparatus for co-extruding "lean meat" and "fat" phases for pet food, demonstrate the foundational concept of building complex food structures by controlled material deposition (Dolan and Connor 1983). More recently, patent application US20200323238A1, assigned to a major food and beverage company, describes an extrusion method for creating meat analogues with a fibrous macrostructure by inducing controlled shear and temperature gradients. This process generates a "sheared fibre and gap structure" that mimics muscle tissue, providing a direct, patented method for transforming a homogenous slurry into a texturally suitable material for printing (Pibarot et al. 2020). MLA nearly 10 years ago first reviewed 3D printing – more information see: <https://www.mla.com.au/research-and-development/reports/2016/review-of-market-acceptance-and-value-proposition-for-3d-printed-meat/>

The hardware for precisely depositing viscous food materials is well-developed and patented. Key capabilities include:

- **Multi-ingredient printing:** Multi-ingredient printing: A patent (US10349663B2) from a food printing technology company covers a system with multiple cartridges for simultaneous and synchronised printing of various ingredients, enabling complex, multi-layered food items. This is crucial for combining a meat base with a distinct supplement formulation (GreyB 2025a).
- **Viscosity and flow control:** Patents address the challenges of printing thick, non-Newtonian fluids like meat slurries. A food printing technology company has patented pneumatic systems for material consistency (US11660811B1) and anti-drip technology for viscous materials (US10384389B2) (GreyB 2025a). Other patents, such as CN105595386A, describe heating materials at the printer outlet to modify viscosity, applicable to animal fats (Chen et al. 2018).
- **Precision and customisation:** Patent US20180116272A1 describes a system where food items are printed based on consumer information, such as dietary restrictions or preferences (Hardee et al. 2018). This provides a direct framework for linking a pet's specific health data to a customised supplement formulation printed on demand.

These patented hardware systems indicate that the core mechanical challenges of food printing are largely addressed. The primary innovation opportunity lies in formulation engineering.

12.2.2. Printable Meat Matrix: Ingredient Stability and Compatibility

The viability of a 3D-printed red-meat supplement depends on the formulation of the "meat" component. The patent landscape reveals three distinct technological pathways for creating this printable matrix, each with a different level of near-term commercial viability.

- **Pathway 1: Stabilised Red-Meat Slurries (Near-Term Viability)**

This pathway utilises actual red meat. The technical hurdle of microbial spoilage is addressed by patent application US20140271994. This patent details a method for creating a "cultured meat slurry" by inoculating ground meat paste with lactic acid bacteria and a fermentable carbohydrate source. Fermentation lowers the pH to below 5.0, deactivating pathogenic and spoilage organisms and extending refrigerated shelf-life to several months (Smittle and Phelps 2014). This patent directly addresses the ingredient stability problem, transforming perishable raw meat into a consistent, safe, and stable industrial ingredient suitable for 3D printing. The patent also notes the optional use of proteolytic enzymes to reduce slurry viscosity, optimising it for extrusion-based printing (Smittle and Phelps 2014).

- **Pathway 2: Meat Analogues (Mid-Term Viability & High-Quality Texture)**

This approach, exemplified by companies specialising in alternative protein products, uses primarily plant-based ingredients to replicate whole-muscle meat structures (GreyB 2025b). Patent US20220125072A1 describes a meat analogue with distinct protein, fat, and optional "blood" components, 3D-printed simultaneously from separate nozzles to create a non-homogenous, multi-material structure mimicking meat marbling and texture (Ben-Shitrit et al. 2025). While focused on plant-based meat, these principles could be adapted to use a stabilised red-meat slurry (from Pathway 1) as the "protein ink," printed alongside a specially formulated tallow- or lard-based "fat ink."

- **Pathway 3: Cultured (Cell-Based) Meat (Long-Term Aspiration)**

This pathway involves 3D bioprinting using "bio-inks" of living animal cells. Patents in this area include a cultivated meat company's printable, edible scaffolds for cell growth (WO2022162662A1) (Levenberg et al. 2022) and another cultivated meat company's foundational patent for edible microcarriers (US9752122B2) (Marga et al. 2017). A cultivated meat technology company has also patented high-resolution inkjet bioprinting methods for precise cell placement (Shaffer 2021). Despite technological sophistication, this pathway is not commercially viable for pet supplements in the near to mid-term due to costs, complex sterile production, scalability issues, and a nascent regulatory framework (Atkins 2023).

12.2.3 Precision: Dosage and Stability of Active Ingredients

A key advantage of 3D printing is the ability to deliver personalised and precise dosages of active ingredients, a level of customisation not readily attainable with traditional mass-produced pet foods (All Pet Food 2024).

Patented frameworks for personalised and multi-material printing already exist. Patent US20180116272A1 describes systems that modify food recipes based on consumer-specific data, providing the technical precedent for a system where a pet's health profile dictates the precise amount of supplement to be printed (Hardee et al. 2018). Hardware patents from food printing technology companies, detailing multi-cartridge systems, provide the physical means to execute this (GreyB 2025a).

The primary technical consideration in dosage is ensuring the bioavailability and stability of the active ingredients. Many nutraceuticals (e.g., vitamins, probiotics, omega-3s) are sensitive to the heat, pressure, and oxidation inherent in extrusion-based printing. Simply mixing them into the red-meat slurry could lead to degradation. A solution, drawn from the animal feed manufacturing industry, is microencapsulation. Companies specialised in technologies like spray cooling and granulation to coat active ingredients in protective matrices, are creating stable powders with controlled-release properties (Erbo Spraytec AG 2021).

The convergence of multi-material food printing and feed additive encapsulation points to an innovation area. A superior method would involve developing a separate, third ink: a printable encapsulated supplement paste. This would entail:

1. Encapsulating the desired nutraceutical using an established method (e.g., fat coating) to create a protected, stable powder.
2. Formulating this protected powder into a distinct, printable paste using food-grade binders and carriers.
3. Utilising a multi-cartridge 3D printer to co-print the "meat ink" and this "supplement ink" in precise, digitally controlled ratios.

This approach decouples the processing conditions of the meat matrix from sensitive active ingredients, ensuring supplement stability and bioavailability, and enabling dosage precision. This method also creates multiple avenues for proprietary intellectual property in the composition of both the meat and supplement inks, and the integrated manufacturing method for personalised products.

12.3 Consumer & Veterinarian Willingness-to-Pay

The willingness-to-pay (WTP) for premium and innovative pet health products in the Australian market is a complex interplay of emotional, functional, and practical drivers for pet owners, while

veterinarians are primarily influenced by clinical evidence, regulatory compliance, and economic considerations. Understanding these distinct yet interconnected value equations is crucial for the successful introduction of a novel 3D-printed, red-meat-based pet supplement.

12.3.1 Pet Owner Willingness-to-Pay: A Multi-Layered Value Equation

Australian pet owners demonstrate a WTP for products that align with their perception of pets as integral family members, a trend amplified by the "humanisation" overarching trend (Grand View Research 2025a). This emotional investment underpins a market where total pet-related expenditure exceeded \$33 billion in 2022 (Cosgrove 2025).

Key drivers of pet owner WTP include:

- **Emotional Connection & "Pet Parent" Identity:** The emotional bond drives owners to view pet health spending as a responsibility rather than a discretionary expense (McVeigh 2023). This is evident in the average annual spend of \$3,218 on a dog, with the total lifetime cost of approximately \$25,000 viewed as a worthwhile investment (Cosgrove 2025). Products that reinforce the owner's identity as a loving and responsible caregiver command a premium (Denniss 2004).
- **Functional Benefits & Problem-Solving:** The most direct driver of WTP is a product's ability to address specific, tangible health concerns. A notable 63% of Australian pet owners report at least one active health concern for their pet, with dental problems, arthritis/hip/joint issues, and anxiety being common (McVeigh 2023). The Australian pet supplement market is segmented by these functional needs, with "Skin & Coat," "Hip & Joint," and "Digestive Health" being the largest categories (Grand View Research 2025b). Studies indicate a willingness to pay a premium for products with specific health claims; for instance, "allergy relief" claims commanded a 17% price premium in a relevant US study (Lovett 2025). Proactive and preventative care also drives higher spending, with routine vet visitors spending significantly more monthly than those who only visit for emergencies (McVeigh 2023).
- **Personal Values Considerations & Clean Label:** Mirroring human consumer trends, pet owners increasingly seek products that align with their personal values. This includes a strong demand for "clean label" products with transparent, simple, and recognisable ingredients, avoiding artificial additives (Market Report Analytics 2025; Grand View Research 2025d). Ingredient provenance is also critical, with 49% of Australian owners preferring pet food made from "ethically raised and sourced animal meat" (Gupta 2024). Sustainability is an emerging but growing ethical driver, with 54% of pet food consumers globally willing to pay a premium for sustainable products, though this premium is typically lower (8%) than for human food (Kerwin 2024).
- **Practicality: Convenience, Personalisation, and Trust:** Convenience, particularly through online retail and subscription models, is highly valued (TechSci Research 2025; Multani 2024). Personalised food options, tailored to a pet's specific needs, create immense value by validating the owner's belief in their pet's uniqueness, justifying a premium price (Verified Market Research 2024; Barker 2025). Trust heuristics are also powerful, with veterinarian endorsement serving as the most influential validation of a product's quality and efficacy (Monaco et al. 2024).

12.3.2 Veterinarian Willingness-to-Adopt: Clinical, Pragmatic, and Economic Drivers

Veterinarians act as gatekeepers and influencers in the Australian pet health market. Their willingness to adopt and recommend new products is driven by a distinct set of clinical, pragmatic, and economic considerations.

Key drivers of veterinarian adoption include:

- **Clinical Evidence & Regulatory Compliance:** Veterinarians prioritise scientific validation, seeking proven safety and efficacy (Elrod and Hofmeister 2019). Products that have successfully navigated the Australian Pesticides and Veterinary Medicines Authority (APVMA) registration process gain significant credibility, as this signals assessment for quality, safety, and efficacy (APVMA 2015). They rely on peer-reviewed literature (e.g., Australian Veterinary Journal) and expert guidelines (Australian Veterinary Association 2025). Nutraceuticals like Omega-3 fatty acids (94.4% recommendation rate) and glucosamine/chondroitin (92.9% recommendation rate) are widely adopted due to extensive clinical studies (Elrod and Hofmeister 2019).
- **Pragmatism & Client Demand:** While scientifically grounded, veterinarians are also pragmatic. They often exhibit professional skepticism towards new trends lacking strong evidence, such as raw food diets, due to documented considerations of bacterial contamination and nutritional imbalance (Paszkowski 2025b). However, they are open to adjunctive and complementary therapies, with 78% recommending nutraceuticals when clients request them, and over 71% regularly recommending them, often for preventative purposes (73%) (Elrod and Hofmeister 2019).
- **Economic Realities & Practice Management:** Veterinary clinics operate as businesses, increasingly under economic pressure from rising operating costs and staff shortages (Flanagan 2025). The rise of corporate ownership has intensified the focus on profitability (Flanagan 2025). Therefore, veterinarians assess new products not only on clinical merit but also on their business case: whether they create new revenue streams, improve client retention, or enhance practice efficiency. Products that offer healthy profit margins and encourage repeat purchases are economically attractive (Conroy 2019).

12.3.3 Bridging the Perception Gap: Strategic Implications for a 3D-Printed, Red-Meat Supplement

The success of a 3D-printed, red-meat-based pet supplement hinges on effectively bridging the perception gap between pet owners and veterinarians regarding both the red meat ingredient and the 3D printing technology.

- **Red Meat Perception:** Pet owners generally view red meat as high-quality, natural, and desirable, often associating it with "ancestral" diets (Flynn et al. 2019). This creates an initial appeal. However, veterinarians harbor concerns about raw red meat diets due to considerations of bacterial contamination and nutritional imbalance (Paszkowski 2025b). In addition to simply cooking the meat, the 3D-printed format can address this in a different way by delivering the desired nutritional profile and palatability of red meat in a safe, precisely formulated manner, mitigating bacterial risks through controlled manufacturing processes. The strategic narrative should emphasise "the power of red meat, enhanced and made safe by science."
- **3D Printing Technology Perception:** Within the veterinary community, 3D printing is highly regarded as a cutting-edge medical tool associated with surgical precision, enhanced safety,

and personalised patient care (Materialise. 2021). In contrast, general consumers may perceive 3D-printed food as "unnatural," "ultra-processed," or potentially unfamiliar, reflecting "food technology neophobia" (Monaco et al. 2024; All Pet Food. 2023). The strategic approach must leverage the positive veterinary perception to recontextualise the technology for consumers. Messaging should focus on the functional benefits enabled by 3D printing, such as "precision nutrition" (micro-dosing and accurate nutrient placement), "enhanced bioavailability" (optimal digestion and absorption), and "personalised dosing" (tailored to individual pet needs) (All Pet Food. 2023). This shifts the narrative from "unnatural food" to an "advanced nutritional delivery system."

By strategically positioning the product to address the specific value drivers of both pet owners and veterinarians, a 3D-printed, red-meat-based supplement can overcome initial skepticism and establish itself as a high-value, trusted therapeutic solution in the Australian market.

12.4. Competitive Positioning & Differentiation Strategy

The Australian pet health sector, mirroring global trends, is characterised by competition driven by the "humanisation" of pets and a demand for premium, health-focused products (Fortune Business Insights 2025; Precedence Research 2025a). In this market, differentiation is a foundational requirement for sustainable brand building and pricing power (Oktopost 2025).

12.4.1 Current Competitive Landscape

The competitive landscape in the Australian pet health sector is shaped by a mix of global leading companies, omnichannel retailers, and agile disruptors, each employing distinct strategies to capture market share.

- **Global Leaders (Scale, Science, and Integration):** Major global pet care companies dominate the global market, leveraging scale, scientific expertise, and broad portfolios (Mars, Incorporated 2025; Nestlé Global 2025). A leading global pet care company differentiates through significant R&D investment and vertical integration, owning iconic food brands and a large network of veterinary clinics (Mars, Incorporated 2025). Another major global pet care company employs a CPG model, with a broad portfolio from value brands to super-premium lines, and a strategy of innovation and premiumisation (Nestlé Global 2025; Intellectual Market Insights 2025; Goybo 2025).
- **Omnichannel Major Retailers (Experience, Convenience, and Ecosystem):** Leading online and omnichannel pet retailers successfully blend digital and physical channels to create experience-driven ecosystems. Their innovation in e-commerce includes subscription models, and expanding into high-margin services like pet pharmacy and telehealth (Pawsitive Results Marketing 2024). Pet retailers also leverage their physical footprint by integrating veterinary clinics and grooming salons into their stores, offering omnichannel convenience through options like in-store collection of online orders (Petco Health and Wellness Company, Inc. 2024; Silberstein 2024).
- **Disruptors (Agility, Focus, and Narrative):** An ecosystem of startups identifies and exploits weaknesses of incumbents. This includes DTC fresh food brands challenging traditional kibble with human-grade nutrition; sustainability-first startups using novel ingredients and tech-driven platforms unbundling traditional pet care with specialised services like telehealth and wellness apps (1-800-D2C 2024; Boil Agency 2025; Enterprise League 2025).

12.4.2 Differentiation Strategies in Action

Differentiation in the pet sector is a complex tapestry woven from ingredients, science, technology, and brand values.

- **Ingredient-Led Differentiation:** This strategy directly leverages the humanisation trend. Brands differentiate with human-grade & fresh/frozen ingredients, a focus on natural & organic formulations, and the use of novel proteins like kangaroo, venison and cell-cultured meat (1-800-D2C 2024; Grand View Research 2025e; Intellectual Market Insights 2025; Boil Agency 2025; BoortmaltX 2025).
- **Science-Led Differentiation:** This strategy positions pet food as a tool for optimising health, often leveraging veterinary authority. It is dominated by veterinary & prescription diets built on extensive scientific research and clinical trials (Intellectual Market Insights 2025). It also includes functional & life-stage formulas segmented for specific needs like weight management or joint support (Howarth 2025).
- **Technology-Led Differentiation:** Pet tech is a dynamic frontier, embedding technology into everyday items for convenience and peace of mind. This includes GPS collars, AI-powered litter boxes, and smart feeders (1-800-D2C 2024; Zigpoll 2025). Innovations are at the intersection of health and technology, creating a new paradigm of preventative wellness through wearable health monitors and AI algorithms (Enterprise League 2025).

The Direct-to-Consumer (DTC) model is a powerful strategic advantage for differentiation, allowing brands to gather detailed pet information for hyper-personalised products and services, creating a virtuous cycle of data collection and competitive advantage (Allpetfood 2023).

12.4.3 Strategic Implications for Red Meat Ingredients + 3D Printing

The competitive landscape highlights several key considerations for a proof-of-concept involving red meat ingredients and 3D printing in pet supplements:

- **Premiumisation and Humanisation Alignment:** The use of red meat ingredients aligns with the premiumisation trend and the humanisation of pets. Owners are willing to pay more for ingredients perceived as superior, natural, and beneficial for their pets' health (Harris Williams 2024).
- **Novelty and Differentiation:** While red meat is a common protein, its application in 3D-printed supplement forms is novel. This offers a point of differentiation in a crowded market, appealing to tech-savvy and innovation-seeking consumers.
- **Science-Backed Claims:** To command a premium and gain veterinary trust, any health claims for 3D-printed red meat supplements must be rigorously science-backed. This aligns with the "science-led differentiation" strategy employed by market leaders.
- **Sustainability Narrative:** The sourcing of red meat ingredients will be critical. If the red meat can be sourced sustainably, it can tap into the "values-led differentiation" trend, mitigating potential environmental considerations associated with traditional meat production.
- **Personalisation Potential:** 3D printing inherently allows for customisation. This aligns with the future frontier of "hyper-Personalisation," enabling tailored dosages, nutrient profiles, or even shapes based on individual pet needs, breed, or health conditions. This level of Personalisation is a differentiator against mass-produced supplements.
- **Trust and Transparency:** Given past industry controversies, transparency regarding ingredient sourcing, manufacturing processes (especially for 3D printing), and scientific validation will be paramount to build consumer and veterinarian trust.

- **Niche Market Entry:** Initially, a 3D-printed red meat supplement might target a specific niche, such as pets with particular dietary needs, those requiring precise nutrient delivery, or owners seeking cutting-edge, personalised solutions. This "niche/focus strategy" allows a challenger to gain a foothold without directly competing with established mass-market products.

By strategically leveraging the premium nature of red meat, the Personalisation capabilities of 3D printing, and a strong scientific and transparent narrative, a proof-of-concept can carve out a unique and defensible competitive position in the evolving Australian pet health sector.

12.5 Case Studies of Novelty Pet Supplements

The pet supplement market is a centre of innovation, driven by consumer demand for advanced, natural, and personalised health solutions. This section examines several case studies of "novelty" pet supplements, analysing their market positioning, the scientific evidence (or lack thereof) supporting their claims, and the regulatory challenges they face. These examples provide valuable insights into the opportunities and pitfalls for a 3D-printed, red-meat-based supplement.

12.5.1 Cannabidiol (CBD) in Companion Animals

CBD represents a prominent novelty ingredient in the pet supplement space. Its market growth is fueled by anecdotal reports and a consumer desire for natural alternatives, yet it operates within a regulatory vacuum (Towards Healthcare 2025).

12.5.1.1 Market Dynamics

The CBD pet market is experiencing substantial growth. Forecasts project market sizes ranging from \$250 million to \$780 million in 2023-2024, and are expected to exceed \$5.4 billion by 2034, reflecting high CAGRs of 21-33% (Towards Healthcare 2025). This expansion is driven by the humanisation trend, a preference for natural plant-based alternatives, and the broader destigmatisation of cannabis (Gray 2025; Towards Healthcare 2025). North America currently leads the market. While dog products dominate sales, the cat-specific CBD market is a key growth area, particularly for conditions like arthritis where traditional medications can have severe feline side effects (Grand View Research 2025c; Towards Healthcare 2025).

12.5.1.2 Therapeutic Applications & Claims vs. Clinical Evidence:

- **Osteoarthritis and Pain Management:** CBD is widely marketed as an analgesic for osteoarthritis (OA) (Hyland 2024). A 2018 Cornell University study showed significant decreases in owner-reported pain and increased activity in osteoarthritic dogs receiving 2 mg/kg of CBD twice daily (Gamble et al. 2018). However, a subsequent 2021 study using objective gait analysis found no significant improvement in locomotion, suggesting a "owner placebo effect" may influence subjective reports (Yeung and Uquillas 2025). Consequently, the scientific evidence for CBD as an adjunctive pain therapy remains debated and requires further validation (Yeung and Uquillas 2025).
- **Anxiety and Stress:** This is the most common reason for CBD use, cited by 65% of users (Grand View Research 2025c). Recent research provides support in this area. A 2024 study found that daily CBD dosing significantly reduced physiological and behavioural stress indicators, such as serum cortisol and whining, in dogs during car travel (Flint et al. 2024). Similarly, a study showed that a single oral dose (4 mg/kg) significantly relieved stress from car travel and separation in dogs, reducing cortisol levels and whining (WALTHAM 2025). These studies provide an evidence base for managing situational anxiety in dogs.

- **Epilepsy:** CBD is also promoted as an anticonvulsant (Hyland 2024). Research studies indicate that CBD can significantly decrease the number of seizure days in dogs with drug-resistant idiopathic epilepsy, with a potential dose-dependent effect (Rozental et al. 2023).

12.5.1.3 Regulatory & Safety Challenges:

The CBD pet market operates in regulatory ambiguity. The FDA has not approved CBD for animal use and classifies products making health claims as unapproved animal drugs, issuing warning letters to violators (FDA 2023; Towards Healthcare 2025). The American Veterinary Medical Association (AVMA) cautions veterinarians against recommending non-FDA-approved products due to legal and professional liability (American Veterinary Medical Association 2023a). This creates a dilemma where veterinarians often avoid the topic, leaving owners to rely on unvetted online information (College of Veterinary Medicine at MSU 2019).

A safety concern is THC contamination, as THC is toxic to dogs and cats. Due to a lack of oversight, quality control, purity, and labelling accuracy vary widely among products (MSPCA-Angell 2023). This environment fosters a market built on emotional and anecdotal marketing, making it lucrative but inherently fragile. The first FDA-approved CBD product would likely marginalise non-approved brands, reshaping the competitive landscape (Supliful 2023).

12.5.2 Functional Fungi

Functional mushrooms are an emerging category, capitalising on traditional medicine and modern research for applications in immune support, cancer therapy, and cognitive function. This category emphasises sourcing, formulation, and quality communication for ingredients whose benefits are not immediately apparent (Natchez Trace Veterinary Services 2023).

12.5.2.1 Myco-Nutrition for Pets

Key fungi used in pet supplements include Turkey Tail, Reishi, Lion's Mane, Cordyceps, Shiitake, and Maitake (Natchez Trace Veterinary Services 2023). Their therapeutic potential is attributed to bioactive compounds, primarily beta-glucans, which modulate the immune system (Standard Process Veterinary Formulas 2025). Turkey Tail is notable for its Polysaccharopeptide (PSP) and Polysaccharide-K (PSK) content, which have been researched for their anti-tumor and immune-enhancing properties (Natchez Trace Veterinary Services 2023).

There has been evidence for immune and cancer support for such products. 2012 Pilot Study: A pilot study found that dogs with hemangiosarcoma (an aggressive cancer) treated with a PSP-rich Turkey Tail derivative had significantly longer survival times (median 199 days) compared to untreated dogs (median 86 days). These results were comparable or superior to some chemotherapy protocols and were achieved without side effects (Brown et al. 2012). 2022 Follow-up Study: A larger, more recent study comparing chemotherapy, Turkey Tail, and a combination of both yielded nuanced results. It did not find a significant improvement in survival with the combination therapy and identified potential sex-based differences in response (Basedow and Hass 2024). This highlights that while promising, Turkey Tail warrants further investigation as a supportive therapy (Basedow and Hass 2024) - however it does not represent a significant threat to red meat options.

12.5.2.2 Emerging Applications and Sourcing Differentiators:

Evidence for other functional mushrooms like Reishi, Shiitake, and Maitake is less direct, largely supported by in vitro studies or human/rodent research, with limited direct clinical trials in dogs and cats (Natchez Trace Veterinary Services 2023). Lion's Mane is marketed for cognitive health, Reishi for

adaptogenic properties, and Cordyceps for energy and stamina, but these claims currently lack robust, pet-specific clinical data (American Kennel Club 2023; CBD Dog Health 2023; Fera Pets 2023).

As these are "credence goods" where quality is not immediately apparent, brands differentiate through proxies for quality (Standard Process Veterinary Formulas 2025). Key differentiators include:

- **Fruiting Body vs. Mycelium:** Brands emphasise the use of "100% fruiting bodies," which are the richest source of beta-glucans, contrasting them with lower-cost mycelium grown on grain substrates that can dilute the active compounds (Fera Pets 2023; Standard Process Veterinary Formulas 2025).
- **Sourcing and Contamination:** Because mushrooms are bio-accumulators that can absorb toxins like heavy metals and pesticides, brands highlight USDA Organic certification and controlled growing environments to build consumer trust (Earth Buddy Pet 2025; Feed & Additive 2025).
- **Extraction and Bioavailability:** Proper hot water or dual-extraction methods are crucial to break down the chitin in fungal cell walls, making the active compounds bioavailable. Brands often emphasise their specific extraction methods as a mark of a superior product (Earth Buddy Pet 2025).

12.5.3 Novel and Alternative Proteins

This category addresses the need for therapeutic solutions for food sensitivities. The term "novel protein" has both a precise clinical definition and a broader marketing application, creating a point of conflict (Thrive Pet Healthcare 2025).

12.5.3.1 *Definition of novel proteins*

A Therapeutic Tool vs. Marketing Claims: In veterinary medicine, a "novel protein" is a source to which a pet has had no prior exposure, such as goat, kangaroo, venison, or duck (Thrive Pet Healthcare 2025). Its primary medical use is in elimination trials to diagnose and manage adverse food reactions like allergies, intolerances, and IBD. Veterinarians recommend prescribed novel protein diets for these trials due to their stringent manufacturing processes that prevent cross-contamination (Thrive Pet Healthcare 2025).

This clinical purpose is in conflict with marketing trends. While veterinarians advise against feeding a wide variety of proteins to healthy young animals to "preserve" the novelty of certain proteins for potential future allergy diagnosis (Thrive Pet Healthcare 2025), brands actively promote novel proteins as premium, and for dietary variety, using terms like "exotic" or "ancestral" (Beco 2024). This repurposes a clinical term into a marketing term, creating confusion for pet owners caught between veterinary advice and compelling marketing.

12.5.3.2 *Alternative Proteins, Insect Protein and Algal Oil:*

- **Insect Protein:** Derived from sources like black soldier fly larvae and crickets, insect protein is emerging as a sustainable and novel, hypoallergenic protein source (Gingr 2025; Glanbia Nutritionals 2025; PetKing Global 2025). It requires significantly less land, water, and feed, and produces fewer emissions than traditional livestock. Furthermore, the exoskeletons of insects are rich in chitin, which functions as a prebiotic fibre to support gut health (Jiminy's 2023). Consumer acceptance is growing, with 3% of U.S. dog owners reporting they have purchased insect protein food (Glanbia Nutritionals 2025).
- **Algal Oil:** As a source of the omega-3 fatty acids EPA and DHA, algal oil is challenging the dominance of fish oil (Pentlands Publishing 2024). It is marketed on a sustainability narrative,

as it bypasses the marine food chain entirely and avoids the risk of heavy metal contamination found in some fish (DOG by Dr Lisa 2025). It offers a vegan, pure source of omega-3s, making it an alternative for pets with fish allergies (Pentlands Publishing 2024; Simon Veterinary Surgical 2024). While the benefits of EPA and DHA for conditions like atopic dermatitis and OA are well-established, most of the foundational research used fish oil (Magalhães et al. 2021). Algal oil marketing thus relies heavily on its compelling sustainability story and the logical assumption of equivalent biological performance (DOG by Dr Lisa 2025).

12.5.4 Probiotics

This rapidly advancing field focuses on modulating the pet's internal ecosystem, moving from general wellness products to data-driven personalised nutrition (Atuahene et al. 2024). The gut microbiota is a foundation of pet wellness, playing a role in digestion, nutrient absorption, vitamin synthesis, intestinal barrier integrity, and immune system regulation (Atuahene et al. 2024). Dysbiosis, or an imbalance in this microbial community, is linked to GI disorders like chronic enteropathy and IBD, as well as systemic conditions such as allergies (Yang and Wu 2023).

Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit (Atuahene et al. 2024). Systematic reviews confirm their influence on gut microbiota, immune responses, and gut barrier function (Atuahene et al. 2024). However, efficacy is strain-specific. For example, the strain *Enterococcus faecium* SF68 has been shown to be effective for managing acute diarrhea in dogs and cats, while certain *Lactobacillus* and *Bifidobacterium* strains can promote a balanced microbiota and reduce inflammation (Karukayil Gopalakrishnan et al. 2025). To be effective, live bacteria must survive manufacturing, storage, and the acidic environment of the digestive tract. Therefore, factors like microencapsulation technology and delivering a sufficient dosage (measured in Colony Forming Units, or CFUs) are critical for therapeutic effect (Karukayil Gopalakrishnan et al. 2025; Sivamaruthi et al. 2021).

The field is expanding beyond simple probiotics to a comprehensive "biotic" toolkit for more nuanced interventions:

- **Prebiotics:** These are indigestible fibres (e.g., FOS, MOS, and chitin from insects) that act as food for beneficial gut bacteria, encouraging their growth and activity (Jiminy's 2023).
- **Postbiotics:** These are the beneficial compounds produced by probiotic bacteria during fermentation (e.g., short-chain fatty acids, enzymes) or are heat-killed microorganisms that still exert immune benefits (Glanbia Nutritionals 2025). Postbiotics offer greater stability than live probiotics and are not affected by antibiotics.

The ultimate frontier is hyper-Personalisation. The convergence of at-home microbiome analysis kits (using DNA sequencing), artificial intelligence, and genetic testing enables the creation of personalised cocktails of probiotic strains, prebiotics, and postbiotics designed to address an individual pet's specific microbial imbalances (Research and Markets 2025). This data-driven approach creates a defensible competitive advantage, allowing for the continuous refinement of formulations based on measured health outcomes (Hardt 2025). This evolution signifies a market shift from generic "gut health" supplements to precision therapeutics, raising the barrier to entry and rewarding scientific validation over simplistic marketing.

13. Risk Assessment & Mitigation

13.1 Regulatory Approval Risks & Mitigation Pathways

Introducing a pet supplement, particularly one leveraging advanced technologies like 3D printing and novel red-meat ingredients, involves regulatory approval considerations. These considerations stem from the Australian regulatory landscape, the nature of the technology and ingredients, and the potential for misclassification. Effective mitigation requires a proactive strategy that integrates regulatory foresight with robust internal controls and strategic external engagement.

13.1.1 Regulatory Ambiguity and Classification Risks

The primary consideration for a 3D-printed pet nutraceutical in Australia is its regulatory classification, which directly dictates the approval pathway and associated requirements. As detailed in Section 9.1, the Australian framework presents a nuanced pathway for such innovative products, requiring careful classification to navigate regulatory requirements.

- **Risk of Misclassification as a Veterinary Chemical Product:** If the 3D-printed supplement makes any explicit therapeutic claims (e.g., "treats arthritis," "cures digestive issues"), it will be classified as a VCP and fall under the stringent purview of the Australian Pesticides and Veterinary Medicines Authority (APVMA 2024). This necessitates a thorough registration process, requiring scientific data to substantiate efficacy and safety, including data on the manufacturing process (APVMA 2024). The application of 3D printing could introduce specific considerations for data requirements, as the APVMA would need assurance that the process maintains ingredient stability and safety.
- **Mitigation:**
 - Precise Claim Management: A key mitigation strategy is to meticulously craft all marketing and labelling claims to avoid therapeutic language. Focus on general wellness, nutritional support, or "supports healthy function" rather than "treats" or "cures" (APVMA 2024). This aligns the product with the END product pathway, which offers an efficient route for APVMA exemption.
 - Early APVMA Consultation: Engage in pre-submission discussions with the APVMA to seek informal guidance on the proposed product's classification and data requirements. This proactive dialogue can clarify expectations and facilitate a smoother regulatory process (APVMA 2024).
- **Risk of Non-Compliance with END Product Criteria:** Even when aiming for END status, failure to meet any of the four mandatory tests (ingredients, manufacturing, labelling, claims) will disqualify the product from exemption, potentially requiring APVMA registration (APVMA 2025b). The "manufacturing" test is critical for 3D-printed products, as existing quality assurance (QA) systems (e.g., AS 5812) may require adaptation for additive manufacturing processes.
- **Mitigation:**
 - Robust Quality Assurance for 3D Printing: Develop and implement a QA system specifically tailored to 3D printing, ensuring consistency, safety, and traceability of the "inks" and the final product. This system should align with principles of Good Manufacturing Practices (GMP) and ideally seek certification under AS 5812 to demonstrate adherence to industry best practices (APVMA 2025b; PFIAA 2016).

- Ingredient Pre-Approval/GRAS Status: Ensure all red-meat derivatives and other ingredients are on recognised "Generally Recognised As Safe" (GRAS) lists or have a strong scientific basis for safety, aligning with the END product ingredient test (APVMA 2025b).
- **Risk of Misleading/Deceptive Claims under Australian Consumer Law (ACL):** Regardless of APVMA classification, all marketing and labelling claims are subject to the Australian Competition and Consumer Commission (ACCC) and the ACL's prohibition on misleading or deceptive conduct (ACCC 2025). Overstating benefits or making unsubstantiated claims, even if non-therapeutic, can lead to penalties and reputational damage.
- **Mitigation:**
 - Evidence-Based Marketing: All claims, even general wellness claims, must be substantiated by credible scientific evidence. Invest in research and studies to support product benefits.
 - Legal Review of All Communications: Conduct legal review of all product labels, marketing materials, and online content to ensure compliance with ACL and avoid ambiguous language that could be interpreted as misleading (Givoni 2025).

13.1.2 Technical and Safety Approval Risks

The application of 3D printing introduces specific technical and safety considerations that regulators would scrutinise, even for END products.

- **Risk of Microbial Contamination:** The geometries and potential for difficult-to-clean surfaces in 3D food printers, combined with the use of red-meat ingredients, require careful management to prevent microbial growth and contamination (Zhu et al. 2023).
- **Mitigation:**
 - Hygienic Design and Materials: Utilise 3D printer designs and materials that are food-grade, easily cleanable, and resistant to microbial colonisation.
 - Validated Sanitation Protocols: Implement validated sanitation protocols for all printing equipment and environments.
 - Ingredient Stabilisation: Leverage patented technologies for stabilising red-meat slurries (e.g., fermentation to lower pH) to reduce microbial load before printing (Smittle and Phelps 2014).
 - Post-Processing Sterilisation/Treatment: Explore post-printing treatments (e.g., drying, UV light, or other non-thermal methods) that can further reduce microbial risks without compromising active ingredients.
- **Risk of Active Ingredient Degradation and Inaccurate Dosage:** Many nutraceuticals are sensitive to heat, pressure, and oxidation, which can occur during 3D printing processes. This requires careful management to ensure efficacy and consistent dosing in the final product (Riaz et al. 2009).
- **Mitigation:**
 - Microencapsulation of Active Ingredients: As discussed in Section 9.2.3, microencapsulate sensitive active ingredients to protect them from degradation during the printing process and ensure controlled release and bioavailability (Erbo Spraytec AG 2021).
 - Multi-Material Printing Strategy: Develop a multi-ink printing system where the red-meat base is printed separately from a concentrated, protected "supplement ink." This decouples the processing conditions of the meat from the sensitive nutraceuticals (InsightsGate 2025).

- In-Process and Finished Product Testing: Implement in-process quality control and finished product testing for active ingredient potency and consistency across batches. This includes stability testing to ensure shelf-life claims are met.
- **Risk of Unintended Chemical Leaching from Printer Components:** Regulators would require assurance that all materials in contact with the product during printing are food-safe and do not leach chemicals into the pet supplement (Boissonneault 2024).
- **Mitigation:**
 - Food-Grade Materials Certification: Source 3D printing equipment and consumables (e.g., nozzles, build plates) that are certified food-grade and provide documentation of material safety.
 - Migration Testing: Conduct migration testing to demonstrate that no substances transfer from the printer components to the food product under various printing conditions.

13.1.3 Mitigation through Strategic Positioning and Future Regulatory Foresight

- **Strategic Niche Positioning:** Initially target a niche market where the benefits of 3D printing (e.g., personalisation, enhanced palatability for picky eaters, precise dosing for specific conditions) offer a compelling advantage. This allows for controlled market entry and data collection.
- **Advocacy and Collaboration:** Engage with industry bodies (e.g., PFIAA, AVA) and potentially the APVMA to advocate for clearer regulatory guidelines for 3D-printed pet food and supplements. Participate in discussions to help shape future frameworks, potentially drawing parallels with the TGA's "medical device production system" (MDPS) model for human medical devices, which regulates the entire system (printer, software, materials) rather than just the end product (Therapeutic Goods Administration 2025). This proactive engagement can help optimise the long-term regulatory environment.
- **Transparency and Traceability:** Implement end-to-end traceability for all ingredients, especially red-meat derivatives, and for the 3D printing process itself. This transparency builds consumer and veterinarian trust and facilitates rapid response in case of quality issues.

By proactively addressing these regulatory and technical considerations through meticulous planning, robust scientific validation, and strategic engagement, a 3D-printed red-meat pet supplement can navigate the Australian regulatory landscape and establish a strong, defensible market position.

13.2 Supply-Chain Quality & Traceability Risks

The expansion of the pet supplement sector, driven by the humanisation of pets, has placed strain on a supply chain that is often fragmented and opaque. This creates considerations related to quality, safety, and traceability, which can have financial, reputational, and legal consequences for brands and impact pets (Allied Market Research 2024; Grand View Research 2023).

13.2.1 Overview of the Pet Supplement Supply Chain

The journey of a pet supplement from raw ingredient to finished product involves a global network, presenting points where quality can be compromised and traceability lost (Global Logistical Connections, Inc 2023).

13.2.1.1 The Global Sourcing of Ingredients

The integrity of the final product is linked to the quality and safety of its raw materials, which are procured from a diverse global network (Global Logistical Connections, Inc 2023). Key ingredient categories and their inherent risks include:

- **Animal-Derived Ingredients:** Common sources for protein and fat, such as meat and bone meals, animal fats, and by-products. Sourcing from the human food processing industry requires careful management of handling and quality standards to prevent contamination or degradation (Global Logistical Connections, Inc 2023; Hanseatic Agri 2025b; Contract Manufacture Animal Products 2023).
- **Marine-Derived Ingredients:** Valued for omega-3s, sources like fish meals and purified oils require attention to sustainability and potential contamination with heavy metals (Hanseatic Agri 2025b).
- **Botanical and Vegetable-Derived Ingredients:** This category includes herbal extracts (e.g., chamomile, turmeric), functional mushrooms, and vegetable components. The global and often wild-sourced nature of botanicals necessitates careful sourcing to prevent misidentification, adulteration, and contamination with pesticides or heavy metals (Superior Supplement Manufacturing 2025; Nutrasource 2024).
- **Synthesised and Fermented Ingredients:** Most vitamins, minerals, amino acids, and probiotics are produced industrially. While designed for high purity, careful management is needed to prevent contamination with solvents or unwanted by-products from the manufacturing process (Nutrasource 2024).

Brands often rely on contract manufacturers for procurement, which necessitates clear communication regarding the origin and quality of these ingredients (Gembah 2025).

13.2.1.2 Manufacturing Models and Distribution Channels

The chosen production and distribution models impact risk profiles. Brands may opt for in-house production, which offers maximum control but requires capital investment, a model typically reserved for large corporations (MarketsandMarkets 2025). More commonly, brands partner with a Contract Development and Manufacturing Organisation (CDMO), which requires trust and rigorous oversight (ResearchAndMarkets.com 2024). The lowest barrier to entry is private label (or white label) manufacturing, where a single facility produces for many brands. This model requires careful oversight, as a quality failure at one facility can trigger recalls across multiple labels, as seen in the 2007 melamine crisis (Supliful 2025; AAFCO 2025c).

Once produced, supplements are distributed through offline channels like pet specialty stores and veterinary clinics, which offer expert advice and foster trust, or through online channels (ResearchAndMarkets.com 2024). The online segment, including e-commerce dominant companies and direct-to-consumer (DTC) websites, is the fastest-growing, offering convenience and selection (Grand View Research 2023). However, this shift removes traditional gatekeepers like veterinarians, placing the burden of due diligence on consumers and requiring careful product selection (Hewitt 2025).

13.2.2 Chain of Vulnerabilities: Quality and Contamination Risks

The global and fragmented nature of the supply chain creates points requiring careful management at every stage.

13.2.2.1 Raw Material Contamination and Adulteration

Ingredients require careful management to prevent a range of contaminants during cultivation, harvesting, storage, or initial processing (Nutrasource 2024).

- **Chemical Hazards:** Potential threats include heavy metals (lead, arsenic, cadmium, mercury) from soil and water, pesticide residues on botanicals, and mycotoxins like aflatoxin from molds (FDA 2025; Rumbeisha and Morrison 2010). Aflatoxin contamination, in particular, has been responsible for pet food recalls that have led to pet illness and death (Rumbeisha and Morrison 2010).
- **Biological Hazards:** Pathogenic bacteria such as *Salmonella*, *E. coli*, and *Listeria monocytogenes* require careful management, especially in raw animal-derived ingredients, to protect the health of both pets and their human handlers (AAFCO 2025c).
- **Economic Adulteration:** This involves the substitution of declared ingredients with cheaper, lower-quality, or entirely different substances for financial gain (AAFCO 2025c). The 2007 melamine crisis, where melamine was added to wheat gluten to artificially inflate protein content readings, is an example of this fraud, which led to pet deaths (AAFCO 2025c). Adulteration has also been documented in botanical ingredients (Du et al. 2025).

13.2.2.2 Manufacturing and Formulation Hazards

Careful process controls are essential during manufacturing to prevent issues.

- **cGMP Violations:** Failure to follow current Good Manufacturing Practices (cGMPs) can lead to cross-contamination between product lines, contamination from facility issues like leaks, and inadequate sanitation (FDA 2025).
- **Formulation Errors and Product Stability:** Inaccurate dosages, resulting in either sub-potent or super-potent products, are quality control failures. Recalls have been initiated due to excesses of Vitamin D3 and methionine (Rumbeisha and Morrison 2010). Independent studies reveal instances of inaccurate labeling for active ingredients like chondroitin sulfate and CBD, highlighting the importance of accurate labeling (Finno 2020; Smiley-Jewell and Lein 2022). A Certificate of Analysis (COA) for each batch is an important indicator of quality control (Champion Bio 2025). Furthermore, manufacturing processes like heat extrusion can degrade sensitive nutrients, making stability testing essential to validate "best by" dates and ensure potency throughout the product's shelf life (Rumbeisha and Morrison 2010; Superior Supplement Manufacturing 2025).

13.2.2.3 Packaging and Distribution Risks

The final stages of the supply chain also present considerations, including packaging failures that allow moisture, oxygen, or light to degrade the product (AQI Service 2025).

13.2.3 The Traceability Imperative: Consequences and Solutions

Traceability is a fundamental component of risk management, consumer safety, and brand trust.

- **Financial Costs:** The direct costs of a recall are substantial, averaging USD 10 million for food companies, a figure that excludes the indirect costs of litigation and lost future sales (Akselsen 2022).
- **Reputational Damage:** In the digital age, news of recalls spreads instantly, eroding consumer trust and potentially impacting affected brands (Champion Bio 2025).

- **Legal and Regulatory Consequences:** Recalls invite scrutiny from regulators, leading to fines and civil lawsuits. Legislation like the FDA's Food Safety Modernisation Act (FSMA) increases liability for all parties across the supply chain (Petfood Industry 2023).

The problem of *Salmonella* recalls highlights how inefficient traceability can force broad recalls, increasing costs and delaying the removal of products from the market (FDA 2025; Cleaver 2025).

Advanced technologies are crucial for building the transparent and resilient supply chains necessary to manage these considerations.

- **DNA Barcoding:** This technology acts as a genetic fingerprint to authenticate plant species, providing a tool to combat adulteration of botanical ingredients. It is most effective when used on raw, unprocessed materials (Chen et al. 2023; Balaji and Parani 2022).
- **Blockchain:** By creating an immutable, decentralised ledger, blockchain technology can provide an end-to-end audit trail. It records every movement and transformation of an ingredient from source to shelf, enabling rapid and precise tracing during a recall. However, its integrity depends on the accuracy of the initial data entry (Dock Labs 2025; Wheatley 2018).

These technologies are components within a comprehensive quality management system that must also include rigorous supplier vetting, independent third-party audits, and robust physical testing. Their immediate value lies in building consumer trust by providing verifiable proof of quality and sourcing claims (Champion Bio 2025).

13.3 Market Adoption Risks (Education, Pricing)

The Australian pet supplement market, while experiencing growth driven by pet humanisation, faces market adoption considerations rooted in a "trust deficit." This deficit stems from an interplay of consumer education gaps and a price-value conundrum, creating hurdles for new and premium-priced products (IMARC Group 2024; Grand View Research 2025b).

13.3.1 The Education Gap: A Primary Barrier to Adoption and Trust

An education gap impacts the confident adoption of pet supplements. Consumers are frequently caught between credible veterinary advice and a volume of online information, leading to confusion, skepticism, and cautious purchasing behaviour (Chen 2025; Vet Practice Magazine 2016).

13.3.1.1 Consumer Knowledge Gap: Myths, Misconceptions, and Misinformation

A foundational consideration is that many pet owners operate under misconceptions about pet nutrition. Key myths include:

- **The Myth of Universal Need:** Many owners believe all pets require supplements, even those on "complete and balanced" diets. In reality, high-quality commercial foods are nutritionally complete, and unnecessary supplementation should be carefully considered (Chen 2025).
- **The Myth of Inherent Safety:** There is an assumption that any supplement available for purchase is inherently safe and effective. However, Australia's regulatory landscape for many supplements means that quality, purity, and efficacy can vary between products (Spanner 2020).
- **The Myth of Remedial-Only Use:** While therapeutic use is a market driver, the concept of preventive supplementation requires a nuanced, evidence-based application rather than blanket use across all pets (MuttGut 2024).

- **The Myth of Species Crossover:** The humanisation trend leads many owners to assume that human supplements are safe for pets, despite different metabolic pathways and the potential for toxicity (Chen 2025).

This knowledge void makes consumers highly susceptible to emotionally driven but scientifically unsubstantiated marketing, which ultimately undermines long-term trust in the category (Spanner 2020).

13.3.1.2 Credibility Conflict: Veterinary Counsel vs. The Uncontrolled Digital Landscape

Pet owners are caught in a credibility conflict, torn between their trusted veterinarian and the vast, unregulated, and often conflicting information available on the internet.

- **The Veterinary Channel:** Veterinarians are a trusted source of information, with 59% of consumers seeking their advice for supplement purchases (Copeland 2022). Vets can provide personalised, evidence-based recommendations. However, products sold through veterinary clinics are typically more expensive due to the lower purchasing power of individual clinics and the embedded costs of professional consultation (Berwick Clyde Vet 2025).
- **The Unregulated Online Environment:** Online channels offer convenience, a wider selection, and lower prices, often 30-50% less than vet clinics (Berwick Clyde Vet 2025). However, this space is fraught with misinformation, counterfeit products, and unsubstantiated claims that are not policed (Cheng 2025; Givoni 2025). This dynamic encourages "showrooming," where owners seek veterinary advice but purchase online, which can impact the perceived value of veterinary expertise and influence recommendations (Berwick Clyde Vet 2025).

13.3.1.3 Misleading Scientific Claims and the Efficacy Deficit: The Importance of Proof

A gap exists between the health claims made by many supplements and the scientific evidence to support them, leading to a consumer-perceived "efficacy deficit." For many popular categories, such as glucosamine and chondroitin, clinical evidence shows "modest benefits," while the general health benefits of fish oil in already healthy pets require further evidentiary support (Vetster Editorial Team 2024).

To compensate, brands often engage in unsubstantiated scientific marketing using scientific-sounding language and unregulated marketing phrases like "natural," "human-grade," and "veterinarian formulated" to create a perception of validity without robust, peer-reviewed evidence (Bray 2020; Chadwick Nutrition 2025). This is an important issue because consumers are more likely to repurchase a product when they can see tangible results (e.g., a shinier coat, improved mobility). For supplements focused on long-term wellness or prevention, where benefits are invisible, the brand's trustworthiness becomes the sole proxy for value, making the product susceptible to consumer skepticism (MarketsandMarkets 2025).

13.3.1.2 Complex Regulatory Landscape: A Fragmented Oversight

Australia's regulatory framework, which is fragmented and largely voluntary, can contribute to market confusion and risk. The Australian Pesticides and Veterinary Medicines Authority (APVMA) regulates products making therapeutic claims, while the Australian Competition and Consumer Commission (ACCC) oversees general consumer law against misleading advertising (Australian Pesticides and Veterinary Medicines Authority 2024; Givoni 2025a). However, most over-the-counter supplements operate under an exemption from APVMA registration if they make no explicit therapeutic claims (Australian Pesticides and Veterinary Medicines Authority 2024). This was a policy choice in 2015 to reduce administrative burden (CHOICE 2025).

The primary industry standard for pet food manufacturing, AS 5812:2017, is voluntary, not mandatory, meaning compliance is not government-enforced (CHOICE 2025). Advocacy groups like the RSPCA have argued for this standard to be made mandatory to protect pets (RSPCA Australia 2025). This structure creates a market with limited consumer protection where consumers may assume products are safe simply because they are sold, a fallacy that highlights the need for independent monitoring, testing, or licensing for products on the shelf (Spanner 2020).

13.3.2 The Price-Value Conundrum: A Barrier to Mass-Market Penetration

The second adoption consideration stems directly from the education gap: justifying a premium price for supplements with intangible benefits and requiring clear efficacy demonstration is challenging.

Australian pet owners are pragmatic and price-conscious. After palatability, price and perceived value are important purchasing drivers for 37% of owners (Buelva 2022). This sensitivity is amplified by rising living costs, which make consumers more cautious with discretionary spending. Supplements, often viewed as non-essential, are susceptible to being cut from household budgets (Oakley-Newell 2023). The central challenge for any supplement brand is balancing its tangible cost against its perceived benefits.

- **Intangible Benefits:** Most supplements offer abstract, preventive, or long-term benefits (e.g., "supports joint health") that are difficult for owners to observe on a daily basis. This impacts the value proposition, as the return on investment is not immediately apparent (MarketsandMarkets 2025).
- **Visible Results Drive Value:** In contrast, products that deliver visible results are more likely to secure repeat purchases (MarketsandMarkets 2025).
- **Trust as a Proxy for Value:** In the absence of visible results, brand trust becomes a critical factor. However, with 63% of pet owners finding pet food labels misleading, there is distrust that brands must overcome (Schleicher et al. 2019). High prices for unproven benefits can be perceived as overpriced, whereas stronger, verifiable proof of efficacy can justify a premium price by de-risking the purchase for the consumer (Schleicher et al. 2019).

Supplement prices vary by retail channel, creating a fragmented and confusing landscape for consumers.

- **Veterinary Clinics:** The most expensive channel, reflecting lower purchasing volumes and embedded professional consultation costs (Berwick Clyde Vet 2025).
- **Online Pharmacies and Retailers:** Typically the cheapest channel, offering discounts of 30-50% and commoditising supplements by uncoupling them from professional advice (Pet Chemist Australia 2025; PetSure 2025a).
- **Specialty Pet Retailers:** Occupy a middle ground with a broader selection but face price competition from online players (Petstock 2025).
- **Supermarkets:** Offer a limited range focused on mass-market brands (New Zealand Trade and Enterprise 2023).

This price disparity drives commoditisation, impacts profit margins, and influences investment in research and development. To succeed, premium brands can differentiate themselves, for example, by creating unique direct-to-consumer (DTC) experiences or personalised subscription models that build a direct relationship with the consumer (New Zealand Trade and Enterprise 2023).

13.4 Technical Scale-Up and IP Risks

Bringing a pet supplement to market, particularly one involving advanced technologies like 3D printing and novel ingredients, requires navigating technical scale-up and intellectual property (IP) considerations. These challenges are fundamental to ensuring product safety, efficacy, and long-term brand defensibility in a demanding market (Miller 2025b).

13.4.1 The Technical Pathway: From Concept to Commercial Scale

The journey from a promising concept to commercial production involves technical challenges that impact product safety, efficacy, and brand reputation.

13.4.1.1 Formulation and R&D: The Triad of Efficacy, Palatability, and Stability

Formulation is a balancing act between three critical, often competing, factors.

- **The Efficacy-Evidence Gap:** A challenge is creating demonstrably effective products. The pet supplement industry often requires more rigorous, species-specific scientific data for many ingredients, leading to extrapolation from human or rodent studies, which can create regulatory considerations (Miller 2025b). While 95% of functional supplement purchases are influenced by health benefit claims, conducting robust clinical trials to substantiate these claims is an investment (PetfoodIndustry 2025).
- **The Palatability Hurdle:** A scientifically sound supplement requires high acceptance by pets to be commercially viable. Achieving high acceptance rates (e.g., 90-97%) often requires specialised flavour bases and palatants, which must be incorporated without compromising the stability of active ingredients or the integrity of the final product (Pet Flavors 2024).
- **The Stability and Bioavailability Challenge:** The formulation must remain stable and potent throughout its shelf life. The efficacious dose of an ingredient may require careful formulation for a practical serving size to prevent underdosing and ensure effectiveness (Miller 2025b). Furthermore, active ingredients are sensitive to heat, oxygen, light, and moisture. Manufacturing processes like high-heat extrusion can degrade nutrients, leading to potency loss (Galli et al. 2024). Finally, the formulation must ensure that active ingredients are digestible and bioavailable to the pet, as ingredient quality or improper processing can reduce nutrient absorption (Cline 2016).

13.4.1.2 Supply Chain Integrity: The Foundation of Product Quality and Safety

Product integrity begins with the quality and safety of raw materials. New entrants must establish robust supplier qualification programs, partnering with reputable distributors who provide comprehensive documentation and traceability, including Certificates of Analysis (CofAs) that are verified by independent third-party testing (Nofalamin 2025; Hanseatic Agri 2025a). This is critical for mitigating contamination considerations from the global supply chain. Key considerations include heavy metals (lead, cadmium, arsenic) that can be introduced via synthetic mineral premixes and pathogenic bacteria like *Salmonella* and *Listeria* in raw animal-derived ingredients, which require careful management to protect both pets and humans (Solutions Pet Products 2024; CDC 2025). The supply chain is also susceptible to broader disruptions like ingredient shortages, freight costs, and scarcity of packaging materials, making the qualification of multiple suppliers for critical ingredients a crucial mitigation strategy (Beaton 2021).

13.4.1.3 The Manufacturing Scale-Up Pathway

Transitioning from pilot-scale to commercial production involves technical, operational, and financial challenges.

- **The Transition from Small Batch to Mass Production:** Startups face Minimum Order Quantities (MOQs) from contract manufacturers (often 5,000-10,000 units), making it essential to find partners with lower MOQs (e.g., 2,500 units) for a lean launch (Matsun Nutrition 2025). Scaling requires strategic facility planning and investment in automation for tasks like ingredient weighing and mixing to improve precision and ensure batch consistency (Townsend 2025; APEC 2024). Scaling up is not a linear process; lab-scale processes may require adaptation at an industrial scale due to changes in physics and fluid dynamics, necessitating that process design and techno-economic analysis begin early in the development cycle (Attaianese et al. 2024).
- **The CDMO Partnership:** Most brands rely on Contract Development and Manufacturing Organisations (CDMOs) for speed-to-market and capital efficiency (GETIDA 2025). However, this creates an IP consideration, as the CDMO may develop and own novel manufacturing processes created during scale-up (Tran 2025). A rigorous vetting process for CDMOs is therefore essential, focusing on quality certifications (e.g., NASC Quality Seal), technical capabilities, scalability, and, most importantly, the terms of the IP agreement (National Animal Supplement Council 2025; Matsun Nutrition 2024; GETIDA 2025).

13.4.2 The Intellectual Property Landscape: Protecting and Defending Innovations

Establishing and defending a unique position in the pet supplement market requires a sophisticated, multi-layered IP strategy. A robust IP strategy integrates several forms of protection.

- **The Patentability Question:** Securing a patent is challenging due to the "non-obviousness" standard, meaning simple combinations of known ingredients are less likely to be patented (PatentFile.org 2016). However, several pathways exist:
 1. Novel Formulations: Patents may be granted for unique ingredient combinations that demonstrate a synergistic effect, but this requires strong scientific evidence (Tran 2025).
 2. Novel Manufacturing Processes: This is often a promising avenue. Unique methods that enhance stability, bioavailability, or enable novel delivery formats (like 3D printing) are highly patentable (Tran 2025).
 3. New Methods of Use: Discovering and substantiating a new therapeutic use for a known ingredient can also be patented (PatentFile.org 2016). The scientific data generated for regulatory purposes can be repurposed to support patent applications, making clinical trials a strategic investment for both optimising the product and creating a valuable IP asset (Miller 2025b). A provisional patent application is a cost-effective first step to secure a filing date (Tran 2025).
- **Trade Secrets and Trademarks:** When patentability is unlikely, trade secrets can protect proprietary information like formulations or supplier lists indefinitely, provided strict confidentiality is maintained (PatentFile.org 2016). However, they offer no protection against reverse engineering. A strong brand, protected by trademarks for names, logos, and taglines, is also a valuable and defensible IP asset that prevents competitors from using confusingly similar branding (PatentFile.org 2016).

Before investing, a freedom-to-operate (FTO) analysis is imperative to determine if a proposed product or process infringes on existing patents (Tran 2025). The pet supplement landscape contains numerous patents covering various formulations and methods (Justia Patents Search 2025). Launching without a clear FTO is a risk that could lead to costly litigation, injunctions, and forced product withdrawal (Tran 2025).

13.4.3 Implications for 3D Printing Technology

The application of 3D printing technology to pet supplements introduces a unique set of technical scale-up and IP considerations that can be leveraged for competitive advantage.

- **Novel Manufacturing Process IP:** The 3D printing process itself, including specific extrusion parameters, material compositions (e.g., the rheology of a red meat paste), and post-processing techniques, offers opportunities for patentable process IP. This is a strong and defensible form of protection compared to simple ingredient combinations (Tran 2025).
- **Formulation for Printability:** Developing red meat-based formulations that are printable (i.e., have the correct viscosity, flow properties, and structural integrity) is an R&D focus. This effort can lead to patentable formulation IP related to the specific blend of red meat, binders, and other excipients that enable the 3D printing process.
- **Personalisation and Customisation IP:** The ability of 3D printing to create customised shapes, sizes, and dosages for individual pets (e.g., based on breed, weight, or health data) can be a source of IP, particularly if combined with proprietary, data-driven personalisation algorithms. Ensuring consistent quality, speed, and cost-effectiveness at scale will require engineering and process optimisation, which can in turn generate valuable and defensible process IP (Attaianese et al. 2024).
- **Freedom-to-Operate for Printing Technologies:** A thorough FTO analysis must extend beyond supplement ingredients to include existing patents on 3D printing technologies, especially those related to food or pharmaceutical applications, to avoid infringement.

By strategically focusing on patenting the novel 3D printing processes, the unique printable red meat formulations, and the data-driven personalisation capabilities, a proof-of-concept can build a robust and defensible IP portfolio, creating a competitive advantage in the pet supplement market.

14. Conclusion

The present study confirms a significant and commercially viable opportunity for the Australian red meat industry within the nation's large, resilient, and rapidly growing pet supplement market. The project synthesises market data, consumer behaviour, veterinary health priorities, and the regulatory landscape to provide a strategic roadmap for developing and launching premium, red meat-based pet supplements. The core opportunity lies in leveraging the high-quality perception of Australian red meat to meet a clear consumer demand for natural, science-backed preventative health solutions, driven by the powerful "humanisation" of pets trend.

Key learnings from this project indicate that market success is not contingent on ingredient novelty alone, but on a strategic approach to product formulation, claims substantiation, and regulatory navigation. A primary knowledge gap identified is the need for pet-specific clinical data to validate the efficacy of novel red meat derivatives for specific health applications. Such evidence is critical for gaining the trust of veterinarians and justifying premium price points to discerning consumers. Furthermore, while advanced manufacturing like 3D printing presents a compelling frontier for

differentiation through personalisation, its application requires the development of a clear regulatory framework and robust quality assurance systems to address safety and consistency concerns.

14.1 Key Findings

- **Strong Market Viability:** The Australian pet supplement market is a substantial and high-growth sector, valued within a broader AUD \$2.9 billion pet healthcare segment and projected to grow at a CAGR of 5.2% or higher. This growth is underpinned by non-cyclical consumer trends, primarily the humanisation of pets and a focus on preventative wellness.
- **Clear Consumer Demand:** A distinct consumer demographic, driven by Millennials and Gen Z, is actively seeking and willing to pay a premium for natural, functional, and scientifically backed supplements. These consumers already perceive red meat as a high-quality protein source, creating a strong foundation for market entry.
- **Strategic Opportunity in Red Meat Ingredients:** A significant opportunity exists to add value to red meat outputs by moving beyond commodity ingredients. Specifically, rebranding nutrient-dense organ meats like beef liver as "superfoods" aligns perfectly with consumer trends and can transform lower-value products into high-margin ingredients.
- **Defined Health Targets:** The most commercially attractive opportunities are in supplements targeting high-cost, prevalent health conditions where owners seek preventative solutions. These include joint support (the largest market segment), skin and coat health, and digestive wellness, which are among the most frequent and expensive reasons for veterinary visits.
- **Viable Regulatory Pathway:** A clear, lower-burden pathway to market exists through the "Excluded Nutritional or Digestive (END)" product classification. This allows for market entry by focusing on general wellness claims (e.g., "supports joint health") rather than making direct therapeutic claims that would trigger a more onerous APVMA registration process (e.g., "treats arthritis").
- **Innovation and Differentiation Potential:** Advanced manufacturing, specifically 3D printing, offers a unique opportunity for market differentiation by enabling personalised supplements with precise dosages. While technically feasible, this pathway faces regulatory ambiguity. A defensible intellectual property position can be built around patenting the novel manufacturing processes and printable red meat-based formulations.
- **Critical Success Factors:** Long-term success is critically dependent on three factors: generating robust scientific evidence to substantiate health claims and gain veterinary endorsement; implementing rigorous supply chain management and quality control to ensure product safety and mitigate recall risk; and building consumer trust through transparent, evidence-based marketing to justify a premium price.

14.2 Benefits to Industry

14.2.1 Practical application of the project's insights and implications to the Australian red meat industry:

- **Value-Adding Strategy:** This report provides a direct strategy for the red meat industry to increase the value of its outputs. By leveraging processing innovations and marketing organ meats as premium "superfood" ingredients, the industry can create high-margin products from materials that may otherwise be treated as lower-value by-products.
- **Targeted Product Development Roadmap:** The findings offer a clear guide for product innovation, identifying the most lucrative health segments and consumer needs. This allows

the industry to focus R&D investment on developing formulations that address validated market gaps, such as fortifying a red meat base with anti-inflammatory omega-3s or clinically-proven probiotics.

- **Phased Market Entry Plan:** The analysis of the regulatory landscape provides a low-risk, phased market entry strategy. Companies can first launch a product under the END classification to establish a market presence and generate revenue, while simultaneously gathering data to potentially pursue a higher-value, APVMA-registered therapeutic product in the future.
- **Risk Management Framework:** The project outlines the primary risks, regulatory classification, supply chain integrity, and consumer trust, and provides actionable mitigation strategies. This includes specific guidance on claim language, the use of traceability technologies such as blockchain, and the necessity of science-backed marketing to build a reputable brand.

14.2.2 Benefits to the wider red meat industry because of this project and its outcomes:

- **New High-Value Revenue Streams:** By entering the resilient and fast-growing pet wellness sector, the Australian red meat industry can diversify its revenue base and capture significant value. This project provides the blueprint to access a share of a multi-billion-dollar domestic market, improving overall industry profitability.
- **Enhanced Brand Equity and Perception:** Successfully launching a line of premium, scientifically-validated pet supplements reinforces the global image of Australian red meat as a safe, high-quality, and nutritious product. This creates a positive perception, enhancing brand equity across both consumer and B2B markets.
- **Fosters Innovation and Competitiveness:** This research acts as a catalyst for innovation, encouraging the industry to move up the value chain from raw material supplier to developer of sophisticated consumer health products. Embracing the opportunities in advanced formulation and manufacturing technologies such as 3D printing positions the industry as a forward-thinking leader in a high-growth global market.

15. Strategic Insights and Future Directions

This section synthesises the key findings from the present study to provide strategic insights and actionable recommendations for stakeholders in the Australian red meat industry. It outlines the primary challenges and successes of the project, and details future directions for research, development, and market adoption to capitalise on the identified opportunities in the red meat-based pet supplement market.

15.1 Key Challenges and Successes

The project successfully navigated a complex market landscape to identify both significant hurdles and a clear, viable path to commercial success. These insights are critical for shaping future investment decisions.

15.1.1 Key Challenges Identified:

- **Navigating a Claims-Based Regulatory System:** The primary regulatory challenge is not the ingredients themselves, but the marketing claims made about the final product. A failure to strategically manage claim language could inadvertently classify a product as a Veterinary

Chemical Product, triggering a costly and time-consuming registration process with the APVMA.

- **Overcoming the Consumer Trust Deficit:** The market is characterised by a gap in scepticism towards unsubstantiated claims. Justifying a premium price for a preventative product, whose benefits are not immediately visible, requires building significant brand trust and providing verifiable proof of efficacy.
- **Managing Supply Chain Complexity:** The global supplement ingredient supply chain is fragmented and opaque, posing significant risks of contamination, adulteration, and inconsistent quality. Ensuring product safety and integrity is a critical operational hurdle that directly impacts brand reputation and consumer safety.
- **Addressing Novel Technology Hurdles:** While novel technologies such as 3D printing offers a powerful point of differentiation, it faces considerable challenges, including regulatory ambiguity, the need for robust quality assurance systems to prevent microbial contamination, and potential consumer neophobia towards "unnatural" food production methods.

15.1.2 Key Successes and Supporting Evidence:

- **Validation of a High-Growth Market Opportunity:** The project confirms that the Australian pet supplement market is a substantial, resilient, and rapidly growing sector. This growth is driven by the powerful "humanisation" of pet's trend, ensuring sustained consumer demand for premium wellness products.
- **Identification of a Clear Economic Value Proposition:** A key outcome is quantifying the tangible economic benefits for consumers, strengthening the case for adoption. By demonstrating that proactive supplementation can lead to significant long-term savings on reactive veterinary care for common conditions like osteoarthritis and skin allergies, the project provides a powerful marketing and value justification tool.
- **Definition of a Low-Risk Market Entry Pathway:** The research clearly outlines a strategic, lower-burden regulatory pathway via the "Excluded Nutritional or Digestive" product classification. This enables companies to enter the market through a phased entry strategy, generating revenue and building a market presence before investing in the clinical data required for higher-level therapeutic claims.
- **Pinpointing a High-Value Ingredient Strategy:** The project identified a clear strategy to add significant value to red meat outputs by rebranding low-cost by-products into premium "superfood" ingredients, directly aligning with prevailing consumer trends.

These findings collectively de-risk future investment. The challenges highlight where strategic resources must be allocated, specifically towards clinical validation, quality control, and evidence-based marketing. The successes confirm that the underlying market fundamentals are strong, the consumer need is real, and a clear, commercially viable roadmap exists.

15.2 Recommendations

The following recommendations are proposed to guide the Australian red meat industry in pursuing opportunities within the pet supplement space. These recommendations are informed by both the findings of this report and a review of the Meat & Livestock Australia Strategic Plan 2030 (Meat & Livestock Australia 2025) to ensure their relevance and alignment with industry priorities.

15.2.1 Future R&D

- **Prioritise Pet-Specific Clinical Efficacy Trials:** The most significant knowledge gap identified is the lack of pet-specific clinical data for red meat derivatives. Future R&D investment should be directed towards conducting robust clinical trials to validate the efficacy of specific red meat ingredients for high-demand health applications, such as joint support and skin health. This evidence is essential for gaining veterinarian endorsement, substantiating premium pricing, and pursuing future APVMA registration for therapeutic products.

- **Focus on Formulation for Palatability and Stability:** To capture the underserved and fast-growing feline market, R&D should focus on developing highly palatable formulations, particularly in powder and liquid forms. Further research is also needed to ensure the stability and bioavailability of sensitive, high-value active ingredients (e.g., probiotics, omega-3s) when combined within a red meat matrix and subjected to various manufacturing processes.
- **Develop Patentable 3D Printing Processes and Formulations:** To build a defensible competitive advantage, R&D should focus on the technical challenges of 3D printing. This includes developing proprietary, printable formulations with optimal stability, and patenting the novel manufacturing processes that protect active ingredients.

15.2.2 Practical Application of Project Insights

- **Initiate Product Development for the END Pathway:** Stakeholders can immediately use this report's findings to begin developing supplements for the END regulatory pathway. This involves formulating a red meat base and fortifying it with scientifically-backed ingredients like marine-sourced omega-3s and clinically-proven probiotic strains to target the joint, skin, and digestive health categories.
- **Construct an Evidence-Based Marketing Strategy:** Marketing and communication strategies should be built around the core project insights. This includes using the clear ROI data to frame the product as a smart financial investment in a pet's long-term health, employing approved non-therapeutic language ("supports," "maintains") to align with END classification, and transparently communicating the quality and safety of the red meat source.
- **Implement Rigorous Supply Chain and Quality Control Systems:** To mitigate risk and build a premium brand, companies should immediately implement advanced traceability and quality control measures. Adopting technologies like blockchain for ingredient traceability or DNA barcoding for botanical authentication can provide a verifiable guarantee of product safety and authenticity, turning a key market risk into a competitive advantage.

15.2.3 Development and Adoption Activities:

- **Establish a Veterinarian Engagement Program:** To overcome the consumer trust deficit, the industry should develop a proactive engagement program for veterinarians. This involves sharing peer-reviewed clinical data as it becomes available, providing educational resources on the role of nutrition in preventative health, and positioning red meat-based supplements as credible, science-backed tools for clinical practice.
- **Lead Industry Collaboration on Novel Manufacturing Standards:** To pave the way for innovations like 3D printing, the red meat industry should take a leadership role in collaborating with pet food manufacturers and regulatory bodies. The goal would be to develop a clear Quality Assurance framework for 3D-printed nutraceuticals, potentially modelled on existing frameworks for human medical devices, to reduce regulatory ambiguity and foster industry-wide adoption.
- **Launch a Consumer Education Initiative:** A targeted consumer education campaign should be developed to address the identified knowledge gaps around preventative care and product efficacy. This initiative should focus on explaining the science behind key ingredients, demonstrating the long-term value proposition, and teaching consumers how to interpret labels, thereby empowering them to make informed purchasing decisions and building trust in evidence-based products.

16. References

1-800-D2C (2024) The 71 Most Popular Pet Brands of 2025. Available at: <https://www.1800d2c.com/brand-category/pet> (Accessed: 16 August 2025).

AAFCO (2025a) Treats and Chews. Available at: <https://www.aafco.org/consumers/understanding-pet-food/treats-and-chews/> (Accessed: 16 August 2025).

AAFCO (2025b) What's in the Ingredients List?. Available at: <https://www.aafco.org/consumers/understanding-pet-food/whats-in-the-ingredients-list/> (Accessed: 16 August 2025).

AAFCO (2025c) When Things Go Wrong. Available at: <https://www.aafco.org/consumers/understanding-pet-food/when-things-go-wrong/> (Accessed: 16 August 2025).

ACANA. (2025) Red Meat Recipe. Available at: <https://www.acana.com/en-US/dogs/dog-food/red-meat-recipe/ds-aca-red-meat.html> (Accessed: 16 August 2025).

ACCC (2025) False or misleading claims. Available at: <https://www.accc.gov.au/consumers/advertising-and-promotions/false-or-misleading-claims> (Accessed: 16 August 2025).

Addiction Pet Foods (2025) How Venison meets your Pet's Nutritional Needs. Available at: <https://addictionpet.com/blog/how-venison-meets-your-pets-nutritional-needs/> (Accessed: 16 August 2025).

Adolphe, J. (2017) Dog Food Ingredients: Past, Present & Future. Available at: <https://www.groomertogroomer.com/dog-food-ingredients-past-present-future/> (Accessed: 16 August 2025).

AgFood Fund. (2024) What's fuelling the pet food industry? Humanisation. Available at: <https://www.agfood.com.au/post/what-s-fuelling-the-pet-food-industry-humanisation> (Accessed: 16 August 2025).

Agriculture Victoria. (2025) Victorian pet census | Animal welfare. Available at: <https://agriculture.vic.gov.au/livestock-and-animals/animal-welfare-victoria/animal-welfare/victorian-pet-census> (Accessed: 16 August 2025)

Akselsen, C. (2022) How Strong Traceability Programs Reduce Risks of Food Recalls, Food Logistics. Available at: <https://www.foodlogistics.com/safety-security/food-safety/article/22184349/kezzler-how-strong-traceability-programs-reduce-risks-of-food-recalls> (Accessed: 16 August 2025).

Ali, M. (2025) What Are The Benefits of Vegan Pet Food?, Wild Earth, 18 April. Available at: <https://wildearth.com/blogs/dog-knowledge/what-are-the-benefits-of-vegan-pet-food> (Accessed: 16 August 2025).

All Pet Food (2024) Pet food trends 2024: What to expect. Available at: <https://en.allpetfood.net/entradas/trends/> (Accessed: 16 August 2025).

All Pet Food. (2023) Production of pet food with 3D printing: myth or possibility?, All Pet Food Magazine N°14 -English version-. Available at:

https://issuu.com/allexttruded/docs/revista_2023_edic_14_eng/s/17862289 (Accessed: 16 August 2025).

Allied Market Research (2024) Pet Supplement Market Size, Share & Trends Report - 2035. Available at: <https://www.alliedmarketresearch.com/pet-supplement-market-A06522> (Accessed: 16 August 2025).

Allpetfood (2023) The DTC market is growing exponentially in the pet food industry. Available at: <https://en.allpetfood.net/entrada/the-dtc-market-is-growing-exponentially-in-the-pet-food-industry-54989> (Accessed: 16 August 2025).

American Cancer Society (2025a) Chemotherapy Side Effects. Available at: <https://www.cancer.org/cancer/managing-cancer/treatment-types/chemotherapy/chemotherapy-side-effects.html> (Accessed: 16 August 2025).

American Cancer Society (2025b) Monoclonal Antibodies and Their Side Effects. Available at: <https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/monoclonal-antibodies.html> (Accessed: 16 August 2025).

American Cancer Society (2025c) Targeted Therapy. Available at: <https://www.cancer.org/cancer/managing-cancer/treatment-types/targeted-therapy.html> (Accessed: 16 August 2025).

American Kennel Club (2023) Medicinal Mushrooms for Dogs: Uses, Side Effects, and Alternatives. Available at: <https://www.akc.org/expert-advice/health/medicinal-mushrooms-for-dogs/> (Accessed: 16 August 2025).

American Veterinary Medical Association (2023) Cannabis use and pets. Available at: <https://www.avma.org/resources-tools/animal-health-and-welfare/animal-health/cannabis-use-and-pets> (Accessed: 16 August 2025).

American Veterinary Medical Association (2025) Raw diets for dogs and cats. Available at: <https://www.avma.org/resources-tools/avma-policies/raw-or-undercooked-animal-source-protein-cat-and-dog-diets> (Accessed: 16 August 2025).

American Veterinary Medical Association. (2022) 2022 AVMA Pet Ownership and Demographics Sourcebook. Available at: <https://ebusiness.avma.org/files/ProductDownloads/eco-pet-demographic-report-22-low-res.pdf> (Accessed: 16 August 2025).

American Veterinary Medical Association. (2023) 2023 Pet Owner Attitude Survey: Key Findings. Available at: <https://www.avma.org/sites/default/files/2023-11/AVMA-2023-Pet-Owner-Attitude-Survey-For%20Release-20231101.pdf> (Accessed: 16 August 2025).

Animal Emergency Service (2022) The Ultimate Guide To Tick Paralysis - Everything You Need to Know. Available at: <https://animalemergencyservice.com.au/blog/the-ultimate-guide-to-tick-paralysis/> (Accessed: 16 August 2025).

Animal Medicines Australia (2022) Pets in Australia: A national survey of pets and people. Available at: https://animalmedicinesaustralia.org.au/wp-content/uploads/2022/11/AMAU008-Pet-Ownership22-Report_v1.6_WEB.pdf (Accessed: 16 August 2025).

Animal Medicines Australia (2023) Parasite control in pets: Frequently asked questions. Available at: https://animalmedicinesaustralia.org.au/wp-content/uploads/2023/05/AMA-Parasite-Control-in-Pets-FAQs_Final24May.pdf (Accessed: 16 August 2025).

Animal Medicines Australia. (2016) Pet Ownership in Australia 2016. Available at: https://animalmedicinesaustralia.org.au/wp-content/uploads/2016/12/AMA_Pet-Ownership-in-Australia-2016-Report_sml.pdf (Accessed: 16 August 2025)

Animal Medicines Australia. (2019) Pets in Australia: A national survey of pets and people. Available at: https://animalmedicinesaustralia.org.au/wp-content/uploads/2019/10/ANIM001-Pet-Survey-Report19_v1.7_WEB_high-res.pdf (Accessed: 16 August 2025)

Animal Necessity (2025) Ocu-GLO® Ocular Support for Dogs and Cats. Available at: <https://animalnecessity.com/all-natural-pet-care-supplement-products/ocu-glo-rx-natural-dog-eye-care.html> (Accessed: 16 August 2025).

APEC (2024) Overcoming pet food processing challenges for expansion. Available at: <https://www.apecusa.com/blog/overcome-petfood-processing-challenges/> (Accessed: 16 August 2025).

APVMA (2015) Guidelines for therapeutic pet foods that require registration as veterinary chemical products. Available at: <https://www.apvma.gov.au/registrations-and-permits/data-guidelines/veterinary-data-guidelines/specific-guidelines/therapeutic-pet-foods> (Accessed: 16 August 2025).

APVMA (2024) Animal feed products. Available at: <https://www.apvma.gov.au/registrations-and-permits/chemical-product-registration/animal-feed-products> (Accessed: 16 August 2025).

APVMA (2025a) Label content – veterinary products. Available at: <https://www.apvma.gov.au/registrations-and-permits/labelling-codes/veterinary-labelling-code/label-content> (Accessed: 16 August 2025).

APVMA (2025b) Stockfeed and petfood regulation. Available at: <https://www.apvma.gov.au/registrations-and-permits/chemical-product-registration/stockfeed-petfood-regulation> (Accessed: 16 August 2025).

APVMA (2025c) Veterinary Labelling Code Therapeutic pet food products – specific requirements. Available at: <https://www.apvma.gov.au/registrations-and-permits/labelling-codes/veterinary-labelling-code/specific-labelling-requirements-veterinary-chemical-products/therapeutic-pet-food> (Accessed: 16 August 2025).

AQI Service (2025) Pet Products Quality Control: A Complete Guide for Owners. Available at: <https://aqiservice.com/pet-products-quality-control-guide/> (Accessed: 16 August 2025).

Arki Labs (2025) Veterinary Medicines - Agriculture. Available at: <https://aklabs.com.au/veterinary-medicines-agriculture/> (Accessed: 16 August 2025).

Atkins, L. (2023) Veganuary: Culturing an appetite; advances in 3D bioprinting. Available at: <https://www.mewburn.com/news-insights/culturing-an-appetite-advances-in-3d-bioprinting> (Accessed: 16 August 2025).

Attaianese, L., Andreutti, S. and Fenizia, M. (2024) The ghost of scale-up in precision fermentation, AgroFOOD Industry Hi Tech, 35(3). Available at:

https://digital.teknoscienze.com/agofood_industry_hi_tech_35_3_2024/precision_fermentation_-the_ghost_of_scale-up_in_precision_fermentation (Accessed: 16 August 2025).

Atuahene, D., Mukarram, S.A., Balouei, F. and Antwi, A. (2024) Gut Health Optimization in Canines and Felines: Exploring the Role of Probiotics and Nutraceuticals, *Pets*, 1(2), pp. 135-151. DOI: <https://doi.org/10.3390/pets1020011>

Austin and Kat (2025) Plant Power: Our Guide to Plant-Based Dog Food & Supplements. Available at: <https://www.austinandkat.com/pages/plant-based-for-dogs> (Accessed: 16 August 2025).

Australia Wide First Aid (2024) Keeping Pets Healthy: Common Diseases. Available at: <https://www.australiawidefirstaid.com.au/resources/keeping-pets-healthy> (Accessed: 16 August 2025).

Australian Animal Oral Care. (2025) How much does Dog Teeth Cleaning cost ?. Available at: <https://www.australiananimaloralcare.com/post/how-much-does-dog-teeth-cleaning-cost> (Accessed: 16 August 2025).

Australian Competition and Consumer Commission (2025) About the ACCC. Available at: <https://www.productsafety.gov.au/about-us/about-the-accc> (Accessed: 16 August 2025).

Australian Housing and Urban Research Institute. (2021) Understanding pet policies for Australian households. Available at: <https://www.ahuri.edu.au/analysis/brief/understanding-pet-policies-australian-households> (Accessed: 16 August 2025)

Australian National Audit Office (2006) Regulation of Pesticides and Veterinary Medicines. Available at: <https://www.anao.gov.au/work/performance-audit/regulation-pesticides-and-veterinary-medicines> (Accessed: 16 August 2025).

Australian Pesticides and Veterinary Medicines Authority (2015) Guidelines for therapeutic pet foods that require registration as veterinary chemical products. Available at: <https://www.apvma.gov.au/registrations-and-permits/data-guidelines/veterinary-data-guidelines/specific-guidelines/therapeutic-pet-foods> (Accessed: 16 August 2025).

Australian Pesticides and Veterinary Medicines Authority (2016) Submission 21 - Australian Pesticides and Veterinary Medicines Authority (APVMA) - Regulation of Agriculture - Public inquiry. Available at: https://www.pc.gov.au/_data/assets/pdf_file/0007/195856/sub021-agriculture.pdf (Accessed: 16 August 2025).

Australian Pesticides and Veterinary Medicines Authority (2024) Animal feed products. Available at: <https://www.apvma.gov.au/registrations-and-permits/chemical-product-registration/animal-feed-products> (Accessed: 16 August 2025).

Australian Pesticides and Veterinary Medicines Authority (2025) Stockfeed and petfood regulation. Available at: <https://www.apvma.gov.au/registrations-and-permits/chemical-product-registration/stockfeed-petfood-regulation> (Accessed: 16 August 2025).

Australian Pet Organics. (2025) Ingredients. Available at: <https://www.aporganics.com.au/pages/ingredients> (Accessed: 16 August 2025).

Australian Veterinary Association (2009) Vaccination of dogs and cats. Available at: http://dogswest.com/dogswest/d/Members/Members_Notifyboard/JJ707Z5MWNX7RON0J9SCOY7

GHROUXA/ICX7QMTBLNUGAO8.pdf/AVA+Vaccination+Position+Statement.pdf (Accessed: 16 August 2025).

Australian Veterinary Association (2023) Brachycephalic dog breeding. Available at: <https://www.ava.com.au/policy-advocacy/policies/companion-animals-health/brachycephalic-dog-breeding/> (Accessed: 16 August 2025).

Australian Veterinary Association (2025) Australian Veterinary Journal. Available at: <https://www.ava.com.au/library-resources/australian-veterinary-journal/> (Accessed: 16 August 2025).

Australian Veterinary Association. (2024) AVA 2023/24 Workforce Survey Report. Available at: https://www.ava.com.au/siteassets/advocacy/workforce-survey/ava-2023_2024-workforce-survey-report.pdf (Accessed: 16 August 2025).

Balaji, R. and Parani, M. (2022) DNA Barcoding of the Market Samples of Single-Drug Herbal Powders Reveals Adulteration with Taxonomically Unrelated Plant Species, *Diversity*, 14(6), p. 495. Available at: <https://www.mdpi.com/1424-2818/14/6/495> (Accessed: 16 August 2025).

Baldo, B.A. (2022) Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies, *Antibodies*, 11(1), p. 17. Available at: <https://www.mdpi.com/2073-4468/11/1/17> (Accessed: 16 August 2025).

Ballard, H. (2025) 10 Australia Pet Ownership Statistics & Facts: 2025 Update. Available at: <https://www.dogster.com/statistics/australia-pet-ownership-statistics> (Accessed: 16 August 2025)

Barbeau-Grégoire, M., Otis, C., Cournoyer, A., Moreau, M., Lussier, B. and Troncy, E. (2022) A 2022 Systematic Review and Meta-Analysis of Enriched Therapeutic Diets and Nutraceuticals in Canine and Feline Osteoarthritis, *International Journal of Molecular Sciences*, 23(18), p. 10384. Available at: <https://pmc.ncbi.nlm.nih.gov/articles/PMC9499673/> (Accessed: 16 August 2025).

Barker, M. (2025) Fresh Dog Food Delivered: Our Interview with Lyka Pet Food. Available at: <https://mollybarker.com.au/blogs/blog-post/is-homemade-dog-food-healthier> (Accessed: 16 August 2025).

Barlow, A. (2025) Proof of Concept Study: Investigation of the Feasibility and Viability of Freeze-dried Bovine Blood Products (FD-BBP) as Functional Food and Nutraceutical Ingredients. Report no. P.PSH.1517. North Sydney, NSW: Meat & Livestock Australia. Available at: <https://www.mla.com.au/research-and-development/reports/2024/p.psh.1517---food-safe-collection-and-preservation-of-bovine-blood-for-use-as-an-ingredient-in-nutraceuticals-and-functional-foods---poc> (Accessed: 16 August 2025).

Barrington, K. (2025) The 7 Best Lamb Cat Food Formulas. Available at: <https://cats.com/best-lamb-cat-food> (Accessed: 16 August 2025).

Barroso, C., Fonseca, A.J.M. and Cabrita, A.R.J. (2024) Vitamins, Minerals and Phytonutrients as Modulators of Canine Immune Function: A Literature Review, *Veterinary Sciences*, 11(12), p. 655. Available at: <https://pmc.ncbi.nlm.nih.gov/articles/PMC11680413/> (Accessed: 16 August 2025).

Basedow, K. and Hass, J.A. (2024) Turkey Tail Mushroom For Dogs, DogCancer.com. Available at: <https://www.dogcancer.com/articles/supplements/turkey-tail-mushroom-for-dogs/> (Accessed: 16 August 2025).

Bauer, J.E. (2011) Therapeutic use of fish oils in companion animals, Journal of the American Veterinary Medical Association, 239(11), pp. 1441–1451. Available at: <https://avmajournals.avma.org/view/journals/javma/239/11/javma.239.11.1441.xml> (Accessed: 16 August 2025).

Beaton, L. (2021) Supply chain challenges top pet industry concern in 2022 | PetfoodIndustry, PetfoodIndustry. Available at: <https://www.petfoodindustry.com/pet-food-market/article/15468433/supply-chain-challenges-top-pet-industry-concern-in-2022> (Accessed: 16 August 2025).

Beco (2024) What is Novel Protein Dog Food?. Available at: <https://www.becopets.com/blogs/news/what-is-novel-protein-dog-food> (Accessed: 16 August 2025).

Ben-Shitrit, E., Tomsov, A., Mandelik, D., Dikovsky, D. and Silberstein, S. (2025) Meat analogues and methods of producing the same. U.S. Patent US12376608B2. Available at: <https://patents.google.com/patent/US20220125072A1/en> (Accessed: 16 August 2025).

Berwick Clyde Vet (2025) Should I Order From an Online Pet Pharmacy Or At My Vet? Available at: <https://berwickclydevet.com.au/should-i-order-from-an-online-pet-pharmacy-or-at-my-vet/> (Accessed: 16 August 2025).

Best Friends Veterinary Hospital (2025) Is Beef Liver Good For Dogs | Best Friends Veterinary Hospital. Available at: <https://bestfriendsvet.org/blog/is-beef-liver-good-for-dogs/> (Accessed: 16 August 2025).

Bet Pets (2025) Is Venison a Novel Protein? Exploring the Benefits for Your Dog's Health. Available at: <https://www.btpets.com/post/is-venison-a-novel-protein-exploring-the-benefits-for-your-dog-s-health> (Accessed: 16 August 2025).

Bharani, K.K., Devarasetti, A.K., Bobbili, R., Khurana, A., Veera Hanuman, D.D., Gudepu, R. and Guda, S. (2025) The role of Ashwagandha in modulating gut parameters in dogs—a randomized double-blind placebo-controlled trial, Frontiers in Veterinary Science, 11, pp. 1491989. Available at: <https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2024.1491989/pdf> (Accessed: 16 August 2025).

BlueGenes (2024) A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care. Available at: <https://bluegeneslab.com/news/a-review-of-realworld-evidence-on-preemptive-pharmacogenomic-testing-for-preventing-adverse-drug-reactions-a-reality-for-future-health-care> (Accessed: 16 August 2025).

Boil Agency (2025) Gutsy: Challenger Dog Food Brand | Boil®. Available at: <https://www.boil.agency/work/gutsy> (Accessed: 16 August 2025).

Boissonneault, T. (2024) Food-grade 3D printing: Is PLA Food-Safe? Available at: <https://www.wevolver.com/article/is-pla-food-safe> (Accessed: 16 August 2025).

Bond Vet (2023) Pancreatitis in Dogs: Diagnosis, Treatment, and Recovery. Available at: <https://bondvet.com/b/pancreatitis-in-dogs> (Accessed: 16 August 2025).

BoortmaltX (2025) 10 Innovative Pet Food Startups To Watch In 2023. Available at: <https://www.boortmaltx.com/blogs/10-innovative-pet-food-startups-to-watch-in-2023> (Accessed: 16 August 2025).

Boothe, D. (2024) Transdermal Medications. Available at: <https://veterinarianpartner.vin.com/default.aspx?pid=19239&catId=225989&id=11938493> (Accessed: 16 August 2025).

Bosch, G., Zhang, S., Oonincx, D.G.A.B. and Hendriks, W.H. (2014) Protein quality of insects as potential ingredients for dog and cat foods, Journal of Nutritional Science, 3, pp. e29. DOI: <https://doi.org/10.1017/jns.2014.23>

Bow Wow Meow (2024) Dog insurance – Pet insurance claims for dogs in Australia. Available at: <https://bowwowinsurance.com.au/pet-community/pet-talk/dog-insurance-pet-insurance-claims-for-dogs-in-australia/> (Accessed: 16 August 2025).

Bray, K. (2020) Are premium pet foods worth the money? Available at: <https://www.choice.com.au/outdoor/pets/products/articles/premium-pet-food> (Accessed: 16 August 2025).

Brisbane Pet Surgery. (2025) Vet and Pet Pricing Guide | Affordable Vet Brisbane. Available at: <https://www.brisbanepetsurgery.com.au/pricing-guide> (Accessed: 16 August 2025).

Brooks, W. (2020) Silymarin (Milk Thistle). Available at: <https://veterinarianpartner.vin.com/default.aspx?pid=19239&catId=102894&id=4952130> (Accessed: 16 August 2025).

Brown, D.C., Reetz, J., Eaton, B., Smith, P.J., Sorenson, C.N., Culp, W.T.N., Sasson, A. and Shofer, F.S. (2012) Single Agent Polysaccharopeptide Delays Metastases and Improves Survival in Naturally Occurring Hemangiosarcoma, Evidence-Based Complementary and Alternative Medicine, 2012, pp. 1-9. Available at: <https://pmc.ncbi.nlm.nih.gov/articles/PMC3440946/> (Accessed: 16 August 2025).

Buck Wild Bison. (2024) The Surprising Benefits of Bison Meat in Your Dog's Diet. Available at: <https://buckwildbison.com/blogs/bison-blog/the-surprising-benefits-of-bison-meat-in-your-dogs-diet> (Accessed: 16 August 2025).

Budget Direct (2024) Pets in Australia Survey and Statistics 2024. Available at: <https://www.budgetdirect.com.au/pet-insurance/guides/pets-in-australia-survey.html> (Accessed: 16 August 2025).

Budget Pet Products (2025) Natural Animal Solutions (NAS) Omega 3 6 And 9 Oil With Pump And Cap Supplement For Dogs Cats And Horses 2L. Available at: <https://www.budgetpetproducts.com.au/product/natural-animal-solutions-nas-omega-3-6-and-9-oil-with-pump-and-cap-supplement-for-dogs-cats-and-horses-2l/25790> (Accessed: 16 August 2025).

Buelva, A. (2022) National survey reveals Australians spending on pets, PetfoodIndustry. Available at: <https://www.petfoodindustry.com/news-newsletters/pet-food-news/article/15469415/national-survey-reveals-australians-spending-on-pets> (Accessed: 16 August 2025).

Business Daily Media (2025) The newest player in Australia's pet wellness industry. Available at: <https://www.businessdailymedia.com/business-news/26554-the-newest-player-in-australia-s-pet-wellness-industry> (Accessed: 16 August 2025).

Business Research Insights (2025) Pet Supplements and Nutraceuticals Market Size, Growth Report, 2034. Available at: <https://www.businessresearchinsights.com/market-reports/pet-supplements-and-nutraceuticals-market-123855> (Accessed: 16 August 2025).

Business Wire (2024) Pet Honesty® Unveils Liquid Supplements, New Format Innovation for Dogs. Available at: <https://www.businesswire.com/news/home/20240807932431/en/Pet-Honesty-Unveils-Liquid-Supplements-New-Format-Innovation-for-Dogs> (Accessed: 16 August 2025).

BVA (2024) Is it safe to feed my dog a plant-based diet?. Available at: <https://www.bva.co.uk/news-and-blog/blog-article/is-it-safe-to-feed-my-dog-a-plant-based-diet-hold-the-greens-only-meals-why-the-jury-is-still-out-on-vegan-dog-diets/> (Accessed: 16 August 2025).

Callahan, C. (2023) Is feeding a raw meat-based diet worth the health risks?, dvm360, 54(7), pp. 24. Available at: <https://www.dvm360.com/view/is-feeding-a-raw-meat-based-diet-worth-the-health-risks-> (Accessed: 16 August 2025).

CARE for Pets™. (2025) STUDY: Nearly 8 out of 10 Pet Owners Underestimate the Cost of Care During a Pet's Lifetime. Available at: <https://www.pets.care/news/2025/06/new-synchrony-study-finds-nearly-8-out-of-10-pet-owners-underestimate-the-cost-of-care-during-a-pets-lifetime/> (Accessed: 16 August 2025).

CareFirst Specialty Pharmacy (2025) Veterinary Transdermal. Available at: <https://www.cfspharmacy.pharmacy/veterinary-medicine/veterinary-transdermal> (Accessed: 16 August 2025).

CBD Dog Health (2023) Mushroom for Cats | MycoCat Mushroom Extract Blends. Available at: <https://cbddoghealth.com/product-category/mushrooms-for-cats/> (Accessed: 16 August 2025).

CDC (2025) About Pet Food Safety - CDC. Available at: <https://www.cdc.gov/healthy-pets/about/pet-food-safety.html> (Accessed: 16 August 2025).

Chadwick Nutrition (2025) Chadwick Nutrition: Canine Nutritionist. Available at: <https://www.chadwicknutrition.com.au/> (Accessed: 16 August 2025).

Champion Bio (2025) Traceability & Ethical Sourcing: The Future of Quality Supplements. Available at: <https://www.champion-bio.com/news-detail/traceability-ethical-sourcing-supplements/> (Accessed: 16 August 2025).

Chen, A. (2025) Vet Talk: Pet food and supplement myths you need to know, The Straits Times. Available at: <https://www.straitstimes.com/life/vet-talk-pet-food-and-supplement-myths-you-need-to-know> (Accessed: 16 August 2025).

Chen, B., Zang, P., Sheng, G., Yu, Y., Dong, H., Chen, P., Yang, J. and Liu, L. (2018) 3D food printing method and 3D food printer. China Patent CN105595386B. Available at: <https://patents.google.com/patent/CN105595386A/en> (Accessed: 16 August 2025).

Chen, K., Zhang, M., Bhandari, B. and Sun, J. (2021) Novel freeze drying based technologies for production and development of healthy snacks and meal replacement products with special nutrition and function: A review, Drying Technology, 40(8), pp. 1-16. Available at: https://www.researchgate.net/publication/354133075_Novel_freeze_drying_based_technologies_for_production_and_development_of_healthy_snacks_and_meal_replacement_products_with_special_nutrition_and_function_A_review (Accessed: 16 August 2025).

Chen, S., Yin, X., Han, J., Sun, W., Yao, H., Song, J. and Li, X. (2023) DNA barcoding in herbal medicine: Retrospective and prospective, *Journal of Pharmaceutical Analysis*, 13(5), pp. 431–441. Available at: <https://PMC10257146/> (Accessed: 16 August 2025).

Cheng, I. (2025) Vets warn against counterfeit pet supplements, medication sold online, *The Straits Times*. Available at: <https://www.straitstimes.com/singapore/vets-warn-against-counterfeit-pet-supplements-medication-sold-online> (Accessed: 16 August 2025).

Chewy (2025a) Pet Compound Pharmacy: Compounded Medication for Dogs & Cats. Available at: <https://www.chewy.com/b/pet-compounding-pharmacy-11718> (Accessed: 16 August 2025).

Chewy (2025a) Best Dog Vitamins & Supplements - Low Prices (Free Shipping). Available at: <https://www.chewy.com/b/vitamins-supplements-374> (Accessed: 16 August 2025).

Chircop, K. (2024) How much is pet insurance? Comparing monthly policies vs. vet bills. Available at: <https://www.madpaws.com.au/blog/how-much-is-pet-insurance/> (Accessed: 16 August 2025).

CHOICE (2025) Pet food regulation - CHOICE. Available at: <https://www.choice.com.au/outdoor/pets/products/articles/pet-food-regulation> (Accessed: 16 August 2025).

CHOICE. (2024) Saving for vet bills vs pet insurance: What's best?. Available at: <https://www.choice.com.au/money/insurance/pet/articles/saving-for-vet-bills-vs-pet-insurance> (Accessed: 16 August 2025).

Choosi (2025) The cost of a vet visit in 2025. Available at: <https://www.choosi.com.au/pet-insurance/articles/cost-of-vet-visit-2025> (Accessed: 16 August 2025).

chrisandtonya519 (2025) Is Venison a Novel Protein? Exploring the Benefits for Your Dog's Health. Available at: <https://www.btpets.com/post/is-venison-a-novel-protein-exploring-the-benefits-for-your-dog-s-health> (Accessed: 16 August 2025).

Clearly Loved Pets (2025) The Humanization of Pets: How Our Furry Friends Have Become Family. Available at: <https://clearlylovedpets.com/blogs/clearly-loved-pets-blog/the-humanization-of-pets> (Accessed: 16 August 2025).

Cleaver, L. (2025) Pet food recalls highlight need for collaborative, streamlined response, PetfoodIndustry. Available at: <https://www.petfoodindustry.com/safety-quality/pet-food-recalls/article/15738406/pet-food-recalls-highlight-need-for-collaborative-streamlined-response> (Accessed: 16 August 2025).

Cleveland Clinic (2023) Tyrosine Kinase inhibitors (TKIs): Uses & Side Effects. Available at: <https://my.clevelandclinic.org/health/treatments/24984-tyrosine-kinase-inhibitors> (Accessed: 16 August 2025).

Cline, J. (2016) The Importance of Pet Food Digestibility & Palatability - Ray Allen Manufacturing. Available at: <https://www.rayallen.com/blog/the-importance-of-pet-food-digestibility-palatability/> (Accessed: 16 August 2025).

Coates, J. (2023) A guide to cat vitamins and supplements, ManyPets. Available at: <https://manypets.com/us/blog/cat-vitamins-supplements-guide/> (Accessed: 16 August 2025).

Coghill, S. (2023) Pet owner cops \$8,500 vet bill after 'terrifying' backyard encounter, Yahoo News Australia. Available at: <https://au.news.yahoo.com/pet-owner-cops-8500-vet-bill-after-terrifying-backyard-encounter-002543086.html> (Accessed: 16 August 2025).

Cognitive Market Research (2025) The global Pet Supplements Market size will be USD 2651.8 million. Available at: <https://www.cognitivemarketresearch.com/pet-supplements-market-report> (Accessed: 16 August 2025).

College of Veterinary Medicine at MSU (2019) Canines and Cannabis—Is CBD Safe for Your Pet?. Available at: <https://cvm.msu.edu/news/perspectives-magazine/perspectives-fall-2019/canines-and-cannabis-is-cbd-safe-for-your-pet> (Accessed: 16 August 2025).

Conroy, S. (2019) The benefits of subscription services, Vet Practice Magazine. Available at: <https://www.vetpracticemag.com.au/the-benefits-of-subscription-services/> (Accessed: 16 August 2025).

Contract Manufacture Animal Products (2023) Pet Food & Supplement Manufacturing Process. Available at: <https://www.contractmanufactureanimalproducts.com/pet-food-supplement-manufacturing-process/> (Accessed: 16 August 2025).

Cooper, J. (2024) Best Health Benefits of Beef Liver for Dogs. Available at: <https://bugsys.com.au/blogs/news/best-health-benefits-of-beef-liver-for-dogs> (Accessed: 16 August 2025).

Copeland, J. (2022) Why brands should get to know pet supplement consumers. Available at: <https://www.alltech.com/blog/why-brands-should-get-know-pet-supplement-consumers> (Accessed: 16 August 2025).

Corman, A. (2025) Beef Allergy in Dogs: Symptoms, Causes, and Treatments. Available at: <https://total.vet/dog-allergy-food-beef/> (Accessed: 16 August 2025).

Cornell University College of Veterinary Medicine (2025) The power of probiotics. Available at: <https://www.vet.cornell.edu/departments-centers-and-institutes/riney-canine-health-center/canine-health-information/power-probiotics> (Accessed: 16 August 2025).

Cornell University College of Veterinary Medicine. (2025) Human animal bond. Available at: <https://www.vet.cornell.edu/departments-centers-and-institutes/riney-canine-health-center/canine-health-information/human-animal-bond> (Accessed: 16 August 2025).

Cosgrove, N. (2025) 13 Surprising Australian Pet Spending Statistics to Know in 2025. Available at: <https://www.dogster.com/statistics/pet-spending-statistics-australia> (Accessed: 16 August 2025).

Davidson, L. (2025) Snake Bite First Aid For Dogs & Cats. Available at: <https://www.yourvetonline.com/snake-bite-first-aid-for-dogs-cats/> (Accessed: 16 August 2025).

Davies, R.H., Lawes, J.R. and Wales, A.D. (2019) Raw diets for dogs and cats: a review, with particular reference to microbiological hazards, Journal of Small Animal Practice, 60(6), pp. 329–339. Available at: <https://pubmed.ncbi.nlm.nih.gov/31025713/> (Accessed: 16 August 2025).

Denniss, R. (2004) Overconsumption of pet food in Australia. Available at: https://australiainstitute.org.au/wp-content/uploads/2020/12/WP60_8.pdf (Accessed: 16 August 2025).

Department of Agriculture, Water and the Environment (2021) Australian Government response to the report of the Senate Rural and Regional Affairs and Transport Committee: Regulatory approaches to ensure the safety of pet food. Available at:
<https://www.agriculture.gov.au/about/reporting/obligations/government-responses/regulatory-approaches-ensure-safety-pet-food> (Accessed: 16 August 2025).

Department of Climate Change, Energy, the Environment and Water (2022) Australian Government response to the report of the Senate Rural and Regional Affairs and Transport Committee: Regulatory approaches to ensure the safety of pet food. Available at:
<https://www.dcceew.gov.au/about/reporting/obligations/government-responses/regulatory-approaches-ensure-safety-pet-food> (Accessed: 16 August 2025).

Department of Health (2023) Food Standards Australia New Zealand (FSANZ). Available at:
<https://www.health.gov.au/contacts/food-standards-australia-new-zealand-fsanz> (Accessed: 16 August 2025).

Devarasetti, A.K., Bharani, K.K., Khurana, A., Anand, S., Kollipaka, R., Saranu, V.D.T., Hanuman, D.D.V., Addanki, V.K. and Banothu, A.K. (2024) Adaptogenic Ashwagandha root extract modulates inflammatory markers in feline stress management: a double-blind placebo-controlled clinical trial, Journal of Applied Animal Research, 52(1), pp. 2335921. DOI:
<https://www.tandfonline.com/doi/full/10.1080/09712119.2024.2335921>

Dial A Vet (2025) How much is a vet appointment for a dog in Australia? Available at:
<https://www.dialavet.com/blog/how-much-is-a-vet-appointment-for-a-dog-in-australia> (Accessed: 16 August 2025).

Díaz-Regañón, D., Llorca, C., Sainz, Á., Rodríguez-Franco, F., Villaescusa, A., Olmeda, P. and García-Sancho, M. (2025) Exploring the popularity of raw meat-based diets for dogs and cats: A cross-sectional opinion survey in Spain, Vet Rec, 196(10), pp. e5013. Available at:
<https://pmc.ncbi.nlm.nih.gov/articles/PMC12082787/> (Accessed: 16 August 2025).

DiLonardo, M.J. (2024) The 13 Best Dog Supplements, The Spruce Pets. Available at:
<https://www.thesprucepets.com/best-dog-supplements-7483519> (Accessed: 16 August 2025).

Dock Labs (2025) Blockchain Food Traceability: Enhancing Transparency and Safety. Available at:
<https://www.dock.io/post/blockchain-food-traceability> (Accessed: 16 August 2025).

DOG by Dr Lisa (2025) Algal Oil - a Better Alternative to Fish Oil. Available at:
<https://dogbydrlisa.com/blogs/tips/algal-oil-a-better-alternative-to-fish-oil> (Accessed: 16 August 2025).

Dog Food Advisor (2024) What Are the Best Meats for Dogs? Available at:
<https://www.dogfoodadvisor.com/canine-nutrition/best-meats-for-dogs/> (Accessed: 16 August 2025).

Dog Is Human (2025) Daily Multivitamin. Available at:
<https://dogishuman.com/products/multivitamin> (Accessed: 16 August 2025).

DogCancer.com (2024) Curcumin for Dogs. Available at:
<https://www.dogcancer.com/articles/supplements/curcumin-for-dogs/> (Accessed: 16 August 2025).

Dolan, F.H. and Connor, M.S. (1983) Apparatus for mixing and extruding simulated meat mix for pet food. U.S. Patent 4372734. Available at: <https://patents.justia.com/patent/4372734> (Accessed: 16 August 2025).

Domínguez-Oliva, A., Mota-Rojas, D., Semendric, I. and Whittaker, A.L. (2023) The Impact of Vegan Diets on Indicators of Health in Dogs and Cats: A Systematic Review, Veterinary Sciences, 10(1), pp. 52. Available at: https://www.researchgate.net/publication/366973976_The_impact_of_vegan_diets_on_indicators_of_health_in_dogs_and_cats_a_systematic_review (Accessed: 16 August 2025).

Du, J., Zhou, K., Jiang, H., Hu, S., Zhang, W., Zheng, Q., Zhou, G. and Zhang, N. (2025) Individual and combined contamination of the toxic metals in commercial cat and dog food, Scientific Reports, 15, p. 13237. Available at: <https://PMC12006530/> (Accessed: 16 August 2025).

Earth Buddy Pet (2025) Medicinal Mushrooms for Dogs & Cats: Immune, Allergy & Aging Support. Available at: <https://www.earthbuddypet.com/pages/medicinal-mushrooms> (Accessed: 16 August 2025).

Elanco (2025) Omega Fatty Acids for Dogs and Cats. Available at: <https://yourpetandyou.elanco.com/us/health-and-care/omega-fatty-acids-dogs-and-cats> (Accessed: 16 August 2025).

Elrod, S.M. and Hofmeister, E.H. (2019) Veterinarians' attitudes towards use of nutraceuticals, Canadian Journal of Veterinary Research, 83(4), pp. 291–297. Available at: <https://PMC6753883/> (Accessed: 16 August 2025).

Enterprise League (2025) 20 thriving pet startups with amazing innovations (2025). Available at: <https://enterprisleague.com/blog/pet-startups/> (Accessed: 16 August 2025).

Erbo Spraytec AG (2021) Erbo Spraytec AG Invests in R&D and Innovation to Stand Out in Feed Additives Manufacturing – INDUSTRY PERSPECTIVES. Available at: <https://www.feedinfo.com/perspectives/erbo-spraytec-ag-invests-in-r-d-and-innovation-to-stand-out-in-feed-additives-manufacturing-industry-perspectives/227504> (Accessed: 16 August 2025).

Everyday Insurance (2025) 10 common dog health problems: Common canine conditions & costs. Available at: <https://insurance.everyday.com.au/insurance-talk/10-common-pet-insurance-claims-dogs.html> (Accessed: 16 August 2025).

Farmer Pete's. (2025) Australian Pet Industry Trends: Top Insights and Statistics for 2024. Available at: <https://www.farmerpetes.com.au/blogs/blog/australian-pet-industry-trends> (Accessed: 16 August 2025).

FDA (2018) Get the Facts! Raw Pet Food Diets can be Dangerous to You and Your Pet. Available at: <https://www.fda.gov/animal-veterinary/animal-health-literacy/get-facts-raw-pet-food-diets-can-be-dangerous-you-and-your-pet> (Accessed: 16 August 2025).

FDA (2020) Long Term Follow-Up After Administration of Human Gene Therapy Products. Available at: <https://www.fda.gov/media/113768/download> (Accessed: 16 August 2025).

FDA (2023) FDA's Regulation of Pet Food. Available at: <https://www.fda.gov/animal-veterinary/animal-health-literacy/fdas-regulation-pet-food> (Accessed: 16 August 2025).

FDA (2024) Pet Food. Available at: <https://www.fda.gov/animal-veterinary/animal-food-feeds/pet-food> (Accessed: 16 August 2025).

FDA (2025) Chemical Contaminants. Available at: <https://www.fda.gov/animal-veterinary/biological-chemical-and-physical-contaminants-animal-food/> chemical-contaminants (Accessed: 16 August 2025).

FEDIAF (2024) Vegetarian diets. Available at: <https://europeanpetfood.org/pet-food-facts/fact-sheets/nutrition/vegetarian-diets/> (Accessed: 16 August 2025).

Feed & Additive (2025) The potential of functional mushrooms for immune support in companion animals. Available at: <https://www.feedandadditive.com/the-potential-of-functional-mushrooms-for-immune-support-in-companion-animals/> (Accessed: 16 August 2025).

Fera Pets (2023) USDA Organic Mushroom Blend for Immune Support. Available at: <https://www.ferapets.com/products/usda-organic-mushroom-blend-for-immune-support> (Accessed: 16 August 2025).

Field, N. (2024) This is what it really costs to have a pet | Money magazine. Available at: <https://www.moneymag.com.au/real-cost-having-pets-australia> (Accessed: 16 August 2025).

Finno, C.J. (2020) Veterinary Pet Supplements and Nutraceuticals, Nutrition Today, 55(2), pp. 97–101. Available at: <https://pmc.ncbi.nlm.nih.gov/articles/PMC7802882/> (Accessed: 16 August 2025).

Flanagan, P. (2025) Australian veterinary practice market: Who's buying in 2025?. Available at: <https://www.rsm.global/australia/insights/australian-veterinary-practice-market> (Accessed: 16 August 2025).

Flint, H.E., Hunt, A.B.G., Logan, D.W. and King, T. (2024) Daily dosing of cannabidiol (CBD) demonstrates a positive effect on measures of stress in dogs during repeated exposure to car travel, Journal of Animal Science, 102. DOI: <https://academic.oup.com/jas/article/doi/10.1093/jas/skad414/7582589>

Flynn, M., Jenkinson, D., Green, P., Green, J. and Cheng, E. (2019) Review of Pet Food Category – Identifying high value opportunity spaces for Australian red meat industry (insights2innovation). Available at: https://www.mla.com.au/contentassets/2beb438475dd40fa9eaf4851ee7e831e/v.rmh.0091_final_report.pdf (Accessed: 16 August 2025).

Food Standards Australia New Zealand (2019) What we do. Available at: <https://www.foodstandards.gov.au/about-us/whatwedo> (Accessed: 16 August 2025).

Food Standards Australia New Zealand (2025) Food Standards Code legislation. Available at: <https://www.foodstandards.gov.au/food-standards-code/legislation> (Accessed: 16 August 2025).

Food Standards Australia New Zealand (2025) Food Standards Code. Available at: <https://www.foodstandards.gov.au/food-standards-code> (Accessed: 16 August 2025).

Forbes, S.L., Trafford, S. and Surie, M. (2018) Pet Humanisation: What is it and Does it Influence Purchasing Behaviour?, Dairy and Vet Sci J, 5(2), pp. 1–5. Available at: <https://juniperpublishers.com/jdvs/pdf/JDVS.MS.ID.555659.pdf> (Accessed: 16 August 2025).

Fortune Business Insights (2025) Pet Supplements Market Size, Share & Growth Report, 2032. Available at: <https://www.fortunebusinessinsights.com/pet-supplements-market-109797> (Accessed: 16 August 2025).

Fortune Business Insights. (2025) Pet Care Market Size, Share, Trends | Growth Analysis[1]. Available at: <https://www.fortunebusinessinsights.com/pet-care-market-104749> (Accessed: 16 August 2025).

Gaffud, A. (2024) What You Need To Know About Beef Allergy in Dogs. Available at: <https://paworigins.com/blogs/vet-blogs/what-you-need-to-know-about-beef-allergy-in-dogs> (Accessed: 16 August 2025).

Galli, G.M., Andretta, I., Martinez, N., Wernick, B., Shastak, Y., Gordillo, A. and Gobi, J. (2024) Stability of vitamin A at critical points in pet-feed manufacturing and during premix storage, *Frontiers in Veterinary Science*, 11. Available at: <https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2024.1309754/full> (Accessed: 16 August 2025).

Gamble, L.-J., Boesch, J.M., Frye, C.W., Schwark, W.S., Mann, S., Wolfe, L., Brown, H., Berthelsen, E.S. and Wakshlag, J.J. (2018) Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs, *Frontiers in Veterinary Science*, 5, p. 165. Available at: <https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2018.00165/full> (Accessed: 16 August 2025).

GapOnly (2024) Tick Paralysis: Prevention, Treatment, and Essential Tips. Available at: <https://gaponly.com.au/pethub/tick-paralysis-in-pets/> (Accessed: 16 August 2025).

Garmon Corp. (2025) Private Label Pet Supplement Manufacturers. Available at: <https://garmoncorp.com/> (Accessed: 16 August 2025).

Gembah (2025) Selecting a Dog Product Manufacturer: Quality, Compliance, and Scalability Considerations for 2025. Available at: <https://gembah.com/blog/dog-product-manufacturers/> (Accessed: 16 August 2025).

GETIDA (2025) Best practice pet supplement manufacturing. Available at: <https://getida.com/resources/blog/product-sourcing/best-practice-pet-supplement-manufacturing/> (Accessed: 16 August 2025).

getthewordout.com.au. (2025) Pets Living Their Best Lives: The pet wellness ... - PRESS RELEASE. Available at: <https://getthewordout.com.au/press-release/press-release-pets-living-their-best-lives-the-pet-wellness-trend-thats-seeing-aussies-put-their-money-where-their-pets-mouths-are/> (Accessed: 16 August 2025).

Gingr (2025) Dietary Trends in Pet Nutrition for 2024. Available at: <https://www.gingrapp.com/blog/dietary-trends-in-pet-nutrition-for-2024> (Accessed: 16 August 2025).

Givoni, S. (2025a) Navigating the Law around Pet Food Claims. Available at: <https://sharongivoni.com.au/barking-up-the-right-tree-navigating-the-law-around-pet-food-claims/> (Accessed: 16 August 2025).

Givoni, S. (2025b) Pet Food Packaging: Legal Requirements in Australia. Available at: <https://sharongivoni.com.au/pet-food-packaging-legal-requirements/> (Accessed: 16 August 2025).

Glanbia Nutritionals (2025) Navigating New Horizons in Pet Food & Treat Trends. Available at: <https://www.glanbianutritionals.com/en/nutri-knowledge-center/insights/navigating-new-horizons-pet-food-treat-trends> (Accessed: 16 August 2025).

Global Logistical Connections, Inc (2023) The Pet Food Supply Chain Explained. Available at: <https://glc-inc.com/2023/06/the-pet-food-supply-chain/> (Accessed: 16 August 2025).

Global Market Insights (2025) Pet Supplement Market Size, Share, Trend & Forecast, 2034. Available at: <https://www.gminsights.com/industry-analysis/pet-supplement-market> (Accessed: 16 August 2025).

Gollakner, R. and Yuill, C. (2022) Milk Thistle or Silymarin. Available at: <https://vcahospitals.com/know-your-pet/milk-thistle-or-silymarin> (Accessed: 16 August 2025).

Gyobo. (2025) How Nestlé Purina Stays Ahead with Quality and Trust. Available at: <https://www.gyobo.com/post/how-nest%C3%A9-purina-stays-ahead-with-quality-and-trust-gyobo> (Accessed: 16 August 2025).

Grand View Research (2024) Pet Supplements Market Size, Share & Trends Report, 2030. Available at: <https://www.grandviewresearch.com/industry-analysis/pet-supplements-market> (Accessed: 16 August 2025).

Grand View Research (2025a) Asia Pacific Pet Food Market Size | Industry Report, 2030. Available at: <https://www.grandviewresearch.com/industry-analysis/asia-pacific-pet-food-market-report> (Accessed: 16 August 2025).

Grand View Research (2025b) Australia Pet Supplements Market Size & Outlook, 2022-2030. Available at: <https://www.grandviewresearch.com/horizon/outlook/pet-supplements-market/australia> (Accessed: 16 August 2025).

Grand View Research (2025c) CBD Pet Market Size, Share & Growth Analysis Report, 2030. Available at: <https://www.grandviewresearch.com/industry-analysis/cannabidiol-pet-market> (Accessed: 16 August 2025).

Grand View Research (2025d) Clean Label Ingredients Market Size & Share Report, 2030. Available at: <https://www.grandviewresearch.com/industry-analysis/clean-label-ingredients-market-report> (Accessed: 16 August 2025).

Grand View Research (2025e) U.S. Pet Food Market Size & Share | Industry Report, 2030. Available at: <https://www.grandviewresearch.com/industry-analysis/us-pet-food-market-report> (Accessed: 16 August 2025).

Grand View Research. (2024) Pet Supplements Market Size, Share & Trends Report, 2030. Available at: <https://www.grandviewresearch.com/industry-analysis/pet-supplements-market> (Accessed: 16 August 2025).

Grange Co-op (2025) Mars Petcare Us Inc Products. Available at: <https://www.grangecoop.com/mars-petcare-us-inc-1/?page=2> (Accessed: 16 August 2025).

Gray, E. (2025) How Big Is the Pet CBD Market in 2025? Statistics & Trends. Available at: <https://www.dogster.com/statistics/pet-cbd-market-statistics> (Accessed: 16 August 2025).

Greenpet (2024) fat dog Archives - Greenpet. Available at: <https://greenpet.com.au/tag/fat-dog/> (Accessed: 16 August 2025).

GreyB (2025a) BeeHex 3D Printed Food Patents: Revolutionizing Culinary Innovation. Available at: <https://insights.greyb.com/beehex-3d-printed-food-patents/> (Accessed: 16 August 2025).

GreyB (2025b) Redefine Meat's 3D-Printed Plant-Based Meat: Patents & Innovation. Available at: <https://insights.greyb.com/redefine-meats-3d-printed-plant-based-meat-patents-innovation/> (Accessed: 16 August 2025).

Greystanes Vet. (2024) Low-Cost Dog Dental Cleaning: Complete Price Guide. Available at: <https://www.greystanesvet.com.au/post/low-cost-dog-dental-cleaning-complete-price-guide> (Accessed: 16 August 2025).

Guo, X., Wang, Y., Zhu, Z. and Li, L. (2024) The Role of Plant Extracts in Enhancing Nutrition and Health for Dogs and Cats: Safety, Benefits, and Applications, Veterinary Sciences, 11(9), p. 426. Available at: <https://www.mdpi.com/2306-7381/11/9/426> (Accessed: 16 August 2025).

Gupta, M. (2024) Revealed: Australian pet owners increasingly prefer sustainable pet food. Available at: <https://globalpetindustry.com/news/revealed-australian-pet-owners-increasingly-prefer-sustainable-pet-food/> (Accessed: 16 August 2025).

Hamilton, A. (2024) Bimatoprost Ophthalmic. Available at: <https://vcahospitals.com/know-your-pet/bimatoprost-ophthalmic> (Accessed: 16 August 2025).

Hanly Vet Clinic. (2024) Desexing Price Guide. Available at: <https://hanlyvet.com.au/desexing-price-guide/> (Accessed: 16 August 2025).

Hanseatic Agri (2025a) Guide to Sourcing High Quality Raw Materials for Pet Food - Hanseatic Agri. Available at: <https://www.hanseatic-agri.com/guide-to-sourcing-high-quality-raw-materials-for-pet-food/> (Accessed: 16 August 2025).

Hanseatic Agri (2025b) Petfood Raw Materials. Available at: <https://www.hanseatic-agri.com/petfood-raw-materials/> (Accessed: 16 August 2025).

Hardee, C.J., Joroff, S.R., Nesbitt, P.A. and Schneider, S.E. (2018) Methods and systems for 3d printing food items. U.S. Patent Application 20180116272. Available at: <https://patents.google.com/patent/US20180116272A1/en> (Accessed: 16 August 2025).

Hardt, A. (2025) The future of pet nutrition: Personalization, PetfoodIndustry. Available at: <https://www.petfoodindustry.com/news-newsletters/petfood-forum-news/article/15737844/the-future-of-pet-nutrition-personalization> (Accessed: 16 August 2025).

Harris Williams (2024) Pet Food: Hungry for Premium, Innovative Products. Available at: <https://www.harriswilliams.com/our-insights/cons-pet-food-hungry-for-premium-innovative-products> (Accessed: 16 August 2025).

Harsini, F., Knight, A. and Smith, B. (2024) Should dogs and cats be fed vegan diets?, Frontiers in Veterinary Science, 11, p. 1430743. Available at: <https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2024.1430743/full> (Accessed: 16 August 2025).

HealthforAnimals. (2022) Global Trends in the Pet Population. Available at: <https://healthforanimals.org/reports/pet-care-report/global-trends-in-the-pet-population/> (Accessed: 16 August 2025)

Heinze, C.R. (2018) When Less is More: Sensible Use of Supplements, Petfoodology. Available at: <https://sites.tufts.edu/petfoodology/2018/11/16/sensible-use-of-supplements/> (Accessed: 16 August 2025).

Hennet, P., Servet, E. and Venet, C. (2006) Effectiveness of an Oral Hygiene Chew to Reduce Dental Deposits in Small Breed Dogs, Journal of Veterinary Dentistry, 23(1), pp. 6-12. DOI: <https://doi.org/10.1177/089875640602300101>

Hewitt, B. (2025) The Booming U.S. Pet Supplement Market: Navigating Growth and Marketing Strategies. Available at: <https://creativethirst.com/blog/the-booming-u-s-pet-supplement-market-navigating-growth-and-marketing-strategies/> (Accessed: 16 August 2025).

Homer, C. and Simon, L. (2025) Finding the best food for pancreatitis in dogs. Available at: <https://www.poochandmutt.co.uk/blogs/health/finding-the-best-food-for-pancreatitis-in-dogs> (Accessed: 16 August 2025).

Honest Paws (2025) Probiotics For Dogs + Prebiotics - Vet Recommended! Available at: <https://www.honestpaws.com/products/probiotics-for-dogs> (Accessed: 16 August 2025).

Houston, D. (2025) Bioavailability and Nutrition - Guides. Available at: <https://www.bigidogpetfoods.com/guides/bioavailability-and-nutrition> (Accessed: 16 August 2025).

Howarth, J. (2025) 7 Top Pet Industry Trends (2025 & 2026). Available at: <https://explodingtopics.com/blog/pet-industry-trends> (Accessed: 16 August 2025).

Hyland, K. (2024) Cannabidiol CBD. Available at: <https://vcahospitals.com/know-your-pet/cannabidiol-cbd> (Accessed: 16 August 2025).

IMARC Group (2024) Australia Pet Supplement Market Size & Outlook | 2033. Available at: <https://www.imarcgroup.com/australia-pet-supplement-market> (Accessed: 16 August 2025).

IMARC Group (2025) Australia pet supplement market size, share, trends and forecast by pet type, source, distribution channel, application, and region, 2025-2033. Available at: <https://www.imarcgroup.com/australia-pet-supplement-market> (Accessed: 16 August 2025).

Innova Market Insights (2024) Pet Health Market Trends in the US. Consumers in the US desire. Available at: <https://www.innovamarketinsights.com/trends/pet-health-market-trends/> (Accessed: 16 August 2025).

InsightsGate (2025) BeeHex 3D Printed Food Patents: Revolutionizing Culinary Innovation. Available at: <https://insights.greyb.com/beehex-3d-printed-food-patents/> (Accessed: 16 August 2025).

Insyncfm. (2025) INSIGHTS - Pet Humanisation. Available at: <https://insyncfm.com.au/wp-content/uploads/2025/04/insync-insights-pet-humanisation.pdf> (Accessed: 16 August 2025).

Intellectual Market Insights. (2025) Global Pet Food Market Top Leading Companies. Available at: <https://www.intellectualmarketinsights.com/blog/global-pet-food-market-top-leading-companies> (Accessed: 16 August 2025).

Jeromin, D. (2018) Supplements-buyer beware!, Veterinary Allergy & Dermatology, Inc. Available at: <https://www.purrfectpet.com/supplements-buyer-beware/> (Accessed: 16 August 2025).

Jessica (2021) Freeze dried VS Cold pressed pet foods. Available at: <https://nutritionrvn.com/2021/06/17/freeze-dried-vs-cold-pressed-pet-foods/> (Accessed: 16 August 2025).

Jiminy's (2023) Traditional Protein vs. Novel Protein - Choosing the Right Dog Food for Your Pet. Available at: <https://jiminys.com/blogs/nutrition/traditional-protein-vs-novel-protein-choosing-the-right-dog-food-for-your-pet> (Accessed: 16 August 2025).

Jose, C. (2025) Rise of alternative proteins: New chapter in pet nutrition. Available at: <https://internationalpetfood.com/rise-of-alternative-proteins-new-chapter-in-pet-nutrition/> (Accessed: 16 August 2025).

Justia Patents Search (2025) Multiple Vitamins Patents and Patent Applications (Class 514/904). Available at: <https://patents.justia.com/patents-by-us-classification/514/904> (Accessed: 16 August 2025).

Kampa, N., Kaenkangploo, D., Jitpean, S., Srithunyarat, T., Seesupa, S., Hoisang, S., Yongvanit, K., Kamlangchai, P., Tuchpramuk, P. and Lascelles, B.D.X. (2023) Study of the effectiveness of glucosamine and chondroitin sulfate, marine based fatty acid compounds (PCSO-524 and EAB-277), and carprofen for the treatment of dogs with hip osteoarthritis: A prospective, block-randomized, double-blinded, placebo-controlled clinical trial, *Frontiers in Veterinary Science*, 10, p. 1033188. Available at: <https://pmc.ncbi.nlm.nih.gov/articles/PMC9929184/> (Accessed: 16 August 2025).

Karukayil Gopalakrishnan, N., Pappuswamy, M., Meganathan, G., Shanmugam, S., Pushparaj, K., Balasubramanian, B. and Kim, I.H. (2025) Influence of Probiotic Administration in Canine Feed: A Comprehensive Review, *Veterinary Sciences*, 12(5), p. 449. DOI: <https://doi.org/10.3390/vetisci12050449>

Kerwin, N. (2024) Survey: Consumers more interested in sustainable pet foods, Petfood Processing. Available at: <https://www.petfoodprocessing.net/articles/18589-survey-consumers-more-interested-in-sustainable-pet-foods> (Accessed: 16 August 2025).

Kim, J., Knowles, S. and Hicks, T. (2023) Reduction of vitamin A in liver for pet food applications. Available at: <https://www.mla.com.au/contentassets/9b2bce5a1b6742869876f89088c67071/p.psh.1430-final-report.pdf> (Accessed: 16 August 2025).

Kinetic Dog Food. (2024) Comparing Meat Sources in Canine Nutrition. Available at: <https://kineticdogfood.com/blogs/top-dog/comparing-meat-sources-in-canine-nutrition> (Accessed: 16 August 2025).

Laila and Me (2024) Australian Pet Food Standards. Available at: <https://www.lailaandme.com.au/blogs/news/australia-pet-food-standards> (Accessed: 16 August 2025).

Lambrakis, L. and Kersey, J. (2021) Whole Animal Nutrition. Available at: <https://simmonspetfood.com/whitepapers/2021/3/23/h71o52urb0tbele6zbwi2rbiaft40j> (Accessed: 16 August 2025).

Lawton, L.E. (2025) All in the Family: Pets and Family Structure, Populations, 1(2), p. 8. Available at: <https://www.mdpi.com/3042-4372/1/2/8> (Accessed: 16 August 2025).

Lee, D., Goh, T.W., Kang, M.G., Choi, H.J., Yeo, S.Y., Yang, J., Huh, C.S., Kim, Y.Y. and Kim, Y. (2022) Perspectives and advances in probiotics and the gut microbiome in companion animals, Journal of Animal Science and Technology, 64(2), pp. 197–217. Available at: <https://pmc.ncbi.nlm.nih.gov/articles/PMC9039956/> (Accessed: 16 August 2025).

Levenberg, S., Ianovici, I., Zagury, Y., Lavon, N. and David, S. (2022) 3d-printable protein-enriched scaffolds. World Intellectual Property Organization Patent WO2022162662A1. Available at: <https://patents.google.com/patent/WO2022162662A1/en> (Accessed: 16 August 2025).

Lever, T. (2025) Identifying Paralysis Ticks On Dogs & Cats | Australia's #1 Pet Store. Available at: <https://www.petcircle.com.au/discover/identify-paralysis-tick> (Accessed: 16 August 2025).

Little, S. (2008) Medicating cats: Transdermal drugs and more (Proceedings). Available at: <https://www.dvm360.com/view/medicating-cats-transdermal-drugs-and-more-proceedings> (Accessed: 16 August 2025).

Lloyd, G. (2025) Novel Protein Diet for Dogs - Better Alternatives?. Available at: <https://www.bonza.dog/2025/05/novel-protein-diet-for-dogs-better-alternatives/> (Accessed: 16 August 2025).

Localvet (2024) Chronic Kidney Disease in Cats. Available at: <https://www.localvet.com.au/TheVetClinic/Images/CKD%20in%20Cats.pdf> (Accessed: 16 August 2025).

Lopez, J. (2025) Are Vets Feeling the Pinch? What Pet Spending Data Really Shows. Available at: <https://www.myvetcandy.com/blog/2025/5/29/are-vets-feeling-the-pinch-what-pet-spending-data-really-shows> (Accessed: 16 August 2025).

Lovett, J. (2025) Dog Owners Willing to Pay More for Food Labeled for Certain Health Attributes. Available at: <https://aaes.uada.edu/news/dog-food-marketing-assesment/> (Accessed: 16 August 2025).

Lyu, Y., Wu, C., Li, L. and Pu, J. (2025) Current Evidence on Raw Meat Diets in Pets: A Natural Symbol, but a Nutritional Controversy, Animals (Basel), 15(3), pp. 293. Available at: <https://pmc.ncbi.nlm.nih.gov/articles/PMC11816250/> (Accessed: 16 August 2025).

Magalhães, T.R., Lourenço, A.L., Gregório, H. and Queiroga, F.L. (2021) Therapeutic Effect of EPA/DHA Supplementation in Neoplastic and Non-neoplastic Companion Animal Diseases: A Systematic Review, In Vivo, 35(3), pp. 1419–1436. DOI: <https://doi.org/10.21873/invivo.12394>

Marga, F.S., Purcell, B.P., Forgacs, G. and Forgacs, A. (2017) Edible and animal-product-free microcarriers for engineered meat. U.S. Patent US9752122B2. Available at: <https://patents.google.com/patent/US9752122B2/en> (Accessed: 16 August 2025).

Market Report Analytics (2025) Clean Label Pet Food in Emerging Markets: Analysis and Projections 2025-2033. Available at: <https://www.marketreportanalytics.com/reports/clean-label-pet-food-182960> (Accessed: 16 August 2025).

Market Research Future (2025) Pet Dietary Supplements Market Size, Growth, Trends, Report 2034. Available at: <https://www.marketresearchfuture.com/reports/pet-dietary-supplements-market-25536> (Accessed: 16 August 2025).

Market.us (2025) Plant-based Pet Food Market Size, Share | CAGR of 7.8%. Available at: <https://market.us/report/plant-based-pet-food-market/> (Accessed: 16 August 2025).

MarketsandMarkets (2025) Pet Dietary Supplements Market Size, Trends, and Forecast. Available at: <https://www.marketsandmarkets.com/Market-Reports/pet-dietary-supplements-market-264349399.html> (Accessed: 16 August 2025).

Marks, S.L. (2003) Where Are We With Transdermal Drug Administration?. Available at: <https://www.vin.com/apputil/content/defaultadv1.aspx?id=3847278&pid=11154> (Accessed: 16 August 2025).

Marlin, D. (2025) Lab-Grown Meat for Dogs: The Future of Pet Food or a Step Too Far?. Available at: <https://askanimalweb.com/lab-grown-meat-for-dogs-the-future-of-pet-food-or-a-step-too-far/> (Accessed: 16 August 2025).

Mars, Incorporated. (2025) Mars Petcare | Mars Global. Available at: <https://www.mars.com/our-brands/petcare> (Accessed: 16 August 2025).

Martin, J. (2006) Presentation to 8th Annual Food Regulations and Labelling Standards Conference “Misleading claims and the Trade Practices Act”. Available at: <https://www.accc.gov.au/system/files/Misleading%20Claims%20and%20the%20Trade%20Practices%20Act.pdf> (Accessed: 16 August 2025).

Marx, M.B. et al. (1988) Demographics of Pet Ownership Among U.S. Adults 21 to 64 Years of Age, Anthrozoös, 2(1), pp. 33–37. Available at: https://www.researchgate.net/publication/233687469_Demographics_of_Pet_Ownership_Among_US_Adults_21_to_64_Years_of_Age (Accessed: 16 August 2025).

Materialise. (2021) Personalized Patient Care in Veterinary Medicine with 3D Printing. Available at: <https://www.materialise.com/en/inspiration/articles/personalized-patient-care-veterinary-neurology> (Accessed: 16 August 2025).

Matsun Nutrition (2024) Organic pet supplement manufacturer: Tips to choose best. Available at: <https://matsunnutrition.com/how-to-choose-the-best-organic-pet-supplement-manufacturer/> (Accessed: 16 August 2025).

Matsun Nutrition (2025) Scaling pet supplement brand: Small batches to big wins. Available at: <https://matsunnutrition.com/scaling-pet-supplement-brand-small-batches-to-big-wins/> (Accessed: 16 August 2025).

Mavromichalis, I. (2016) Understanding vitamin stability in animal feed premixes, Feed Strategy. Available at: <https://www.feedstrategy.com/animal-feed-manufacturing/article/15438594/understanding-vitamin-stability-in-animal-feed-premixes> (Accessed: 16 August 2025).

McCafferty, C. (2025) Study links owner demographics and canine nutrition, DVM360. Available at: <https://www.dvm360.com/view/study-links-owner-demographics-and-canine-nutrition> (Accessed: 16 August 2025).

McConnochie, T. (2024) Canine vaccine hesitancy, Vet Practice Magazine. Available at: <https://www.vetpracticemag.com.au/canine-vaccine-hesitancy/> (Accessed: 16 August 2025).

McDowall, S., Hazel, S.J., Hamilton-Bruce, M.A., Stuckey, R. and Howell, T.J. (2024) Association of Socioeconomic Status and Reasons for Companion Animal Relinquishment, Animals, 14(17), p. 2549. Available at: <https://opal.latrobe.edu.au/n downloader/files/49394101> (Accessed: 16 August 2025)

McGrath, M. (2023) Pet Costs Survey and Statistics 2023. Available at: <https://www.budgetdirect.com.au/pet-insurance/guides/pet-costs-survey.html> (Accessed: 16 August 2025).

McKenzie, B.A. (2010) What Is the Evidence?, JAVMA, Journal of the American Veterinary Medical Association, 237(12), pp. 1382-1383. Available at: <https://avmajournals.avma.org/downloadpdf/journals/javma/237/12/javma.237.12.1382.xml> (Accessed: 16 August 2025).

McVeigh, A. (2023) Paws for thought: decoding Australian's pet health spending. Available at: <https://www.fifthquadrant.com.au/paws-for-thought-decoding-australians-pet-health-spending> (Accessed: 16 August 2025).

Meat & Livestock Australia (2019) Review of pet food category – Identifying high value opportunity spaces for Australian red meat industry (insights2innovation). Available at: <https://www.mla.com.au/research-and-development/reports/2019/review-of-pet-food-category--identifying-high-value-opportunity-spaces-for-australian-red-meat-industry-insights2innovation/> (Accessed: 16 August 2025).

Meat & Livestock Australia (2025) Strategic Plan 2030. Available at: <https://www.mla.com.au/globalassets/mla-corporate/about-mla/documents/mla-2030-strategic-plan-web.pdf> (Accessed: 16 August 2025).

Megna, M. (2025) Pet Ownership Statistics 2025 – Forbes Advisor. Available at: <https://www.forbes.com/advisor/pet-insurance/pet-ownership-statistics/> (Accessed: 16 August 2025).

Melbourne Pet Surgery (2025a) Affordable Vet & Pet Pricing Guide for Various Surgeries and Treatments. Available at: <https://www.melbournepetsurgery.com.au/pricing-guide> (Accessed: 16 August 2025).

Melbourne Pet Surgery (2025b) Brachycephalic Obstructive Airway Syndrome (BOAS). Available at: <https://www.melbournepetsurgery.com.au/boas> (Accessed: 16 August 2025).

Memorial Sloan Kettering Cancer Center (2025) About Cytokine Release Syndrome (CRS) and Neurotoxicity Syndrome. Available at: <https://www.mskcc.org/cancer-care/patient-education/about-cytokine-release-syndrome-crs-and-neurotoxicity-syndrome> (Accessed: 16 August 2025).

Mezher, M. (2017) TGA Weighs Changes to Regulations for Personalized, 3D Printed Devices, RAPS. Available at: <https://www.raps.org/news-and-articles/news-articles/2017/11/tga-weighs-changes-to-regulations-for-personalized> (Accessed: 16 August 2025).

Miller, K. (2025a) Paying More for Scraps? Understanding The True Value of Upcycled Pet Ingredients, BSM Partners. Available at: <https://bsmpartners.net/insights/paying-more-for-scraps-understanding-the-true-value-of-upcycled-pet-ingredients/> (Accessed: 16 August 2025).

Miller, K. (2025b) Pet Supplements: When Science, Cost, and Chews Collide, BSM Partners. Available at: <https://bsmpartners.net/insights/pet-supplements-when-science-cost-and-chews-collide/> (Accessed: 16 August 2025).

Mills, P.C. and Cross, S.E. (2006) Transdermal drug delivery: basic principles for the veterinarian, The Veterinary Journal, 172(2), pp. 218-233. DOI: <https://doi.org/10.1016/j.tvjl.2005.09.006>

Monaco, A., Kotz, J., Al Masri, M., Allmeta, A., Purnhagen, K.P. and König, L.M. (2024) Consumers' perception of novel foods and the impact of heuristics and biases: A systematic review, Appetite, 196, pp. 1–13. Available at: <https://d-nb.info/1345791844/34> (Accessed: 16 August 2025).

Mordor Intelligence (2025a) Australia Pet Food Market Size & Share Analysis - Industry Research Report - Growth Trends. Available at: <https://www.mordorintelligence.com/industry-reports/australia-pet-food-market> (Accessed: 16 August 2025).

Mordor Intelligence (2025b) Pet Dietary Supplements Market - Size, Share & Trends 2025 - 2030. Available at: <https://www.mordorintelligence.com/industry-reports/pet-dietary-supplements-market> (Accessed: 16 August 2025).

Morrison, B.J. (2023) Cosequin vs. Dasuquin: What's The Difference?. Available at: <https://www.petmd.com/general-health/cosequin-vs-dasuquin> (Accessed: 16 August 2025).

MSPCA-Angell (2023) Cannabidiol (CBD) in Canine Epilepsy. Available at: https://www.mspca.org/angell_services/cannabidiol-cbd-in-canine-epilepsy/ (Accessed: 16 August 2025).

Mueller, R.S., Fieseler, K.V., Fettman, M.J., Zabel, S., Rosychuk, R.A.W., Ogilvie, G.K. and Greenwalt, T.L. (2004) Effect of omega-3 fatty acids on canine atopic dermatitis, Journal of Small Animal Practice, 45(6), pp. 293-297. Available at: <https://pubmed.ncbi.nlm.nih.gov/15206474/> (Accessed: 16 August 2025).

Mueller, R.S., Olivry, T. and Prélaud, P. (2016) Critically appraised topic on adverse food reactions of companion animals (2): common food allergen sources in dogs and cats, BMC Veterinary Research, 12(9). Available at: <https://pmc.ncbi.nlm.nih.gov/articles/PMC4710035/> (Accessed: 16 August 2025).

Müller, M.R., Linek, M., Löwenstein, C., Röthig, A., Doucette, K., Thorstensen, K. and Mueller, R.S. (2016) Evaluation of cyclosporine-sparing effects of polyunsaturated fatty acids in the treatment of canine atopic dermatitis, Veterinary Journal, 210, pp. 77-81. Available at: <https://pubmed.ncbi.nlm.nih.gov/26975448/> (Accessed: 16 August 2025).

Muller, S. (2025) Report: Top pet industry trends, Pet Food Processing. Available at: <https://www.petfoodprocessing.net/articles/19415-report-top-pet-industry-trends> (Accessed: 16 August 2025).

Multani, K. (2024) Exploring the Rise of Subscription Boxes for Pet Supplies: How They Transform Shopping Experiences and Boost Customer Loyalty in the Online Pet Market. Available at: <https://www.livingstone.com.au/blog/health/pet-care/2024/11/exploring-the-rise-of-subscription-boxes-for-pet-supplies-how-they-transform-shopping-experiences-and-boost-customer-loyalty-in-the-online-pet-market/> (Accessed: 16 August 2025).

MuttGut (2024) Exposing Common Myths About Pet Supplements. Available at: <https://muttgut.com/blogs/ultimate-guide-to-total-gut-health/exposing-common-myths-about-pet-supplements> (Accessed: 16 August 2025).

myNZTE. (2023) Understanding Australia's pet nutrition market. Available at: <https://my.nzte.govt.nz/article/20230912-understanding-australias-pet-nutrition-market> (Accessed: 16 August 2025).

Natchez Trace Veterinary Services (2023) The Top 4 Immunity Mushrooms for Dogs and Cats. Available at: <https://franklinvet.com/the-top-4-immunity-mushrooms-for-dogs-and-cats/> (Accessed: 16 August 2025).

National Animal Supplement Council (2025) NASC Quality Seal. Available at: <https://www.nasc.cc/nasc-seal/> (Accessed: 16 August 2025).

Natural Dog Company (2025) Dog Skin and Coat Supplement. Available at: <https://naturaldog.com/products/skin-coat-supplement> (Accessed: 16 August 2025).

Nature's Protection (2025) Dry dietetic pet food with insect for adult dogs of all breeds, prone to food allergies. Available at: <https://naturesprotection.eu/dry-dietetic-pet-food-with-insect-for-adult-dogs-of-all-breeds-prone-to-food-allergies> (Accessed: 16 August 2025).

NaturVet (2025) Cat Hairball Aid Supplement - Veterinarian Formulated 2.6 oz. Bag. Available at: <https://naturvet.com/products/hairball-aid-bag> (Accessed: 16 August 2025).

Nestlé Global. (2025) Discover our business strategy. Available at: <https://www.nestle.com/about/strategy> (Accessed: 16 August 2025).

New South Wales Parliament. Legislative Council. Portfolio Committee No. 4 - Regional NSW. (2024) Veterinary workforce shortage in New South Wales. Report no. 58. Sydney: NSW Parliament. Available at: <https://www.parliament.nsw.gov.au/lcdocs/inquiries/2964/Report%20No.%2058%20-%20PC%204%20-%20Veterinary%20workforce%20shortage%20in%20New%20South%20Wales.pdf> (Accessed: 16 August 2025).

New Zealand Trade and Enterprise (2023) Understanding Australia's pet nutrition market. Available at: <https://my.nzte.govt.nz/article/20230912-understanding-australias-pet-nutrition-market> (Accessed: 16 August 2025).

Niemiec, R., Champine, V., Frey, D., Lobdell, A., Steele, A., Vaiden, C., Kogan, L. and Mertens, A. (2024) Veterinary and pet owner perspectives on addressing access to veterinary care and workforce challenges, *Frontiers in Veterinary Science*, 11. Available at: <https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2024.1419295/full> (Accessed: 16 August 2025).

Nofalamin (2025) Pet Supplement Manufacturing: 5 Strategies For Success - Alaska Spring Pharmaceuticals. Available at: <https://alaskaspringpharma.com/pet-supplement-manufacturing-hurdles/> (Accessed: 16 August 2025).

Nutrasource (2024) Ensuring Safety: Addressing Contaminants in Food and Dietary Supplements, Nutrasource Blog, 25 July. Available at: <https://blog.nutrasource.ca/blog/addressing-contaminants-food-dietary-supplements> (Accessed: 16 August 2025).

NutriSource Pet Foods. (2025) Why Feed Bison to Your Dog. Available at: <https://nutrisourcepetfoods.com/blog/why-feed-bison-to-your-dog/> (Accessed: 16 August 2025).

Nyamweya, N.N. and Kimani, S.N. (2020) Chewable Tablets: A Review of Formulation Considerations, *Pharmaceutical Technology*, 44(11), pp. 38–44. Available at:

<https://www.pharmtech.com/view/chewable-tablets-a-review-of-formulation-considerations>
(Accessed: 16 August 2025).

O F Packaging (2025) Helpful Guide To Pet Food Labelling Regulations In Australia. Available at: <https://ofpack.com.au/blog/pet-food-label-requirements-australia/> (Accessed: 16 August 2025).

Oakley-Newell, T. (2023) Global pet supplement market worth \$2.8 billion, Pet Industry News. Available at: <https://petnews.com.au/global-pet-supplement-market-worth-2-8-billion/> (Accessed: 16 August 2025).

Oktopost. (2025) Strategies for differentiation & success. Available at: <https://www.oktopost.com/glossary/competitive-positioning-strategies> (Accessed: 16 August 2025).

Oma's Pride (2024) 7 Remarkable Ways Beef Liver Is Good For Dogs. Available at: <https://omaspride.com/blogs/articles/reasons-beef-liver-is-good-for-dogs> (Accessed: 16 August 2025).

Only Natural Pet (2025) Only Natural Pet Complete Gut Health Complex Probiotics & Digestive Enzymes for Dogs & Cats. Available at: <https://www.onlynaturalpet.com/products/only-natural-pet-complete-gut-health-complex-probiotics-digestion-enzymes-for-dogs-cats> (Accessed: 16 August 2025).

Pacific Pet Supplies (2025) Flea, Tick & Worming - DOG. Available at: <https://pacificpetsupplies.com.au/dog/flea-tick-worm> (Accessed: 16 August 2025).

Paddington Vet (2024) Affordable Veterinary Services in Paddington: Price Guide. Available at: <https://www.paddingtonvet.com.au/price-guide> (Accessed: 16 August 2025).

Pajer, N. (2024) Is Insect Protein Pet Food the Next Big Thing?, Great Pet Care, 15 October. Available at: <https://www.greatpetcare.com/pet-news/insect-protein-pet-food/> (Accessed: 16 August 2025).

Parliament of Australia (2018) Report: Regulatory approaches to ensure the safety of pet food. Available at: https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Rural_and_Regional_Affairs_and_Transport/SafetyofPetFood/~/media/Committees/rrat_ctte/SafetyofPetFood/c03.pdf (Accessed: 16 August 2025).

Parliament of Australia (2025) List of recommendations. Available at: https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Rural_and_Regional_Affairs_and_Transport/SafetyofPetFood/Report/b01 (Accessed: 16 August 2025).

Paszkowski, C. (2025a) Cruciate Ligament Injury in Dogs. Available at: <https://www.petcircle.com.au/discover/cruciate-ligament-disease-in-dogs> (Accessed: 16 August 2025).

Paszkowski, C. (2025b) Raw Diets for Pets. Available at: <https://www.petcircle.com.au/discover/raw-diets-for-pets> (Accessed: 16 August 2025).

PatentFile.org (2016) Patenting a new feed/supplement that we are selling already. Available at: <https://patentfile.org/forum/patent-questions-and-advice/patenting-a-new-feedsupplement-that-we-are-selling-already/> (Accessed: 16 August 2025).

Pawsitive Results Marketing. (2024) Chewy's Successful Strategy for Brand Positioning: How Exceptional Service and Emotional Branding Set Them Apart in the Pet Industry. Available at: <https://pawsitiveresultsmarketing.com/chewys-successful-strategy-for-brand-positioning-how-exceptional-service-and-emotional-branding-set-them-apart-in-the-pet-industry/> (Accessed: 16 August 2025).

Pentlands Publishing (2024) Pet Food Supplement 2024. Available at: https://issuu.com/pentlandspublishing/docs/pet_food_supplement_24_print (Accessed: 16 August 2025).

Pet Chemist (2025) Dog Digestive Supplements - Buy Probiotic Supplements for Dogs. Available at: <https://petchemist.com.au/dog/health/digestive-health/> (Accessed: 16 August 2025).

Pet Chemist Australia (2025) Buy Dog Supplements Online | Pet Chemist Australia. Available at: <https://petchemist.com.au/dog/health/supplements/> (Accessed: 16 August 2025).

Pet Flavors (2024) Palatability - Pet Flavors. Available at: <https://petflavors.com/palatability/> (Accessed: 16 August 2025).

Pet Food Industry Association of Australia (2016) Pet food labelling v5. Available at: <https://pfiaa.com.au/wp-content/uploads/2020/01/5169118.pdf> (Accessed: 16 August 2025).

Pet Food Industry Association of Australia (2020) The Pet Food Industry Association of Australia. Available at: <https://pfiaa.com.au/> (Accessed: 16 August 2025).

Pet Honesty (2024) Dual Texture Urinary Tract Supplement for Cats 2-Pack (Chicken Flavor). Available at: <https://www.pethonesty.com/products/dual-texture-urinary-tract-health-supplement-for-cats-2-pack-chicken-flavor> (Accessed: 16 August 2025).

Pet Insurance Australia (2025) Brachycephalic Dog Breeds List. Available at: <https://www.petinsuranceaustralia.com.au/brachycephalic-dog-breeds/> (Accessed: 16 August 2025).

Pet Memorial Australia. (2025) Pet Ownership Statistics in Australia. Available at: <https://petmemorialaustralia.com.au/pet-ownership-statistics-in-australia/> (Accessed: 16 August 2025)

Pet Releaf (2024) Health Benefits of Omega 3 Algae Oil. Available at: <https://petreleaf.com/blogs/blog/health-benefits-of-omega-3-algae-oil> (Accessed: 16 August 2025).

Petbarn (2025) Greenies Dog Treat Petite Petbarn. Available at: <https://www.petbarn.com.au/greenies-original-dog-treat-petite?sku=136370> (Accessed: 16 August 2025).

Petco Health and Wellness Company, Inc. (2024) Annual Report. Available at: <https://ir.petco.com/static-files/b3a81400-4c15-4ed9-975b-032c6e517648> (Accessed: 16 August 2025).

PetExec. (2025) Pet Industry Trends: Pet Spending Statistics in 2024. Available at: <https://www.petexec.net/resources/marketing/pet-spending-statistics> (Accessed: 16 August 2025).

Petfood Industry (2023) Global pet supplement market predicted to grow. Available at: <https://www.petfoodindustry.com/news-newsletters/pet-food-press-releases/press-release/15469822/global-pet-supplement-market-predicted-to-grow> (Accessed: 16 August 2025).

Petfood Industry (2023) Protect your company against legal costs, financial losses. Available at: <https://www.petfoodindustry.com/safety-quality/pet-food-regulations/article/15463724/protect-your-company-against-legal-costs-financial-losses> (Accessed: 16 August 2025).

Petfood Industry (2025) Study confirms safety, digestibility of cultured protein ingredient for dog food. Available at: <https://www.petfoodindustry.com/nutrition/research-notes/news/15750605/study-confirms-safety-digestibility-of-cultured-protein-ingredient-for-dog-food> (Accessed: 16 August 2025).

PetfoodIndustry (2025) Report: Pet wellness market driven by personalization, science-backed nutrition. Available at: <https://www.petfoodindustry.com/pet-food-market/market-trends-and-reports/news/15746545/report-pet-wellness-market-driven-by-Personalisation-sciencebacked-nutrition-in-2025> (Accessed: 16 August 2025).

PetKing Global (2025) Pet Food Trends in 2025: What's New and What Works. Available at: <https://petkingglobal.com/pet-food-trends-in-2025-whats-new-and-what-works/> (Accessed: 16 August 2025).

PetMD Vet Advisory Panel (2025) 9 Best Probiotics for Dogs in 2025, Recommended By Vets, PetMD. Available at: <https://www.petmd.com/dog/vet-verified/best-probiotics-for-dogs> (Accessed: 16 August 2025).

PetSecure (2017) Costs of managing arthritis in cats and dogs. Available at: <https://www.petsecure.com.au/pet-care/costs-of-managing-arthritis-in-cats-and-dogs/> (Accessed: 16 August 2025).

Petstock (2025) Dog Vitamins & Supplements | PETstock | Petstock.com.au. Available at: <https://www.petstock.com.au/collections/dog-vitamins-supplements> (Accessed: 16 August 2025).

PetSure (2024a) Pet cancer: key information for pet parents. Available at: <https://petsure.com.au/knowledge-hub/pet-cancer/> (Accessed: 16 August 2025).

PetSure (2024b) PetSure launches 2024 Pet Health Monitor report. Available at: <https://petsure.com.au/media-releases/petsure-2024-pet-health-monitor-report/> (Accessed: 16 August 2025)

PetSure (2025a) Behind the price tag: Why pet med costs are rising and how to manage them. Available at: <https://petsure.com.au/knowledge-hub/behind-the-price-tag/> (Accessed: 16 August 2025).

PetSure (2025b) Pet Health Monitor. Available at: <https://petsure.com.au/pet-health-monitor/> (Accessed: 16 August 2025).

Petz Park (2025) High Quality Hip & Joint Supplements for Dogs. Available at: <https://petzpark.com.au/products/hip-joint-supplements-for-dogs> (Accessed: 16 August 2025).

PFIAA (2001) 5169118.pdf. Available at: <https://pfiaa.com.au/wp-content/uploads/2020/01/5169118.pdf> (Accessed: 16 August 2025).

PFIAA (2016) Pet food labelling v5. Available at: <https://pfiaa.com.au/wp-content/uploads/2020/01/5169118.pdf> (Accessed: 16 August 2025).

PFIAA (2018) Report: Regulatory approaches to ensure the safety of pet food. Available at: https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Rural_and_Regional_Affairs_and_Transport/SafetyofPetFood/~/media/Committees/rrat_ctte/SafetyofPetFood/c03.pdf (Accessed: 16 August 2025).

PFIAA (2020) Risk Factors and Managing Obesity in Dogs and Cats. Available at: <https://pfiaa.com.au/incidence-risk-factors-and-managing-obesity-in-dogs-and-cats/> (Accessed: 16 August 2025).

PFIAA (2025) News & Resources. Available at: <https://pfiaa.com.au/news-resources/> (Accessed: 16 August 2025).

PFIAA (2025) Pet Food Standards. Available at: <https://pfiaa.com.au/pet-food-standards/> (Accessed: 16 August 2025).

Phycom (2025) Benefits of Algae Supplements for Dogs, Cats, and Birds. Available at: <https://phycom.eu/benefits-of-algae-as-supplements-for-dogs-cats-bird/> (Accessed: 16 August 2025).

Pibarot, P. et al. (2020) Meat analogues and meat analogue extrusion devices and methods. U.S. Patent Application 20200323238A1. Available at: <https://patents.google.com/patent/US20200323238A1/en> (Accessed: 16 August 2025).

Plużarski, A. and Piórek, A. (2016) Side effects of tyrosine kinase inhibitors — management guidelines, Oncology in Clinical Practice, 12(4), pp. 113–118. Available at: https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/OCP.2016.0004/38572 (Accessed: 16 August 2025).

Portland Pet Food Company (2025) Do Dogs Need Meat | Beef, Chicken, Salmon Dog Food Toppers. Available at: <https://portlandpetfoodcompany.com/blogs/education/do-dogs-need-meat-variety> (Accessed: 16 August 2025).

Precedence Research (2025b) Pet Herbal Supplements Market Size to Hit USD 2.96 Bn by 2034. Available at: <https://www.precedenceresearch.com/pet-herbal-supplements-market> (Accessed: 16 August 2025).

Precedence Research. (2025a) Pet Care Market Size to Reach USD 643.53 Billion by 2034. Available at: <https://www.precedenceresearch.com/pet-care-market> (Accessed: 16 August 2025).

Premier Research (2020) Long-Term Follow-Up in Gene Therapy Trials: Ensuring Patient Engagement & Regulatory Compliance. Available at: <https://premier-research.com/perspectives/long-term-follow-up-in-gene-therapy-trials-ensuring-patient-engagement-regulatory-compliance/> (Accessed: 16 August 2025).

Premrov Bajuk, B. et al. (2021) Insect Protein-Based Diet as Potential Risk of Allergy in Dogs, Animals, 11(7), p. 1942. Available at: https://www.researchgate.net/publication/352860378_Insect_Protein-Based_Diet_as_Potential_Risk_of_Allergy_in_Dogs (Accessed: 16 August 2025).

Product Safety Australia (2025) About the ACCC. Available at: <https://www.productsafety.gov.au/about-us/about-the-accc> (Accessed: 16 August 2025).

Productivity Commission (2016) Submission 21 - Australian Pesticides and Veterinary Medicines Authority (APVMA) - Regulation of Agriculture - Public inquiry. Available at:

https://www.pc.gov.au/_data/assets/pdf_file/0007/195856/sub021-agriculture.pdf (Accessed: 16 August 2025).

Purina Institute (2025) Supplements for Dogs and Cats. Available at: <https://www.purinainstitute.com/centresquare/understanding-pet-food/supplements-for-dogs-and-cats> (Accessed: 16 August 2025).

Purina Pro Plan Veterinary Supplements (2025) Purina Pro Plan Veterinary Supplements. Available at: <https://www.purinaforprofessionals.com/supplements> (Accessed: 16 August 2025).

Raw & Fresh (2022a) The Benefits of Beef Liver For Dogs & Why You Should. Available at: <https://rawandfresh.com.au/blogs/pet-nutrition/beef-liver-benefits-for-dogs> (Accessed: 16 August 2025).

Raw & Fresh (2022b) What Are The AAFCO Nutritional Guidelines For Dog Food? Available at: <https://rawandfresh.com.au/blogs/pet-nutrition/aafcо-australia-nutritional-guidelines> (Accessed: 16 August 2025).

Research and Markets (2025) \$5 Bn Pet Supplements Market Trends, Analysis, and Forecasts 2025-2034 | AI-Driven Personalized Nutrition and CBD-Infused Supplements Transforming Pet Health. Available at: <https://www.globenewswire.com/news-release/2025/07/03/3109881/0/en/5-Bn-Pet-Supplements-Market-Trends-Analysis-and-Forecasts-2025-2034-AI-Driven-Personalized-Nutrition-and-CBD-Infused-Supplements-Transforming-Pet-Health.html> (Accessed: 16 August 2025).

ResearchAndMarkets.com (2024) US Pet Supplements Market Report 2024-2032. Featuring Ark Naturals, Garmon, Kemin Industries, Nestle, Purina Petcare, Novotech Nutraceuticals, Nutramax Laboratories, PetHonesty, Virbac and Zoetis, Business Wire, 11 October. Available at: <https://www.businesswire.com/news/home/20241011619709/en/US-Pet-Supplements-Market-Report-2024-2032-Featuring-Ark-Naturals-Garmon-Kemin-Industries-Nestle-Purina-Petcare-Novotech-Nutraceuticals-Nutramax-Laboratories-PetHonesty-Virbac-and-Zoetis---ResearchAndMarkets.com> (Accessed: 16 August 2025).

Riaz, M.N., Asif, M. and Ali, R. (2009) Stability of Vitamins during Extrusion, Critical Reviews in Food Science and Nutrition, 49(4), pp. 361–368. DOI: <https://doi.org/10.1080/10408390802067290>

RightPaw (2023) RightPaw Brachycephalic Breeding Policy. Available at: <https://rightpaw.com.au/brachycephalic-policy> (Accessed: 16 August 2025).

Rozental, A.J., Weisbeck, B.G., Corsato Alvarenga, I., Gustafson, D.L., Kusick, B.R., Rao, S., Bartner, L.R. and McGrath, S. (2023) The efficacy and safety of cannabidiol as adjunct treatment for drug-resistant idiopathic epilepsy in 51 dogs: A double-blinded crossover study, Journal of Veterinary Internal Medicine, 37(6), pp. 2291–2300. Available at: <https://pmc.ncbi.nlm.nih.gov/articles/PMC10658598/> (Accessed: 16 August 2025).

RPC (2025) Green claims update: June 2025. Available at: <https://www.rpclegal.com/thinking/esg/green-claims-update-june-2025/> (Accessed: 16 August 2025).

RSPCA Australia (2021) Act now to prevent future tragedy: RSPCA says lack of pet food safety regulation is putting Australian pets at risk. Available at: <https://www.rspca.org.au/latest-news/media-centre/act-now-prevent-future-tragedy-rspca-says-lack-pet-food-safety-regulation-0/> (Accessed: 16 August 2025).

RSPCA Australia (2025) RSPCA Australia position statement - Pet food and pet meat. Available at: <https://www.agriculture.gov.au/sites/default/files/sitecollectiondocuments/animal-plant/animal-health/pet-food-safety/rspca-position-statement.pdf.doc> (Accessed: 16 August 2025).

RSPCA Knowledgebase (2023) How many pets are there in Australia?. Available at: <https://kb.rspca.org.au/knowledge-base/how-many-pets-are-there-in-australia/> (Accessed: 16 August 2025).

RSPCA Knowledgebase (2025) What do I need to know about Brachycephalic dogs?. Available at: <https://kb.rspca.org.au/knowledge-base/what-do-i-need-to-know-about-brachycephalic-dogs/> (Accessed: 16 August 2025).

RSPCA New South Wales (2025) Costs of Owning a Pet. Available at: <https://www.rspcansw.org.au/information-and-advice/caring-for-animals/costs-of-owning-a-pet/> (Accessed: 16 August 2025).

RSPCA Pet Insurance (2025) Why is Pet Insurance Important. Available at: <https://www.rspcapetinsurance.org.au/why-pet-insurance-important> (Accessed: 16 August 2025).

RSPCA Pet Insurance. (2020) How much does it cost to visit a vet. Available at: <https://www.rspcapetinsurance.org.au/pet-care/responsible-pet-ownership/how-much-does-vet-visit-cost-2020> (Accessed: 16 August 2025).

RSPCA. (2024) ANIMAL OUTCOMES FROM OUR SHELTERS, CARE AND ADOPTION CENTRES 2023-24. Available at: <https://rspca.sfo2.cdn.digitaloceanspaces.com/public/Uploads/annual-statistics/RSPCA-Report-on-Animal-Outcomes-2023-2024.pdf> (Accessed: 16 August 2025)

Rubio, D.P. and Tisnadibrata, I.L. (2025) What will the latest wave of labeling regulations mean for pet food manufacturers?, GlobalPETS. Available at: <https://globalpetindustry.com/article/what-will-the-latest-wave-of-labeling-regulations-mean-for-pet-food-manufacturers/> (Accessed: 16 August 2025).

Rumbeisha, W. and Morrison, J. (2010) A Review of Class I and Class II Pet Food Recalls Involving Chemical Contaminants from 1996 to 2008, Journal of Medical Toxicology, 7(1), pp. 60–66. Available at: <https://pmc.ncbi.nlm.nih.gov/articles/PMC3614097/> (Accessed: 16 August 2025).

Sandra, D. (2024) 7 Best Probiotic For Dogs in 2025: A Vet's Most Complete and Honest Review, Jope. Available at: <https://petjope.com/blogs/ingredients/best-probiotic-for-dogs> (Accessed: 16 August 2025).

Sandringham Vet Hospital (2025) How Much Does TPLO Surgery Cost for a Dog?. Available at: <https://sandringhamvethospital.com.au/how-much-does-tplo-surgery-cost/> (Accessed: 16 August 2025).

SASH Vets (2025) Fixed Price BOAS Surgery at SASH Vets (NSW). Available at: <https://sashvets.com/fixed-price-boas-surgery/> (Accessed: 16 August 2025).

Schleicher, M., Cash, S.B. and Freeman, L.M. (2019) Determinants of pet food purchasing decisions, Can Vet J, 60(6), pp. 644–650. Available at: <https://pmc.ncbi.nlm.nih.gov/articles/PMC6515811/> (Accessed: 16 August 2025).

Schwarz, P.M., Troyer, J.L. and Walker, J.B. (2007) Animal House: Economics of Pets and the Household, Contributions in Economic Analysis & Policy, 7(1), pp. 35–35. Available at:

https://www.researchgate.net/publication/227377868_Animal_House_Economics_of_Pets_and_the_Household (Accessed: 16 August 2025).

Sentient, The Veterinary Institute for Animal Ethics (2018) The regulation of pet food. Available at: <https://www.sentient.org.au/the-regulation-of-pet-food> (Accessed: 16 August 2025).

Shaffer, E. (2021) MeaTech seeks patent for bioprinting method. Available at: <https://www.meatpoultry.com/articles/25053-meatech-seeks-patent-for-bioprinting-method> (Accessed: 16 August 2025).

Silberstein, N. (2024) From Veterinarians to Lowe's to Marriott: Petco's Partners are Becoming its Key Differentiator, Retail TouchPoints, 6 February. Available at: <https://www.retailtouchpoints.com/topics/retail-innovation/from-veterinarians-to-lowes-to-marriott-petcos-partners-are-becoming-its-key-differentiator> (Accessed: 16 August 2025).

Silver, R.J. (2007) Turmeric for Spicy Health. From: Wynn & Fougere: Veterinary Herbal Medicine. Available at: <https://www.isvma.org/wp-content/uploads/2019/10/SilverTurmericforSpicyHealth.pdf> (Accessed: 16 August 2025).

Simon Veterinary Surgical (2024) The Benefits of Omega-3 Fatty Acids for Dogs with Arthritis | Canine Joint Health and Inflammation Reduction. Available at: <https://www.simonvetsurgical.com/news/benefits-omega-3-fatty-acids-dogs-with-osteoarthritis> (Accessed: 16 August 2025).

Sino Biological (2025) Differences between Chemotherapy and Targeted Therapy. Available at: <https://www.sinobiological.com/research/targeted-therapy/chemotherapy-targeted-therapy> (Accessed: 16 August 2025).

Sivamaruthi, B.S., Kesika, P. and Chaiyasut, C. (2021) Influence of Probiotic Supplementation on Health Status of the Dogs: A Review, Applied Sciences, 11(23), p. 11384. DOI: <https://doi.org/10.3390/app112311384>

Smiley-Jewell, S. and Lein, P.J. (2022) Are animal CBD products safe? Available at: <https://www.openaccessgovernment.org/animal-cbd-products/130983/> (Accessed: 16 August 2025).

Smittle, R.B. and Phelps, J.B. (2014) MEAT SLURRY CULTURE. U.S. Patent Application 20140271994. Available at: <https://patents.justia.com/patent/20140271994> (Accessed: 16 August 2025).

Solís, D., Toro, M., Navarrete, P., Faúndez, P. and Reyes-Jara, A. (2022) Microbiological Quality and Presence of Foodborne Pathogens in Raw and Extruded Canine Diets and Canine Fecal Samples, Frontiers in Veterinary Science, 9. Available at: <https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2022.799710/full> (Accessed: 16 August 2025).

Solutions Pet Products (2024) Contamination of Synthetic Minerals with Heavy Metals in Pet and Agricultural Feed. Available at: <https://solutionspetproducts.com/contamination-of-synthetic-minerals-with-heavy-metals-in-pet-and-agricultural-feed/> (Accessed: 16 August 2025).

South Surrey Veterinary Hospital (2012) How long can you keep your pet's medications?. Available at: <https://southsurreyvethospital.ca/news/how-long-can-you-keep-your-pets-medications-2/> (Accessed: 16 August 2025).

Spanner, A. (2020) Myth 7: If it is sold for pets, it must be safe. Available at: <https://www.walkervillevet.com.au/blog/myth-7-if-it-is-sold-for-pets-it-must-be-safe/> (Accessed: 16 August 2025).

Spanner, A. (2021) Pet Food Allergy Testing | Elimination Diets. Available at: <https://www.walkervillevet.com.au/blog/dog-food-allergy-test/> (Accessed: 16 August 2025).

SPCA New Zealand (2025) The truth behind brachycephalic breeds - appearance over welfare?. Available at: <https://www.spca.nz/advice-and-welfare/article/the-truth-behind-brachycephalic-breeds-appearance-over-welfare> (Accessed: 16 August 2025).

Special Reports Team. (2025) The Impact of Rising Costs on Dog Owners. Available at: <https://total.vet/the-impact-of-rising-costs-on-dog-owners/> (Accessed: 16 August 2025).

Standard Process Veterinary Formulas (2025) Mushroom Complex: Safe & Effective Mushroom Supplement for Dogs & Cats. Available at: <https://www.standardprocess.com/products/mushroom-complex> (Accessed: 16 August 2025).

Stuart, A. (2024) Dog Dental Chews & Treats: Types and Benefits. Available at: <https://www.webmd.com/pets/dogs/dog-dental-treats> (Accessed: 16 August 2025).

Superior Supplement Manufacturing (2025) Pet Supplement Manufacturers // Private Label Pet Vitamins. Available at: <https://www.superiorsupplementmfg.com/contract-manufacturing/pet-supplement-manufacturer/> (Accessed: 16 August 2025).

Supliful (2023) What Are the Best Marketing Strategies for Pet Care Products. Available at: <https://supliful.com/blog/best-marketing-strategies-for-pet-care-products> (Accessed: 16 August 2025).

Supliful (2025) How to Create Your Own Pet Supplements Brand. Available at: <https://supliful.com/blog/how-to-create-your-own-pet-supplements-brand> (Accessed: 16 August 2025).

Supplement Factory UK (2025) The Future of Pet Wellness: How Human Supplement Trends Are Shaping the Global Pet Nutrition Market. Available at: <https://supplementfactoryuk.com/blog/2025/03/the-future-of-pet-wellness-how-human-supplement-trends-are-shaping-the-global-pet-nutrition-market/> (Accessed: 16 August 2025).

Sustainable Pet Foods (2025) Meat-based diets. Available at: <https://sustainablepetfood.info/meat-based-diets/> (Accessed: 16 August 2025).

Sydney Bulldog Clinic (2025) BOAS Surgery. Available at: <https://www.sydneybulldogclinics.com.au/services/boas-surgery> (Accessed: 16 August 2025).

Tazerji, S.S., Elahinia, A., Akhtardanesh, B., Kabir, F., Vazir, B., Duarte, P.M., Hajipour, P., Rehman, A., Ilyas, M.F., Hassanzadeh, S. and Gharieb, R. (2024) Nutritional risks and consequences of meat-only diets for dogs and cats, German Journal of Veterinary Research, 4(1), pp. 62-76. Available at: https://www.researchgate.net/publication/379864511_Nutritional_risks_and_consequences_of_meat-only_diets_for_dogs_and_cats (Accessed: 16 August 2025).

TechSci Research (2025) Australia Pet Grooming Products Market Size and Outlook 2030. Available at: <https://www.techsciresearch.com/report/australia-pet-grooming-market/1700.html> (Accessed: 16 August 2025).

Thach, C. (2025) How much can pet surgery cost in Australia?. Available at: <https://www.finder.com.au/pet-insurance/pet-surgery-cost> (Accessed: 16 August 2025).

The Business Research Company (2025) Global Pet Supplements Market Report 2025. Available at: <https://www.thebusinessresearchcompany.com/report/pet-supplements-global-market-report> (Accessed: 16 August 2025).

The Vet Is In (2016) Benefits of Vitamins & Supplements for Pets. Available at: <https://drbillspetnutrition.com/benefits-of-vitamins-supplements-for-pets/> (Accessed: 16 August 2025).

The Vets (2025) The Vitamins and Minerals Your Dog Needs. Available at: <https://thevets.com/resources/pet-nutrition/dog-vitamins-and-minerals/> (Accessed: 16 August 2025).

Therapeutic Goods Administration (2020) Meeting 3D printing (additive manufacturing) rules for medical devices. Available at: <https://www.tga.gov.au/resources/guidance/meeting-3d-printing-additive-manufacturing-rules-medical-devices> (Accessed: 16 August 2025).

Therapeutic Goods Administration (TGA) (2025) Meeting 3D printing (additive manufacturing) rules for medical devices. Available at: <https://www.tga.gov.au/resources/guidance/meeting-3d-printing-additive-manufacturing-rules-medical-devices> (Accessed: 16 August 2025).

Thrive Pet Healthcare (2025) Novel Protein Diet for Dogs and Cats. Available at: <https://www.thrivepetcare.com/thrive-guide/novel-proteins> (Accessed: 16 August 2025).

Towards Healthcare (2025) CBD Pet Market Captures USD 5476.42 Mn at 32.5% CAGR by 2034. Available at: <https://www.towardshealthcare.com/insights/cbd-pet-market-sizing> (Accessed: 16 August 2025).

Townsend, C. (2025) Scaling up successfully, Pet Food Processing. Available at: <https://www.petfoodprocessing.net/articles/19174-scaling-up-successfully> (Accessed: 16 August 2025).

Tran, B. (2025) Patent strategies for nutraceuticals and dietary supplements. Available at: <https://patentpc.com/blog/patent-strategies-nutraceuticals-dietary-supplements> (Accessed: 16 August 2025).

U.S. Chamber of Commerce (2022) How the Pet Humanization Trend Is Creating New Brands and Business Opportunities | CO. Available at: <https://www.uschamber.com/co/good-company/launch-pad/pet-humanization-trend-creates-business-opportunities> (Accessed: 16 August 2025).

UK Pet Food (2021) Insect-based ingredients in pet food. Available at: <https://www.ukpetfood.org/asset/4316C2BB-4E95-4338-A2E2572759A80050/> (Accessed: 16 August 2025).

UK Pet Food (2025) Pet supplements - are they necessary?. Available at: <https://www.ukpetfood.org/resource/pet-supplements-are-they-necessary.html> (Accessed: 16 August 2025).

Under the Weather Pet (2024) The Best Urinary Tract Supplement for Cats. Available at: <https://www.undertheweatherpet.com/blogs/under-the-weather/the-best-urinary-tract-supplement-for-cats> (Accessed: 16 August 2025).

Under the Weather Pet (2025) The Best Urinary Tract Supplement for Cats. Available at: <https://www.undertheweatherpet.com/blogs/under-the-weather/the-best-urinary-tract-supplement-for-cats> (Accessed: 16 August 2025).

University of Queensland (2023) Data uncovers new tick threat times for Australian pets. Available at: <https://www.uq.edu.au/news/article/2023/08/data-uncovers-new-tick-threat-times-australian-pets> (Accessed: 16 August 2025).

Useful Fly Trading LLC (2025) The advantages and disadvantages of insect-based pet food, GlobalPETS, 8 January. Available at: <https://globalpetindustry.com/news/the-advantages-and-disadvantages-of-insect-based-pet-food/> (Accessed: 16 August 2025).

Verdon, J. (2022) How the Pet Humanization Trend Is Creating New Brands and Business Opportunities | CO— by US Chamber of Commerce. Available at: <https://www.uschamber.com/co/good-company/launch-pad/pet-humanization-trend-creates-business-opportunities> (Accessed: 16 August 2025).

Verified Market Research (2024) Australia Pet Food Market Size, Share, Trends & Forecast. Available at: <https://www.verifiedmarketresearch.com/product/australia-pet-food-market/> (Accessed: 16 August 2025).

Verified Market Research (2025) Europe Pet Nutraceuticals Market Size, Growth And Forecast. Available at: <https://www.verifiedmarketresearch.com/product/europe-pet-nutraceuticals-market/> (Accessed: 16 August 2025).

Vet Practice Magazine (2016) Internet pet care advice—what could possibly go wrong? Available at: <https://www.vetpracticemag.com.au/internet-pet-care-advice-possibly-go-wrong/> (Accessed: 16 August 2025).

Vet Voice. (2025) Improving animal welfare. Available at: <https://www.vetvoice.com.au/ava/improving-animal-welfare/> (Accessed: 16 August 2025).

Veterinary Oral Health Council (2022) Accepted Products. Available at: <https://vohc.org/accepted-products/> (Accessed: 16 August 2025).

VetProductsDirect (2025) Dog Joint Supplements | VetProductsDirect. Available at: <https://www.vetproductsdirect.com.au/dog-supplies/muscle-joint/joint-supplements> (Accessed: 16 August 2025).

VetriScience Pro Line. (2025) Pet Supplement Ingredients. Available at: <https://www.vetriproline.com/ingredients> (Accessed: 16 August 2025).

Vets Love Pets (2025) Shop the Best Dog Flea, Tick & Worming Treatments. Available at: <https://vetslovetpets.com.au/collections/fleas-ticks-worms> (Accessed: 16 August 2025).

VetShopAustralia (2025) Omega 3 & 6 For Dogs | Omega Oil For Dogs | VetShopAustralia. Available at: <https://www.vetshopaustralia.com.au/dog-supplies/dietary-supplements/omega-3-6> (Accessed: 16 August 2025).

VetShopAustralia (2025) Joint Supplements For Dogs | Dog Joint Care - VetShopAustralia. Available at: <https://www.vetshopaustralia.com.au/dog-supplies/muscle-joint/joint-supplements> (Accessed: 16 August 2025).

Vetster Editorial Team (2024) Pet supplements: Which ones are backed by science? Available at: <https://vetster.com/en/wellness/pet-supplements-which-ones-are-backed-by-science> (Accessed: 16 August 2025).

Walkerville Vet (2024) Walkerville Vet Price List | Guide To Vet Costs & Fees. Available at: <https://www.walkervillevet.com.au/walkerville-vet-price-list/> (Accessed: 16 August 2025).

Wall, T. (2025) Some insect-based pet foods imbalanced, low in certain nutrients, Petfood Industry, 29 May. Available at: <https://www.petfoodindustry.com/nutrition/research-notes/article/15747231/some-insectbased-pet-foods-imbalanced-low-in-certain-nutrients> (Accessed: 16 August 2025).

WALTHAM (2025) New study shows cannabidiol (CBD) is effective at reducing stress in dogs. Available at: <https://www.waltham.com/new-study-shows-cannabidiol-cbd-effective-reducing-stress-dogs> (Accessed: 16 August 2025).

Weiner, A.L. and Gilger, B.C. (2010) Advancements in ocular drug delivery, Veterinary Ophthalmology, 13(6), pp. 395-406. DOI: <https://doi.org/10.1111/j.1463-5224.2010.00835.x>

Wellnergy Pets (2025) Hairball Control Cat Chews Omega 6 & 3 Safflower Flaxseed Biotin. Available at: <https://www.wellnergypets.com/products/hairball-supplement-for-cats-for-prevent-and-eliminate-hairballs> (Accessed: 16 August 2025).

Wellness Pet Food Australia. (2025) Quality Ingredients - Natural Dog & Cat Food. Available at: <https://wellnesspetfood.com.au/our-philosophy/quality-ingredients/> (Accessed: 16 August 2025).

Wheatley, R. (2018) Could Blockchain revolutionize the pet food industry?, PetfoodIndustry. Available at: <https://www.petfoodindustry.com/pet-food-market/article/15464573/could-blockchain-revolutionize-the-pet-food-industry> (Accessed: 16 August 2025).

Yale Medicine (2025) Side Effects of Cancer Treatment. Available at: <https://www.yalemedicine.org/conditions/side-effects-cancer-treatment> (Accessed: 16 August 2025).

Yang, Q. and Wu, Z. (2023) Gut Probiotics and Health of Dogs and Cats: Benefits, Applications, and Underlying Mechanisms, Microorganisms, 11(10), p. 2452. DOI: <https://doi.org/10.3390/microorganisms11102452>

Yao, J., Chen, W. and Fan, K. (2023) Novel Efficient Physical Technologies for Enhancing Freeze Drying of Fruits and Vegetables: A Review, Foods, 12(23), p. 4321. Available at: <https://www.mdpi.com/2304-8158/12/23/4321> (Accessed: 16 August 2025).

Yeung, T. and Uquillas, E. (2025) Does oral cannabidiol oil in adjunct to pain medications help reduce pain and improve locomotion in dogs with osteoarthritis?, Veterinary Evidence, 10(1), pp. 1–20. Available at: <https://veterinaryevidence.org/index.php/ve/article/download/701/1080?inline=1> (Accessed: 16 August 2025).

Zealandia. (2025) The Benefits of Feeding Lamb Organs to Cats and Dogs. Available at: <https://www.zealandiapets.com/blogs/news/the-benefits-of-feeding-lamb-organs-to-cats-and-dogs> (Accessed: 16 August 2025).

Zhu, W., Iskandar, M.M., Baeghbali, V. and Kubow, S. (2023) Three-Dimensional Printing of Foods: A Critical Review of the Present State in Healthcare Applications, and Potential Risks and Benefits, *Foods*, 12(17), p. 3287. DOI: <https://doi.org/10.3390/foods12173287>

Zhuang, Z., Wan, G., Lu, X., Xie, L., Yu, T. and Tang, H. (2024) Metabolic engineering for single-cell protein production from renewable feedstocks and its applications, *Advanced Biotechnology*, 2(4), pp. 35. Available at: <https://pmc.ncbi.nlm.nih.gov/articles/PMC11709146/> (Accessed: 16 August 2025).

Zielinski, C. (2025) Country report Australia: The shape of the pet industry 'Down Under'. Available at: <https://globalpetindustry.com/article/country-report-australia-the-shape-of-the-pet-industry-down-under/> (Accessed: 16 August 2025).

Zigpoll (2025) 21 Innovative Strategies Pet Care Business Owners Use to Differentiate Themselves in a Competitive Market. Available at: <https://www.zigpoll.com/content/what-innovative-strategies-has-the-owner-implemented-to-differentiate-their-pet-care-company-in-a-highly-competitive-market> (Accessed: 16 August 2025).

Zion Market Research (2025) Pet Supplements Market Size, Share and Forecast 2034. Available at: <https://www.zionmarketresearch.com/report/pet-supplements-market> (Accessed: 16 August 2025).

17. Appendix - External Peer Review Report

Reviewer: Dr Paul Ramos BS BVSc MVSc MRCVS

<https://www.linkedin.com/in/pwramos/>

The reviewer comments, originally provided in PDF format, have been converted to text and included here in full. No changes have been made to the content and formatting to ensure accuracy and fidelity to the original document.

Review of “Pet Health Supplements Using Australian Red Meat Inputs - Phase 1”

Reviewer: Dr Paul Ramos BS BVSc MVSc MRCVS

Perspective: Practising veterinarian with 20+ years in companion-animal medicine

Overview

This report presents a comprehensive and ambitious exploration of opportunities for the Australian red-meat industry within the pet supplement market. From a veterinary perspective, it's encouraging to see MLA exploring how agriculture can adapt to changing human-animal relationships and find new relevance in pet wellness. The analysis is detailed and forward-looking, but several assumptions - particularly around consumer behaviour, nutrition, and evidence standards - warrant closer scrutiny to ensure any future investment aligns with veterinary science and real-world owner behaviour.

Below are my key takeaways and observations, grouped as constructive critiques followed by positive reflections.

Key Takeaways (Veterinary and Behavioural Perspective)

1. The assumption that preventive supplements reduce veterinary costs - and that owners buy on this basis – may not align with real-world behaviour.

The report argues that red-meat-based supplements could lower long-term veterinary costs by promoting preventative health. In theory, that's appealing and smart. But in practice, this assumption doesn't reflect how most owners make health decisions for their pets.

From over two decades in clinical practice, my experience is this: owners don't act on hypothetical or future savings. Preventive decisions are rarely made because of what might happen years later; they're made when a vet or nurse helps them understand *immediate*

relevance and gives them a plan they can follow.

We see this pattern everywhere, from dental care to weight management to desexing. Owners often agree in principle that prevention is cheaper than cure, but their follow-through only improves when they have ongoing support:

- free dental-check clinics or weight-loss programs that include accountability visits
- short-term goals with visible feedback (“his weight’s down half a kilo - keep going”)
- and trusted guidance that makes the benefit tangible *now*, not years later.

If industry wants to promote preventive supplements credibly, it should consider borrowing from this veterinary model - turning prevention from an abstract “investment” into a guided, trackable process with regular engagement and measurable milestones.

Without this behavioural framing, economic arguments about “saving on vet bills” sound logical but land a bit flat, because **people rarely buy prevention for the distant future, only for an immediate sense of doing the right thing today.**

2. The framing of red meat and organ meats as “superfoods” is scientifically rocky and potentially misleading without nutritional qualification. The report’s portrayal of red meat and organ meats as “superfoods” for pets flirts with oversimplifying their nutritional role and risks overstating their benefits. In clinical nutrition, organ meats are valuable but not universally beneficial - they are potent, concentrated sources of specific nutrients that can easily become excessive or imbalanced.

For example, liver is rich in vitamin A, copper, and iron. While small amounts provide essential micronutrients, excessive inclusion - particularly in small-breed or home-prepared diets - can lead to hypervitaminosis A, causing bone deformities, joint pain, and cervical stiffness, especially in cats and growing dogs. Similarly, kidneys can contribute to excess phosphorus, posing challenges for pets with renal disease, and spleen or heart may vary widely in nutrient density depending on source and freshness. The nutritional profiles of these by-products also depend on the animal’s age, diet, and processing method, which introduces variability rarely captured in marketing speak.

Calling these ingredients “superfoods” can blur the line between nutrient density and *nutritional appropriateness*. It ignores that “more” is not always “better”, particularly in formulated diets where balance and bioavailability are paramount. The term also has no scientific definition, making it more of a marketing claim rather than a veterinary one.

From a practical standpoint, red meat and organ ingredients can play a useful role as functional carriers for other beneficials (e.g., omega-3s, probiotics) rather than being positioned as inherently therapeutic. If the industry wants to substantiate any “functional” claim, it would need species-specific feeding or digestibility studies, not extrapolation from human data. Without that evidence, the “superfood” framing risks diluting scientific credibility and could ultimately undermine trust with veterinarians and discerning pet owners alike.

3. The assumption that cats will readily consume red-meat-based supplements is unsupported by evidence and contradicts established feline behaviour research.

While the report proposes that red-meat-based formulations could “solve” compliance issues in cats, no supporting studies are cited to substantiate this claim. The relevant section (12.1.3)

references feline disease prevalence (FLUTD and CKD) but provides no empirical evidence demonstrating that cats prefer or are more compliant with red meat compared to other protein sources. The suggestion that a “3D-printed, red-meat-based supplement could be highly appealing” is purely hypothetical.

In clinical practice, feline feeding behaviour is one of the most challenging and least predictable aspects of nutrition management. Cats are obligate carnivores but also neophobic

- they are cautious with novel foods and highly sensitive to texture, aroma, temperature, and prior food experiences. Many refuse even premium or therapeutic diets containing real meat. Compliance with nutritional supplements is similarly low; acceptance rates for pastes, powders, and chews can be low unless introduced gradually and paired with familiar flavours.

My own behavioural and welfare research experience reinforces this: in feral cat baiting programs where extensive testing is conducted to develop “irresistible” formulations, no single meat or flavour achieves universal acceptance. Cats often reject baits despite hunger motivation, a (frustrating) reminder that palatability is not synonymous with protein type.

Therefore, assuming that red meat inherently enhances compliance risks oversimplifying a well-known behavioural problem. True progress will come from formulation science and behavioural insight, not ingredient substitution. This means developing feline-specific delivery systems (e.g., microencapsulated powders, dissolvable flavour-neutral pastes, or liquid toppers) and applying evidence-based desensitisation and transition strategies.

Without such research, any claim of “palatability advantage” remains speculative, and potentially misleading if presented as an evidence-based benefit. A more responsible approach would be to explicitly acknowledge the feline compliance barrier and identify it as a priority for future R&D rather than a solved problem.

4. The economic rationale overemphasises extreme-case veterinary costs, distracting from realistic, everyday decision-making.

The report’s argument that pet supplements can offset veterinary costs by preventing chronic diseases relies on highly selective and extreme examples, citing figures like \$10,000-\$20,000 for advanced treatment cases. While such numbers occasionally occur - typically in extreme cases in insured, referral-centre contexts - they are not representative of the majority of pet owners or veterinary practice realities.

From a clinical perspective, invoking these outlier costs is unnecessary and even counterproductive. It frames the problem in sensational rather than practical terms. Most pet owners make decisions under emotional, financial, and situational constraints, not by calculating hypothetical future savings. A family with a dog developing mild arthritis does not think, “this supplement could save me \$10,000 in eight years”; they think, “my dog is limping, what can I afford this month that might help?”

Veterinarians see this behavioural pattern daily. Preventative interventions such as dental prophylaxis, descaling, or weight clinics are often declined until the condition becomes obvious, painful, or urgent. Even when free nurse-led dental checks or obesity clinics are offered, uptake depends on follow-up, reassurance, and visible short-term wins, not on

abstract financial logic.

For this reason, the inclusion of extreme cost figures adds little value. A more credible approach would use typical cost ranges (e.g., \$400–\$1,200 lifetime for moderate arthritis management) and focus on the broader emotional and welfare benefits of prevention - improved comfort, mobility, and quality of life - rather than speculative economic savings.

Ultimately, the success of a preventative wellness product will not hinge on convincing pet owners of distant financial returns, but on making benefits immediate, observable, and emotionally rewarding. Behavioural reinforcement drives compliance; abstract cost-saving arguments do not.

5. The same consumers drawn to “natural” and “wellness” products are often those most sensitive to red-meat’s climate and welfare implications, creating a values contradiction.

The report positions red meat as a “natural” and “nutrient-dense” ingredient that aligns with the wellness movement. But this assumption misses a crucial social reality: the people most likely to buy premium, natural, preventative health products - both for themselves and their pets - are often the same individuals who are climate- and welfare-conscious.

In Australia, conversations around red meat are inseparable from climate change, deforestation, and livestock welfare. For this demographic, red meat doesn’t evoke “nature” and “wellness”, it evokes methane emissions, bulldozed habitat, and animal suffering. These are deeply emotional associations, not easily undone by scientific or nutritional arguments.

So, while the report sees “organ meats” and “red-meat superfoods” as an opportunity, many of the pet owners most aligned with the “humanisation” and “preventative health” trends will experience an ethical dissonance: “How can a product that depends on animal slaughter and deforestation be sold as a wellness supplement for my dog or cat?”

This isn’t an abstract PR problem, it’s a values mismatch that could undermine consumer trust before the product even launches. To reach this audience credibly, the red-meat sector must move beyond marketing language and show tangible sustainability credentials:

- Verified low-carbon or regenerative production systems.
- Transparent welfare standards and traceable sourcing.
- Honest messaging that acknowledges environmental concerns instead of glossing over them.
- Talk to the idea of no-waste, using the entire animal

Until those foundations are in place, “red-meat-based wellness” will struggle to gain traction among the very consumers who drive the premium pet market because to them, “natural” may mean both nutritionally and ethically clean.

6. There is a credibility gap between what veterinarians require as evidence and how the industry currently frames “wellness” and “functional” claims. The report

repeatedly calls for “science-backed” and “evidence-based” marketing but in practice, this phrase is often used a bit loosely. From a veterinary standpoint, the threshold for credible evidence is far higher than what’s typically seen in the supplement industry.

Most nutraceuticals marketed to pet owners rely on extrapolated human data, open-label studies, or surrogate markers of improvement (e.g. coat shine, activity level) rather than blinded, controlled trials in companion animals (sometimes for unavoidable or understandable reasons). This is especially true for new ingredients or manufacturing processes like 3D printing, where there’s little or no published data on safety, digestibility, or bioavailability in dogs or cats.

In a clinical context, veterinarians require replicable, species-specific, peer-reviewed data before recommending a product - especially one claiming to “support joint health,” “reduce inflammation,” or “enhance immunity.” Without that, vets cannot ethically endorse or stock such products, which weakens the entire “veterinarian-trusted” pillar of the strategy.

Moreover, there’s a growing gap between what marketers say (“science-backed”) and what clinicians mean by evidence (controlled, blinded, statistically significant trials). This disconnect can erode trust not only with vets but with increasingly informed consumers, who are quick to scrutinise claims and credentials. Just a quick look into the false conspiracy theories about vets taking money from pet food companies will show what MLA may come up against.

If the red-meat industry genuinely wants veterinary and consumer confidence, it needs to invest in proper clinical validation - not just nutritional analysis or pilot studies, but genuine, peer-reviewed trials demonstrating measurable benefits in pets. This should be paired with transparency about study design and outcomes, so veterinarians can evaluate the evidence themselves.

In short: “science-backed” cannot remain a slogan. In a sector dominated by marketing noise and consumer skepticism, vets are the credibility gatekeepers - and earning their trust requires scientific rigour, not rhetoric.

7. 3D printing is an intriguing concept - but even as a veterinarian, I found it novel and somewhat alien. Public acceptance will take time. The discussion around 3D-printed pet supplements was a surprising aspect of the report. Even as a practising veterinarian familiar with developments in nutrition and manufacturing, I had not encountered this technology in a veterinary or consumer context before. It immediately raised questions for me, not so much about feasibility and regulation, but about perception.

We’ve only just begun seeing the public conversation catch up to ideas like *lab-grown meat* and *plant-based meat substitutes* - both of which are still in their infancy and still attract scepticism and emotional reactions around “unnatural” food. 3D printing, while potentially innovative, sits even further ahead of current public comfort. To most people, “printed” food still sounds synthetic, engineered, and experimental - the opposite of what the natural, wellness-driven pet market is seeking.

In this light, positioning 3D printing as a near-term manufacturing pathway could be premature. The pet supplement audience, particularly those driven by the “humanisation” and “natural wellness” trends, may see it as odd or even off-putting. From a communications

standpoint, the focus should be on *why* 3D printing is used (precision, safety, consistency) rather than *how* it's done.

Before or alongside investing heavily in such technology, the industry would need to validate not only technical viability but also consumer psychology: how owners feel about feeding their pets “printed” products. Until there’s broader acceptance of analogous technologies (like cultured meat), this approach risks alienating exactly the demographic most likely to pay for premium wellness products.

In short, while 3D printing may hold future promise, its commercial success in pet health will depend less on engineering capability and more on public perception and emotional readiness, areas that perhaps should be researched before any major rollout.

Positive Takeaways

1. It’s encouraging to see the red-meat industry thinking beyond food production and seeking relevance in a changing world.

As someone who’s seen pet ownership evolve over decades, from pets as property to pets as family, I found it genuinely refreshing to see an agricultural industry thinking about how it fits into this shift. The report shows an awareness that people no longer separate animal welfare, personal wellbeing, and environmental impact; they see them as connected. That recognition alone is a strength.

It signals that the industry wants to participate in shaping a future where agriculture, animal health, and sustainability coexist - not as opposing forces, but as parts of the same conversation.

2. The focus on using the whole animal is pragmatic, sustainable, and ethically responsible.

The idea of utilising organ meats and by-products that might otherwise go to waste is, at its core, a sustainability win. From an ethical and environmental standpoint, making full use of each animal aligns with circular-economy principles and demonstrates respect for the resource.

If executed with transparency and nutritional rigour, this approach can reduce waste, lower environmental impact per kilogram of protein, and even improve public perception of meat production. It’s one of the most constructive ideas in the report, provided it’s communicated honestly, not as a “superfood” story but as a responsible resource-efficiency strategy.

3. The emphasis on scientific credibility and trust marks a welcome evolution - and positions Australia to lead globally.

It’s encouraging that the report places “science-backed” validation at the centre of its strategy. Even though that term is often used loosely in consumer marketing, acknowledging that trust must be earned through data and transparency is a positive step. If MLA channels its scientific expertise into genuine clinical validation and open communication, it could set a

new international standard for integrity in the pet supplement space. Australia already enjoys global recognition for its safety, quality, and traceability systems; this initiative could extend that reputation into the wellness category - not just as a participant, but as a world leader in responsible innovation.

4. The project demonstrates cross-disciplinary ambition and forward thinking.

The report's integration of behavioural science, market economics, nutrition, and technology shows an understanding that pet health has many moving parts. That kind of higher-level thinking linking industry diversification, veterinary insight, and consumer psychology, is refreshing and commendable. If refined with more grounded assumptions, this could become a model for how agricultural industries pivot toward sustainable solutions in the 21st century.

Closing Comments

Overall, this report shows commendable ambition and awareness of the evolving pet landscape. Its integration of market, behavioural, and scientific perspectives is forward thinking and valuable. My feedback is not to diminish that ambition, but to ensure it's grounded in veterinary evidence, owner psychology, and ethical realities - the factors that ultimately decide whether a "good idea" becomes a trusted, effective, and sustainable product.

If MLA continues this work, I'd encourage the next phase to include practising veterinarians in the design of feasibility and palatability studies, clinical validation protocols, and consumer education frameworks. Doing so would bridge the gap between agricultural innovation and real-world pet health outcomes, the space where meaningful change actually happens.